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Abstract 
 
  Health care systems in Saudi Arabia and elsewhere play a significant role in the 
lives of individuals as well as society at large. Although healthcare aims at enhancing 
the quality of life it can sometimes happen that treatment itself can lead to a diminution 
of the quality of life due to unexpected adverse effects. These problems may cause 
therapeutic failures or even drug-related morbidity and mortality. Consequently there is 
a need to have in place a system, conventionally known as Pharmacovigilance. The 
aims of Pharmacovigilance are to identify, quantify and continuously monitor all drug 
use through a system which would enable all health care professionals such as 
physicians, pharmacists, dentists and nurses to contribute.  
This thesis investigated the present knowledge of and use of, the Pharmacovigilance 
system in Makkah, in the Kingdom of Saudi Arabia. 
A mixed method yielded data that provided depth and breadth to the findings of this 
study. A questionnaire was designed for 170 community pharmacists and 310 
respondents drawn from different medical roles across the seven hospitals in Makkah 
yielded some useful results.  Resistance to change was identified in some groups but it 
was of interest to discover that 72% of respondents who admitted that their knowledge 
was insufficient were, nevertheless, agreed about its importance.   
Key issues from the analysis of the questionnaire were used to design the second phase 
of the sequential mixed method which involved semi structured interviews with seven 
senior pharmacists, one from each of the seven hospitals.  Analysis yielded three 
overarching categories: Technology, Internalisation and Motivation.  A follow up 
feedback survey at the end of a lecture, of a group of pharmacy students enhanced the 
overall findings of the study and revealed a very high degree of interest and acceptance 
of Pharmacovigilance reporting systems and an expressed desire for its inclusion as a 
subject in its own right in their training programme. 
Conflicting epistemological positions inherent in a mixed method are candidly admitted 
and no attempt is made to circumvent this difficulty.  Rather, the enhanced nature of the 
findings is highlighted despite the opposing knowledge claims of both approaches.  
A key finding was that 59% of the respondents were unaware of the Saudi National 
Pharmacovigilance centre (NPC) and reporting arrangements. The problems of lack of 
internet access and of suitable reporting forms were important contributory reasons for 
the under-usage of the system.  
  There is a need to raise awareness of all pharmacists of the importance of the 
knowledge and practice of Pharmacovigilance. Technological solutions should be 
implemented to facilitate reporting at all levels.  Continuing professional development 
should include Pharmacovigilance. Resistance to change can be addressed by 
identifying the motivational factors that can lead to a more wholehearted acceptance of 
the importance of Pharmacovigilance for patient care and well-being.  Indeed, these 
could well be the focus of future studies. 
Keywords: Pharmacovigilance, Holy City of Makkah, Adverse Drug Reactions 
Reporting, Saudi Arabia, Awareness, Attitude, Knowledge.  
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Chapter one 
1 Introduction 
 
“Not all hazards can be known before a drug is marketed”  
        [Committee on Safety of Medicines, Annual Report 1969, 1970]. 
 
1.1 Brief background to the topic of Pharmacovigilance  
1.1.1 A historical perspective 
Today, there is a public expectation that diseases can be cured and/or 
alleviated by medications so as to improve the quality of life. This expectation 
extends from diseases which commonly affect people, such as bacterial 
infections and cardiovascular disease such as hypertension, to the new disease 
such as Human Immunodeficiency Virus / Acquired Immune Deficiency 
Syndrome (HIV/AIDS). To this end, pharmaceutical companies have invested a 
great amount of time and money in both research and development to discover 
new medicines which are necessary to treat a diverse range of diseases, or 
improve the existing treatments, for both established and newly occurring 
conditions.  It almost goes without saying that such medicines have to be safe 
in use and effective against the diseases for which they have been targeted.  
 The historical perspective of the potential "disasters" which can happen 
during medical treatment shows it is not a new phenomenon. It has happened 
from the earliest of recorded times and, in the contemporaneous written 
accounts, – written on clay tablets or papyrus - references are to be found 
expressing concern about the risk of using therapeutic agents and the 
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"sentence" to the individual who prescribed such medicines should any 
problems occur. For example: 
• In 2200BC, The Babylonian Code of "Hammurabi", states that the 
prescriber would have their hand cut off if their treatment could lead to 
the death of the patient (Davies, 1991).   
• In 950BC, Homer almost casually stated that,"Many drugs were excellent 
when mingled and many were fatal" (Stephens, 2004).  
• In 400BC, Hippocrates and then Galen (120 AD) both warned doctors 
that unexpected events may happen when drugs were given to patients - 
what today we would call Adverse Drug Reactions (ADRs) - and they had 
to be very careful in their prescribing habits.  
• Much later, in 13th century Europe, any "consumer" who died after taking 
a prescribed medicine would result in the verdict of the death penalty for 
the prescriber as was decreed by the Hohenstaufen Emperor, Frederick 
II (Roberts, 1992).  
Moving to more recent times:–  
• In 1785, William Withering in his book entitled ‘An Account of the 
Foxglove and some of its Medical Uses’ described digitalis toxicity and 
measured the strength of his tinctures on turkeys to make sure that they 
would not kill his patients, (Withering, 1785). He was correct to very 
careful as since his time there have been numerous reports of ADRs for 
digoxin and other glycosides from digitalis and the fatalities caused by 
these medicinal substances have been recorded (Beard and Lee, 2006). 
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• In 1820, the United State Pharmacopeia (USP) was established 
(Stephens, 2004) to try and make standard formulations a rule rather 
than an exception. 
• In 1848, a 15 year old girl died as a result of undergoing chloroform 
anesthesia in connection with an ingrowing  toenail (Routledge, 1998) 
and this was relatively soon after its introduction into medicines in 
November 1847 (Gordon, 1897). 
• In 1864, the British Pharmacopeia (BP) was established (Stephens, 
2004) which again tried to standardize formulations. 
• In 1922, a formal investigation was instigated by the Medical Research 
Council (MRC) regarding jaundice following the use of arsenic to treat 
syphilis (Beard and Lee, 2006) 
• In 1937, in the United States America (USA), 107 people died due to the 
use of an elixir which included ethylene glycol as an excipient.  
More recently:- 
• In 1954, a number of French patients were poisoned with Stalinon (a tin 
based drug) which a French pharmaceutical company had prepared for 
the treatment of acne (McQueen, 1980).  
• In 1960s, the crucial aspect that drugs must be safe in use was 
demonstrated, when one of the most serious disasters ever to happen for 
medicines use occurred namely, the thalidomide tragedy. Dr William 
McBride is considered one of the originators of Pharmacovigilance by his 
simple yet elegant reports about the unexpected effects of thalidomide 
(McBride, 1961 , Udall, 1962) (see Figure 1). This drug was used during 
pregnancy as a hypnotic and antiemetic and had been marketed as a 
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safe product for the alleviation of morning sickness in early pregnancy. 
This was a novel use for a drug and, because at the time there were no 
other suitable drugs for this condition, rapidly led to its widespread 
distribution and usage. Totally unexpectedly, this was found to cause 
defects in foetal limb development - and produced in those affected 
shorter upper or/and lower limbs which had the appearance of the 
flippers of a seal and so was termed Phocomelia (from Greek φώκη = 
"seal" plus μέλος (plural μέλεα) = "limb" (seal limbed) (see Figure 2). 
Worldwide, around, 10,000 foetuses were affected. Many of these were 
in Germany where the German company "Grűnental" first marketed the 
drug (Waller, 2010). More recently, in Brazil, where the drug was recently 
reintroduced to treat leprosy, the same effect has occurred with more 
than 1000 foetuses being affected, with the last case being born in 1995 
(Pannikar, 2003). 
• During the 1960s, after the disaster of the adverse events of the 
thalidomide tragedy, people were shocked and asked why it had actually 
happened in the first place, This critical question led health regulatory 
authorities to subject all new medications to a full assessment as to their 
potential to cause harm to foetal development and other aspects of 
safety in use (Waller, 2010).  
• In 1970, even after an increase in awareness of the problem of drug 
toxicity, Lely published a study which described how 19 people had died 
from digitalis intoxication, the effect noted by William Withering above, 
which was caused by a production error of the digitalis tablets resulting in 
overdoses occurring (Van Grootheest, 2003).  
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Figure 1: Report from McBride to Lancet Journal in 60`s (60'S at 50, 
2011). 
Figure 2: The thalidomide medication caused Phocomelia (short limbs 
and legs). 
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• Since the early 1990s, the lessons learnt from the thalidomide tragedy 
and other adverse effects which have been reported, has progressively 
led "Health Regulatory Agencies (HRA)" around the world to consider 
increasing the safety of drugs and so ‘preventing’ any harmful events 
occurring.  
 
Today, the term used to describe such a concept is "Pharmacovigilance" 
originally coined in 1990 by Beqaud (Waller, 2010). This is the term which will 
be used throughout this thesis. 
1.1.2 Definition of Pharmacovigilance  
According to Professor Bernard Begaud the originator of the word, 
‘Pharmacovigilance’ it is derived from a French word which means; 
  “a discipline involving detection, evaluation, and prevention of 
undesirable effects of medicines”.  
Of course, the root of the word of Pharmacovigilance is actually derived from 
the Greek ‘Pharmakon’, which means drug and ‘vigilance’, which means 
watchfulness (Stephens, 2004). But despite this simple derivation other authors 
and professionals have formulated their own interpretation of the word. 
 For example the: World Health Organization (WHO) defines pharmacovigilance 
as; 
  “the science and activities relating to the detection, evaluation, 
understanding, and prevention of adverse drug reactions (ADRs) or 
any other drug-related problems” (Härmark and van Grootheest, 2008 , 
WHO, 2012).   
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Another earlier definition by Shakir and Layton (2002) was; 
 "Pharmacovigilance involves the monitoring, detection, evaluation 
and responding to drug safety hazard in human during 
premarketing development and post marketing" (Shakir and Layton, 
2002).  
In contrast, the definition of Pharmacovigilance in the same year by Mann and 
Andrews (2002) was;  
"the study of the safety of marketed drug under the practical 
conditions of clinical usage in large populations" (Mann and 
Andrews, 2002).  
A similar emphasis on safe marketing is found in the Medicines Control Agency 
(MCA) which defines it as; 
 "The process of evaluating and improving the safety of marketed 
product".  
Also, the National Audit Office (NAO) in the United Kingdom (UK); defines it 
simply as;  
"The science of medicines safety monitoring"  
      So, today the WHO definition is still perhaps the best and as such is used 
for the purposes of this thesis, and is the one suggested by Stephens in 2004. 
Despite the great numbers of possible definitions, the actual concept of 
Pharmacovigilance is very widely used and involves the collection of information 
about  ADRs and then taking action to ensure that any medicine is safe, 
effective and does not cause any further ADRs in the future (Cobert and Biron, 
2002). It should be stressed that Pharmacovigilance includes many diverse 
groups of pharmaceuticals namely: synthetic chemical drugs, herbal, traditional, 
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complementary medicines, blood products, vaccines and medical devices. In 
consequence, Pharmacovigilance relates to all types of ADRs issues. 
In the wider perspective Pharmacovigilance can also include medication errors, 
lack of efficacy reports, drug-drug/drug-food interactions, abuse and misuse of 
medicines, using drugs for inappropriate purposes that have insufficient 
scientific basis, substandard medicines, drug-related mortality assessment, and 
finally case reports of acute and chronic poisoning (WHO, 2006).  
So, against this complex problem of nomenclature, we move on to the question 
of why any system of Pharmacovigilance is actually required. 
1.1.3  Why Pharmacovigilance is actually required?  
 In a study by Amery (1999), who entitled his article: "Why there is a need 
for Pharmacovigilance", several points are stressed, one of which was the 
limitations of clinical studies, small group sizes, a very selected group of 
individuals and drugs sometimes used on people who had no underlying 
disease(s) and would, consequently be inadequate to detect drug related 
problem(s) and observations about a new drug after it had been marketed and 
had become widely used. The WHO, has regularly classified the clinical 
development of medicines use into four phases. The first three of these phases 
comprises "pre-marketing surveillance". The fourth phase is the "post–
marketing surveillance" stage. (See Figure 3) (Amery, 1999). Thus, the 
evaluation of the medicine before marketing and before being administered to 
humans as a new medicine is subjected to both significant and rigorous testing 
in animal studies (Freeman, 1991). 
 Although it may not be appropriate to draw direct parallels between 
toxicity in animals and potential risk to humans, these studies present an overall 
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picture of the potential toxicology of a drug and indicate which organs are at 
greatest risk of damage induced by drugs. If the drug passes through such a 
development successfully, then ‘volunteer studies’ are followed by limited 
clinical trials which are followed by more extensive trials so that the data can be 
collected and submitted for approval for a product license for use in the UK. So, 
by the time a drug is marketed, it will usually have been given to fewer than 
3000 people, usually in a series of small studies which has involved fewer than 
100-200 subjects. This limited experience provides an estimate of the most 
suitable dose range, which balances the greatest efficacy against the lowest 
incidence of ADR (Bateman and Chaplin, 1988). 
 A medicine has to pass through each phase in turn before moving to next 
phase. Part of the reason for the problem of predicting ADRs is that however, 
large the Phase III clinical trials they are still limited in terms of the number of 
people studied and may fail to detect adverse effects in the wider population. 
There are three reasons /mechanisms why this is the case: 
1. Clinical trials may fail to identify adverse reactions that are rare. This is 
due to the fact that the incidence rate may be too low either in the target 
population or in the clinical trial population to predict their true number. 
2. Some adverse effects do not occur in the context of clinical trials due to 
either or both of the following factors: 
A. Post-marketing events that may impact on a drug safety profile. 
B. Side-effects that depend upon the environment in which the drug 
is used. 
3. Some adverse effects are not detected due to the lack of the use of 
appropriate detection techniques (Amery, 1999). 
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The information obtained in the evaluations carried out is then submitted to the 
regulatory authorities to obtain a product license for the drug (Freeman, 1991). 
 
 
 
  
 Post-marketing surveillance attempts to detect risks which were not 
perhaps apparent during clinical trials so that any post marketing disasters may 
be avoided (Inman, 1987). The following reasons have been suggested for the 
absolute necessity of post marketing surveillance:  
 
I. Any pre-approval drug trials have limitations arising from the number of 
subjects used which can be considered to be not large enough to reveal 
every possible shortcoming or side effect of a new drug (Novitch, 1985). 
Toxicity reactions may have an incidence during clinical trials but their 
occurrence may be considered coincidental and unrelated to drug 
treatment. It is therefore only after much wider use that serious adverse 
Figure 3: Clinical development of medicines 
(Source: www.WHO.int) 
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reactions to most drugs are actually detected (Bateman and Chaplin, 
1988). 
II. ‘Pre-approval trials can never be long enough’ (Novitch, 1985). Some 
ADRs become apparent only after months or years of continuous 
treatment. Benoxaprofen and practolol are very good examples of drugs 
which can cause very severe ADRs but which were missed in the early 
post marketing experience because of the time required to develop the 
‘pathological’ reactions to the drugs (Bateman and Chaplin, 1988). 
III. Drugs are sometimes used, once they have been approved, in patient 
populations for which they were not tested (Novitch, 1985). For example, 
in the elderly, and because this group of patients may be also subjected 
to poly-pharmacy, and they may have altered pharmacokinetics due to 
age-related impaired renal function, and all  these factors may influence 
the incidence of adverse effects in such groups. Frequently, 
premarketing studies may not have looked at drug use in these 
populations (Roberts, 1992). 
IV. Approved drugs are sometimes used for indications for which they have 
not been tested (Novitch, 1985). This off-license use is usually carried 
out by a physician on their own decision and on their own responsibility. 
Aims and types of Post Marketing Surveillance 
The main aims of post- marketing surveillance are stated to be:  
• It enables hazards to be identified rapidly with minimum exposure of the 
population. 
• It should be able to provide an estimate of the incidence of the ADRs of 
interest or concern.  
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• It should identify any risk factors that may predispose individuals to 
toxicity and 
•  It should provide a means for continuing risk-benefits assessment in the 
population as a whole (Rawlins, 1987).  
 
Types of Post Marketing Surveillance 
Post Marketing Surveillance is divided two types:  
• Data which result from spontaneous reporting. An example is the 
Yellow Card Scheme Reporting (YCS) which is used in the UK. This 
will be discussed at the end of this chapter. 
• Data that are collected by a structured and scientific method, such as 
prescription event monitoring (Rawlins, 1987).  
 
 It is not only at national government level that organizations have been 
established to collect data resulting from post marketing surveillance. The WHO 
(WHO, 2002a) documented that Pharmacovigilance was essential for every 
country in all regions of the world so as try and avoid ADRs or any drug-related 
problem due to the nature of the disease itself or the type of medication actually 
used. This was, and still is, a problem because each country may have 
differences in their cultural attitudes to reporting such events and some effects 
that may be relevant in one part of the world may not be so in another. 
Variability can exist in subjects in which such events are reported for a variety of 
reasons: 
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1. The actual diagnosis of the illness and sicknesses in general and 
treatment practices all vary throughout the world.   
2. There are great differences in terms of personal genetics, the range and 
quality of types of foods eaten and the quality of life of the individuals.  
3. The quantity of medicine(s) taken and the quality of the ingredients used 
by drug-manufacturing processes may vary.                
4. Problems posed by herbal preparations when used along with traditional 
therapy, e.g. herbal remedies, may pose toxicity problems with other 
drugs if taken alone or used together.      
 
 In 1968, the International Drug Monitoring Programme (IDMP) was 
established, under WHO and has played an important role by providing 
information for each country on possible safety issues which may not be 
available to each country on an individual basis. Also, the exchange of 
information about drug risks between countries is a major advantage as it saves 
time and effort for all concerned (WHO, 2002a). Furthermore, when the 
Pharmacovigilance centers were established in most of countries, it was hoped 
it would be very helpful to minimize the problem and be independently 
supported by their own governments.  
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1.1.4 Aims of Pharmacovigilance 
The principal aims of Pharmacovigilance were stated by Stephens in 2004, 
WHO in 2006 and more recently by Aronson in 2012 to be: 
• Early detection of unknown ADRs and drug interactions. 
• Identification of ADRs, and possible mechanisms by which a drug 
produces ADRs plus the risk factors that increase the probability of 
having such events namely: dose, age, gender, disease.  
• Improving public health and ensuring the rational and safe use of drugs 
by continuous assessment of the benefits and risks of drugs and 
ensuring they remain acceptable.  
• Encouraging effective communication between healthcare providers and 
the public which is sometimes the starting step in ADR detection.   
• Education and spreading of all information with regard to drugs for 
regulators, pharmaceutical companies, health professionals and patients 
to improve the prescription, administration and regulation of medicines.  
• Decreasing hospital admissions and death rates, so thereby saving on 
the health budget which is spent on drug-related problems (WHO, 2006 , 
Aronson, 2012 , Stephens, 2004). 
 
1.1.5 Who are the partners for Pharmacovigilance? 
 In 2002, WHO published a document entitled: "Importance of 
Pharmacovigilance safety monitoring of medical products". It has been 
mentioned above about the ‘Pharmacovigilance Partners’ monitoring the safety 
of medicines. Correctly used medicines can positively contribute to the overall 
health of any country's population and today, patients demand their availability 
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because of their positive outcomes. Their correct use, of course, demands the 
co-operation of all the people involved in the process namely patients, 
physicians, pharmacists and nurses. So, Pharmacovigilance is the responsibility 
of everyone, in every region of the world, so that all drugs can be used safely.   
 Furthermore, the Ministry of Health (MOH) or its equivalent in any 
country of the world is not only responsible for monitoring drug safety but also 
needs commitment and collaboration between the different Pharmacovigilance 
partners (WHO, 2002a). A comprehensive list of these ‘partners’ includes:-  
1. Healthcare professionals, for example :- 
A. Prescribers  
B. Nurses 
C. Pharmacists 
2. Patients. 
3. Hospitals and academia. 
4. Pharmaceutical Industry. 
5. The WHO Quality Assurance and Safety (Medicines Team).  
6. National Pharmacovigilance Centers (NPC). 
7. Uppsala Monitoring Center (UMC). 
8. Others. 
 
Each of these ‘partners’ will now be considered individually: -  
The numbering system below is based on the list above to simplify the written 
presentation. 
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1. Healthcare professionals 
 Safe medication is a critical issue for physicians, dentists, pharmacists 
and nurses. They have the responsibility to be aware on behalf of their patients 
of any problems associated with drug therapy including,  
a) The nature of the disease,  
b) the purpose of medication, and  
c) Any potential risks involved in its use. 
  
They also have a responsibility to ensure that their patients have an adequate 
understanding of the nature of the treatment(s) they are taking.  
 
A. Prescribers 
 It is essential that all involved in the process of medication prescribing 
have some knowledge of the potential ADRs, so that an assessment of the 
balance between the benefit and harm is considered before a drug is 
prescribed, dispensed and administered/taken by the patient. Any medication or 
any kind of treatment should consider all these factors including perhaps and 
most importantly, the individual patient and their predisposition to drug toxicity.  
 The desire of the prescriber is to use a medicine to help the patient, not 
harm them, as they hope all drug administration will be without any risk. This 
should facilitate the key recognition that if the patient develops any unexpected 
signs and symptoms it may be drug related and eventually turn out to be due to 
an ADR (Beard and Lee, 2006). Therefore, all the members of the healthcare 
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team are required to be aware of the importance of ADR reporting and that they 
are competent to provide practical information for reporting ADRs.  
 They should have a familiarity with the policy and procedures of ADRs 
reporting and guidance as to how and when to report and where to actually 
send it. Healthcare professionals usually consider that they have a major 
responsibility to be a Pharmacovigilance partner by reporting suspected ADRs. 
The best management of ADRs needs to involve all healthcare professionals in 
any type of hospital whether government or private so as to both observe and 
report unwanted or unexpected ADRs (WHO, 2002a). Sometimes, due to 
inadequate information from the pharmaceutical company or industry or even a 
Food and Drug Administration (FDA), a healthcare professional cannot always 
be blamed if a patient has an ADR (Pitt, 2007) especially so, if it is of an 
idiosyncratic type where its prediction is clearly impossible. 
  But, even when healthcare professionals have enough safety 
information they may misuse it due to not having the patient's full medical 
history and that can lead to ADRs. A good example is Spironolactone which is 
contraindicated in patients with renal dysfunction or hyperkalemia. However, 
some doctors are not aware of this well reported effect and yet still prescribe it.  
 
B.  Nurses 
 Traditionally nurses did not report ADRs. But some new developments 
for ADRs reporting have taken place for nurses and as they are now also able 
to prescribe drugs in some countries such as USA and the UK (van Grootheest 
and Berg, 2004) as such prescribers they have the responsibility to report 
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ADRs. For example, in the UK, some nurses after October 2002 played a 
valuable part in the improvement of Pharmacovigilance by ADRs reporting 
(Morrison-Griffiths et al., 2003). A little later, in the Sweden, nurses could report 
ADRs and so contributed to the improvement of public health by the detection of 
suspected ADRs; (Ulfvarson et al., 2007). Similarity, in Italy, by law nurses can 
report ADRs, and so the state has actively involved them in the 
Pharmacovigilance system. Due to their unique role as caregivers, they 
carefully observe and record signs and symptoms of their patients and so they 
are in a very privileged position to see ADRs.  Currently, the contribution of 
nurses to the rate of reporting in some countries is quite significant, for 
example, Sweden 12%, Canada 16% and in the UK 21%. In contrast, the 
spontaneous nurse reporting in the Italian database is still lower than that in 
other countries (Conforti et al., 2012).  
 All these studies mentioned above; (Morrison-Griffiths et al., 2003),(van 
Grootheest and Berg, 2004), (Ulfvarson et al., 2007) and (Conforti et al., 2012). 
Clearly showed that nurses do represent an important and valuable source of 
reporting for ADRs.  
 
C. Pharmacists 
 The pharmacist, in his major role as a dispenser of medicines, is in a 
"cornerstone position" to be aware of any suspected ADRs. Since this thesis will 
specifically focus on the role of the pharmacist in making a contribution to ADR 
reporting, this will be more thoroughly discussed in the next chapter of this 
thesis.  
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2. Patients 
 In 2005, the reporting system for suspected ADRs by patients to the 
regulatory authorities commenced in the UK via using YCS was implemented. 
In 2009, ADRs reporting by patients in the UK, Sweden, Australia and the USA 
were in the range of 18% to 20%, submitted using three major methods: postal, 
internet and telephone to provide assessment awareness. These methods were 
found fitting for the UK‘s general population and indicated that the awareness 
was low and could be improved. (Fortnum et al., 2011 , McLernon et al., 2011 , 
Anderson et al., 2011a). 
       In the study by Grootheest and Berg (2004), which examined the role of 
patients in reporting ADRs, they concluded that, because patients have a 
positive value and involvement in drug therapy, their concern regarding possible 
adverse effects is a major factor in possible ADR reporting. As a consequence, 
patients’ reports on ADRs should be accepted albeit with care as is now done in 
the UK.  
 The literature, as yet, does not provide any major results in relation to the 
detection of ADRs by patients (van Grootheest and Berg, 2004) more recent 
studies are required to show their contribution worldwide. In any system where 
patients have taken medicines, their views and options about their therapy can 
be invaluable for ADRs reporting. It is, however, a difficult problem to address. 
Often, because of the brevity of the physician’s consultation process, patients 
have little time to understand any warnings that may be given about the 
potential problems of their treatment(s). It could be argued that the inclusion of 
the patient's information leaflet should avoid such difficulties. However, this 
applies to people whose first language is English and, when they are used in 
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Saudi Arabia, where many people who use the medicine do not read a high 
level of English, their value is very difficult if not impossible to assess.   On the 
other hand, in a study by Hughes et al. (2002) ADRs reporting by patients was 
not considered by Pharmacovigilance centers to be equivalent to those of the 
health care professionals as many of ADRs patient reports were incorrectly 
filled in, so increasing the overall workload for little gain (Hughes et al., 2002).  
 Recently, in 2011, the European Parliament debated about whether 
direct patient reporting was beneﬁcial or detrimental to Pharmacovigilance and 
if their contribution should be included in future legislation on 
Pharmacovigilance systems. In Denmark and the Netherlands, it was found that 
the patient reported ADRs were a useful contribution to monitoring drug safety, 
perhaps more so than health professionals, as they did not ‘filter’ any reports 
and contributed additional drug surveillance information at a time when 
healthcare professional reports were actually declining in the USA (McLernon et 
al., 2011). Another study by Arson et.al (2011) concluded that direct patient 
reporting through the YCS is viewed as important by those who have used the 
scheme, in order to provide the patient experience for the beneﬁt of 
Pharmacovigilance, as an independent perspective from those of health 
professionals (Anderson et al., 2011b). 
 
3. Hospitals and academia 
      Co-operation between the pharmaceutical industry, academia and drug 
regulatory authorities has led to the development of Pharmacovigilance as a 
clinical discipline.  
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Only a small number of medical institutions which provide medical student 
education focus on this topic during their curricula in pharmacology. So, the 
majority of healthcare professionals may graduate without an adequate 
background regarding drug ADRs. Therefore, academic centers of 
pharmacology and pharmacy should provide a knowledge of ADRs to 
healthcare professionals and the public by; training, teaching and research. In 
many schools of health and medical institutions the topic is still neglected. 
Consequently, there is a still greater need for integration of Pharmacovigilance 
by clinical practice so as to affect a system for ADR monitoring to protect public 
health as suggested by WHO ten years ago (WHO, 2002a). 
 
4. Pharmaceutical industry 
 Firstly, every company in the pharmaceutical industry has a vital role to 
play in the provision and supervision of drug safety and they must inspect all 
drug related information, from drug development to patient use, and should also 
consider the assessment of the safety of the drug and monitoring system.  
 Secondly, an important role exists in communication between the 
pharmaceutical company and drug regulatory authority that leads to an 
improvement by exchanged information (WHO, 2002a). Traditionally, it has 
always taken appropriate decisions to caution, limit use or withdraw following 
any drug related problem (Roden, 1991). 
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5. The WHO Quality Assurance and Safety: Medicines Team 
 The provision of guidance and support to countries regarding drug safety 
matters is a function of the Quality Assurance and Safety: Medicines Team 
within WHO. The purpose of the department is stated to be: "to help save lives 
and improve health by closing the huge gap between the potential that essential 
drugs have to offer and the reality that for millions of people–particularly the 
poor and disadvantaged – medicines are unavailable, unaffordable, unsafe or 
improperly used" (WHO, 2002a). Clearly, the purpose of Quality Assurance and 
Safety for Medicines team is  
• "To ensure the quality, safety and efficacy of all medicines by 
strengthening and putting into practice regulatory and quality assurance 
standards" (WHO, 2002a). 
Therefore, Pharmacovigilance needs to be applied to all related health 
technologies, including medicines, vaccines, blood products, biotechnology, 
herbal medicines and traditional medicines. 
 
6. Uppsala Monitoring Center (UMC) 
 In the early 1960s, after the infamous ‘Thalidomide disaster’, national 
schemes for collecting information concerning emerging drug hazards were 
implemented, and, in 1968, the WHO set up an international drug monitoring 
programme.  
 Ten years later, in 1978, the UMC was set up and was made responsible 
for leading and managing this programme. Working with the WHO Collaborating 
centre for international drug monitoring UMC, WHO promotes 
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Pharmacovigilance at the country level (WHO-UMC, 2009), and encourages the 
participation in the WHO programme for international drug monitoring. In 
addition, WHO still highlights the importance of collaboration and 
communication at local, regional and international levels, so as to ensure 
Pharmacovigilance delivers the necessary protection to the public.  
 In 2004, the numbers of countries that were participating in this scheme 
was 86, and all these provided the necessary data for the WHO programme 
with the collaborating centre in Uppsala, Sweden. This contrasts with the initial 
established national reporting system for ADRs which was for only 10 countries.  
 In March 2010, the number of countries had grown to 97 and in addition 
there were a further 33 countries as “associate members” (WHO-UMC, 2010).  
 At the end of 2010, the number had increased to 134 countries and they 
were all part of the WHO Pharmacovigilance Programme (WHO, 2012). More 
recently, In May 2012, the number now stands at 142 countries (Figure 4 and 
Table1). It can be seen that the Kingdom of Saudi Arabia (KSA) has been a 
member of the WHO IDMP since 2009 (UMC-WHO, 2012a). 
 On 30 March 2010, new information from the Uppsala monitoring centre 
website (WHO-UMC, 2010) showed that the global ADR database they 
maintain for the WHO programme contains 5 million ADR reports from all the 
countries who are members of the WHO programme.  
 In 2011, the UMC-WHO, which managed the global database of 
Individual Case Safety Reports (ICSRs) and consists of reports of ADRs which 
were received from national centers in the WHO network database, is called 
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"VigiBase". It currently contains over 6 million descriptions of individual cases 
which make a significant contribution to promoting a global ADRs awareness.  
 
  
 
 
 
 
 
As of June 2012, the Vigibase had more than 7 million reports from all over the 
world through pharmacists, patients, doctors, nurses, and individual National 
Pharmacovigilance Centre (NPC) and so provides information on a very useful 
global basis (UMC-WHO, 2011 , UMC-WHO, 2012b , UMC-WHO, 2012c).  
 These comprehensive reports contain evidence about the possible cause 
of harm to patients from drugs. According to their commitment, all countries in 
the WHO programme work collaboratively by gathering and monitoring the 
safety of the drug for their own country meeting one of the important targets of 
the WHO–UMC, which is to exchange this information.  
Figure 4: World map showing the official and associate member countries 
as of August 2011 (UMC-WHO, 2011) 
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 Therefore, all health professionals who are in any way involved with drug 
use are expected to report suspected adverse drug reactions. The professionals 
include pharmacists and physicians and all health professional reports to their 
Pharmacovigilance centre or its equivalent where an assessment of these ADR 
can be made and, if appropriate, reporting them to the Uppsala drug monitoring 
centre.  
 This information about ADRs is extremely useful and helpful as, 
unfortunately, many hospital admissions are caused by drug use. The Uppsala 
centre can therefore clarify any problems should they occur (WHO-UMC, 2010).  
The Uppsala center, to function effectively, requires constant new information 
about ADRs, where and when they occur (WHO, 2002a). 
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Table 1: Countries participating in the WHO Programme for International Drug 
Monitoring, with the year of their joining (Official Member Countries 108) and 
(Associate Members 34) (UMC-WHO, 2012d) 
Andorra 2008  
Argentina 1994  
Armenia 2001  
Australia 1968  
Austria 1991 
Barbados 2008 
Belarus 2006  
Belgium 1977 
Benin 2011  
Botswana 2009  
Brazil 2001  
Brunei Darussalam 2005  
Bulgaria 1975  
Burkina Faso 2010  
Cameroon 2010  
Canada 1968  
Chile 1996  
China 1998  
Colombia 2004  
Dem Rep of Congo 2010  
Costa Rica 1991  
Côte d'Ivoire 2010  
Croatia 1992  
Cuba 1994  
Cyprus 2000  
Czech Republic 1992  
Denmark 1971  
Egypt 2001 
Eritrea 2012  
Estonia 1998  
Ethiopia 2008  
Fiji 1999  
Finland 1974  
France 1986  
Germany 1968  
Ghana 2001  
Greece 1990  
Guatemala 2002 
Hungary 1990 
Iceland 1990 
India 1998  
Indonesia 1990  
Islamic Republic of Iran 1998  
Iraq 2010  
Ireland 1968  
Israel 1973 
Italy 1975 
Japan 1972  
Jordan 2002 
Kazakhstan 2008  
Kenya 2010  
Republic of Korea 1992  
Kyrgyzstan 2003 
Latvia 2002  
Lithuania 2005  
The Former Yugoslav 
Republic of Macedonia 2000 
Madagascar 2009  
Malaysia 1990  
Mali 2011 
Malta 2004  
Mexico 1999  
Republic of Moldova 2003 
Montenegro 2009  
Morocco 1992  
Mozambique 2005 
Namibia 2008  
Nepal 2006  
Netherlands 1968  
New Zealand 1968  
Niger 2012 
Nigeria 2004  
Norway 1971 
Oman 1995 
Peru 2002  
Philippines 1995  
Poland 1972  
Portugal 1993 
Romania 1976  
Russian Federation 1998 
Saudi Arabia 2009  
Senegal 2009  
Serbia 2000  
Sierra Leone 2008  
Singapore 1993  
Slovakia 1993  
Slovenia 2010  
South Africa 1992  
Spain 1984  
Sri Lanka 2000  
Sudan 2008  
Suriname 2007  
Sweden 1968  
Switzerland 1991 
United Republic of Tanzania 
1993  
Thailand 1984  
Togo 2007  
Tunisia 1993  
Turkey 1987 
Uganda 2007  
Ukraine 2002  
United Kingdom 1968  
Uruguay 2001  
U.S.A. 1968  
Uzbekistan 2006 
Venezuela 1995  
Vietnam 1999 
Zambia 2010  
Zimbabwe 1998 
Associate Members (34) 
Albania  
Algeria  
Angola  
Anguilla  
Antigua & Barbuda 
Azerbaijan 
Bahrain 
Bhutan 
Bolivia 
Bosnia and Herzegovina  
British Virgin Islands 
Burundi 
Cambodia 
Cape Verde 
Dominica 
Gambia 
Georgia  
Grenada  
Guinea  
Guinea-Bissau 
Jamaica 
Liberia 
Maldives 
Mauritius 
Mongolia  
Montserrat  
Pakistan  
Panama  
Rwanda 
Saint Kitts and Nevis  
Saint Lucia  
Saint Vincent and the 
Grenadines 
Syrian Arab Republic 
Zanzibar 
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7. The National Pharmacovigilance Centers (NPC) 
 Under UMC, the NPC considers one of its important roles as the post-
marketing surveillance of medicines which is achieved through the mainly core 
of activity of collecting and analysing reports of ADRs. Since it was established 
in 1968, its 10 centers have now grown in 2012 to more than 142. Furthermore, 
the NPC has a significant role for the public and healthcare professionals 
regarding drug safety by training courses and education in Pharmacovigilance 
which stress the importance of ADRs reporting. This greater integration 
facilitates clinical practices and the development of public health policy. 
Moreover, it communicates its information regarding drug related effects for all 
who could benefit, outlining the benefits and potential harm, the effectiveness, 
and relative risk for all patients and the public by the exchange of this 
information between centers in developed/developing countries which have 
established surveillance programmes. The exchange in some cases includes 
using a record linkage and Prescription Event Monitoring systems (PEM).  
The countries which have implemented this are New Zealand (NZ), UK, USA 
and Sweden.  
 Furthermore, most MOHs in their own countries can fund 
Pharmacovigilance National Centers fully or at least in part by comparing 
expenditure of medication with the NPC policies and regulatory guidelines. In 
addition, The International Conference for Drug Regulatory (ICDRA) at their 
Annual Meetings of National Pharmacovigilance provides an unparalleled 
opportunity for the WHO programme for International Drug Monitoring to be 
comprehensively and adequately discussed (WHO, 2002a).   
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8. Others partners of Pharmacovigilance 
 The media, advocacy groups, and lawyers can contribute directly or 
indirectly to the creation of policies and legislation on Pharmacovigilance by 
cooperation and communication with the appropriate authorities (WHO, 2002a).  
 As an understanding of ADRs in central to this thesis, the next section 
entitled ‘Adverse Drug Reactions’ includes more comprehensive details as to 
the nature of the subject and this will be given in some detail.   
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1.2 Adverse Drug Reactions (ADRs):    
 
1.2.1 Definition of Adverse Drug Reactions (ADRs) 
 It should be stated from the very beginning of this section, that there are 
many definitions for adverse drug reactions (ADRs). The WHO’s definition of 
ADRs which has been used for over 38 years is:  
“a response to a drug that is noxious and unintended and occurs 
at doses normally used in man for the prophylaxis, diagnosis or 
therapy of disease, or for modification of physiological function” 
(WHO, 1972).  
In contrast, the more recent definition of Edwards and Aronson (2000) and the 
even more recent one of Aronson (2012) are that an ADRs is: 
“an appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product, which 
predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage 
regimen or withdrawal of the product” (Edwards and Aronson, 2000 
, Aronson, 2012).  
Laurence and Carpenter's (1998) definition specifically excludes minor 
unwanted reactions (e.g., a slight dryness of the mouth):  
“A harmful or significantly unpleasant effect caused by a drug at 
doses intended for therapeutic effect (or prophylaxis or diagnosis) 
which warrants reduction of dose or withdrawal of the drug and/or 
foretells hazard from future administration” (Laurence and 
Carpenter, 1998). 
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Another ADRs definition is that of Beard and Lee (2006);   
"an unwanted or harmful reaction experienced after the 
administration of a drug or combination of drugs under normal 
conditions of use and suspected to be related to the drug" (Beard 
and Lee, 2006).  
The Council for International Organizations of Medical Sciences (CIOMS), 
starting in 1992, working group has been studying the international reporting of 
ADRs also, developed a definition: 
Adverse Drug Reactions; “an undesirable effect suspected of being 
caused by a drug" (CIOMS, 1987). 
 
 In this subject, the terms “adverse reaction” and “adverse effect” are 
interchangeable, except that an adverse effect is seen from the point of view of 
the drug, whereas an adverse reaction is seen from the point of view of the 
patient. However, the terms “adverse effect” and “adverse reaction” must be 
distinguished from “adverse event”. An adverse effect is an adverse outcome 
that can be attributed to some action of a drug; an adverse event is an adverse 
outcome that occurs while a patient is taking a drug, but is not or not 
necessarily attributable to it (Edwards and Aronson, 2000). Some other terms 
that may be useful are given in Figure 5. 
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       Source (CIOMS, 1992) 
 
 
 
 
Figure 5: Some adverse drug reaction terms and their 
definitions 
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1.2.2  ADRs are a Global Problem 
 It is a generally held belief that drugs should cure or alleviate the 
symptoms of disease but should not be harmful to patients. This presumption is 
complex because medicines modify underlying biochemical processes through 
stimulating or blocking receptors and sometimes their lack of specificity can 
lead to unwanted effects. For example, some drugs can have a serious side 
effect which may, in some conditions, be worse that the disease itself, and in 
some cases can actually be fatal. Worldwide medicines are known to be a 
major cause of morbidly and mortality (Pirmohamed et al., 1998). It has been 
claimed that 3% to 6% of all hospital admissions are caused by ADRs 
(Leendertse et al., 2008 , Conforti et al., 2012 , Lucas and Colley, 1992) and 
that during hospitalisation approximately 6% to 10% of patients experience an 
adverse drug reaction (Davies et al., 2009 , Conforti et al., 2012).  
 Based on meta-analysis, Beard and Lee (2006) found that ADRs were 
responsible for 5% of hospital admissions (Beard and Lee, 2006). ADRs 
occurred in 10-20% of inpatients and were responsible for one in a thousand 
deaths in medical wards (Roberts, 1992). Many studies have shown the ADRs 
incidence can affect inpatients and one such study by Mulroy (1973) reported 
that one in 40 consultations was due to drug induced diseases (Mulroy, 1973). 
Also, in the same year, Kellaway (1973) reported an overall ADR incidence of 
32% in 200 patients discharged from hospital who were followed for the 
following 6 months (Davies, 1991).  
 Another study, reported that the rate of children in hospital admissions 
due to ADRs was 2.09% and, of these, that 39.3% were life-threatening 
(Gallagher et al., 2011). Furthermore, several countries have recorded an even 
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worse rate of ADRs but this may be somewhat confusing. The differences in the 
percentages may be different because of actual variations in the ways of 
recording ADR events as some can be included after some forms of surgery 
and they differ by country. For example figures recorded for France 3.2%, 
Sweden 12% (Kees van Grootheest et al., 2004), Norway 11.5% (WHO, 
2002b), NZ 12.9% and Australia 16.6% (Zolezzi and Parsotam, 2005) all show 
the great variation in the recorded figures. 
 In the UK, a study by Pirmohamed et al.(2004) showed that 18 820 
patient admissions in two hospitals were due to ADRs. This represented 6.5% 
and 4% respectively of total hospital bed capacity due to ADRs. The calculated 
annual cost to the National Health Services (NHS) was £466 million 
(Pirmohamed et al., 2004 , Gallagher et al., 2012 , Davies et al., 2009).  Another 
study found the calculated cost to the NHS was nearly £2bn a year to treat 
patients who had an ADRs (Boseley, 2008). Whatever the actual monetary 
figure the problem is both extensive and expensive. 
 In the USA, Lazarou et al. (1998) found, 100,000 deaths a year were due 
to ADRs. In 1994, the year the study data related to, it was found that 6-7% of 
all hospital admissions were due to serious ADRs. They have been considered 
to be the 4th - 6th leading cause of death in the USA (Lazarou et al., 1998). 
Moreover, ADRs cause 4% of all new drug introductions to be withdrawn from 
the market (Ingelman-Sundberg, 2008). They cost on average $5.6 million per 
hospital in the USA (Rockville, 2001). The main effect of ADRs on the patient's 
lifestyle was a serious loss of confidence towards the health care system 
(Pirmohamed and Park, 2007).  
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1.2.3  The occurrence of ADRs  
 Based on data produced by the WHO (2002), ADRs occur for a variety of 
reasons and these they divided into two main types, namely, unpreventable and 
preventable.  
The first are considered unpreventable, for the following reasons:- 
1. The drug would not be expected to cause any negative effects or 
undesirable effects during  medical intervention with absolute certainty 
2. Information about rare events is simply not available until they happen. 
 
 The second are considered preventable, for the following reasons, best 
summarized as - wrong drug, wrong dose and wrong diagnosis. But there are 
others which include: 
1. Medical history for the patient is lacking which may have shown a 
documented previous interaction with a drug or an existing drug allergy.  
2. Use of medication(s) along with prescribed medicines which may cause 
potentially harmful interactive effects. 
3. The patient does not read the patient information leaflet or may not have 
understood the doctor’s advice regarding drug use, risks, 
contraindication or precautions.   
4. Well documented drug-drug interactions and drug-food interaction 
(WHO, 2002c) ignored. 
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1.2.4  The risk of ADRs  
Several factors make the risk of ADRs somewhat greater and according to 
Beard and Lee (2006) these include: 
 
1.2.4.1 Age:   
 ADRs can occur in all age groups. People at especially high risk of ADRs 
may be pediatric adults or elderly, whose immune systems are compromised or 
their drug handling processes are poor. This can happen more commonly in the 
elderly when they have severe and chronic diseases treated by a large number 
of drugs.  
 
1.2.4.2 Gender:   
 Female patients are reported to have a higher susceptibility to ADRs 
than male patients (Davies, 1991) due to different gender related factors, such 
as differences in immunological, pharmacokinetics and hormonal status.  
 
1.2.4.3 Abnormal function of organs:   
 ADRs are very common in patients who have any organ dysfunction 
such as in the kidney and/ or liver. Consequently, to reduce the risk of ADRs in 
this group, a very significant adjustment of dosage is usually required. 
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1.2.4.4 Multiple drug therapy:  
 The prevalence of ADRs and drug interactions is of greater risk when the 
patients take many medicines at the same time. If they do not follow advice this 
may result in:   
• Problems with the timing of drug doses - omission, reducing, 
increasing, or taken at the wrong time when many are taken 
together.   
• Patient satisfaction regarding bad taste or difficulty in swallowing 
of the drug can lead to them not being actually taken.  
 
1.2.5  Classification of ADRs 
ADRs have been classified into a number of different types: 
Severity of Action:  
"Whether the reaction requires treatment, necessitates hospital admission, or is 
life-threatening"  (Lucas and Colley, 1992).  
Not all ADRs pose the same potential problems and based on many studies, for 
example: Lucas and Colley in (1992), Stephens  (2004) and Aronson  (2012) 
these can be classified, based on severity of action of ADRs, into three types 
mild, moderate and severe, which are shown in Table 2.  
1. Pharmacology:  
In contrast to the three types given above, Edwards and Aronson (2000) 
classified ADRs into six types which were: dose-related (Augmented), non-
dose-related (Bizarre), dose-related and time-related (Chronic), time-related 
(Delayed), withdrawal (End of use), and failure of therapy (see Table 3).       
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Table 2: Severity of ADRs 
Types Bothersome Symptoms Patient 
Functional 
Action to taken 
Mild  
(grade 1) 
 
 
Slightly 
 
Dose not alert 
 
Normal activity 
functional 
Continue to use the drug 
because it relieved i.e. 
symptomatic treatment. 
 
Moderate 
(grade 2) 
Troublesome Uncomfortable or 
embarrassing 
Interference 
with function 
but it is  not a 
Hazard 
Adjustment is need either 
by reducing dose or adds 
another drug or changing 
to avoid any ADRs. 
 
Severe 
(grade 3) 
Very annoying Definitely hazard Fatal or life-
threatening 
Discontinue the drug to 
prevent dangerous ADR. 
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Type of 
reaction                             
Mnemonic   Features                                       Examples                                                                  Management 
A: Dose-related                             Augmented ● Common   
● Related to a 
pharmacological 
action of the drug. 
● Predictable 
● Low mortality                                                                                                                                                               
● Toxic effects:  Digoxin toxicity; 
serotonin syndrome with SSRIs. 
● Side effects: Anticholinergic 
effects of tricyclic 
antidepressants                                                         
● Reduce  dose 
or  
Withhold 
●Consider 
effects of
concomitant 
therapy  
B: Non-dose-
related                      
Bizarre ●Uncommon  
● Not related to a                                 
pharmacological  
action of the drug     
●Unpredictable   
● High mortality                                                                                                  
● Immunological  reactions:   
Penicillin hypersensitivity 
● Idiosyncratic  reactions:  
Acute porphyria 
Malignant hyperthermia 
Pseudoallergy (eg, ampicillin rash)   
● Withhold and 
avoid in future 
C: Dose-related 
and time-
related Chronic         
Chronic ● Uncommon   
● Related  to the 
cumulative dose                                         
Hypothalamic-pituitary-adrenal  
axis suppression  by corticosteroids                                          
● Reduce  dose 
or withhold;
withdrawal may 
have to be 
prolonged 
D: Time-related                              Delayed ●Uncommon   
● Usually  dose-
related     
● Occurs  or 
becomes apparent 
sometime after the 
use of the drug                                           
 ● Teratogenesis  (eg, vaginal 
adenocarcinoma with 
diethylstilbestrol)   
● Carcinogenesis 
● Tardive dyskinesia 
● Often 
intractable 
E: Withdrawal                                End of use    ● Uncommon 
● Occurs  soon 
after withdrawal                                
● Opiate withdrawal syndrome   
● Myocardial ischaemia  ((3-
blocker withdrawal) 
of the drug                             
● Reintroduce 
and withdraw 
slowly 
F: Unexpected 
failure of 
therapy   
Failure ● Common     
● Dose-related     
● Often caused by 
drug interactions                                                   
● Inadequate dosage of an oral 
contraceptive,   particularly when 
used with specific  enzyme inducers                   
● Increase  
dosage 
● Consider 
effects of 
concomitant 
therapy 
SSRIs=serotonin-selective reuptake inhibitors. 
 
      (Source: Edwards and Aronson, 2000).       
 
 
 
 
Table 3: Classification of ADRs 
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 There are several classifications of ADRs which have been proposed, 
and most are too complex for routine use. The classifications are based on 
many studies including those of; (Bateman and Chaplin, 1988), Lucas and 
Colley (1992), Stephens (2004), Beard and Lee (2006) and Pirmohamed and 
Park, (2007). Based on a pharmacological classification, there are two broad 
categories of ADRs. These are: 
A. Type "A" (Augmented) 
"Involve exaggerated pharmacologic responses such as beta-blocker-induced 
congestive heart failure" (Lucas and Colley, 1992). 
B. Type "B" (bizarre or idiosyncratic) 
 "Which are idiosyncratic and unpredictable based on a drug's 
pharmacology, and may be immunologically mediated such as Carbamazepine-
induced Thrombocytopenia" (Lucas and Colley, 1992). (Table 4. below shows 
the characteristics of type A and B ADRs). 
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Table 4: Characteristics of type A and type B of ADRs (Pirmohamed and 
Park, 2007). 
 
 
1.2.6 How to recognize ADRs 
 WHO (2002a) reported that it was not always easy to recognize ADRs, if 
the diseases and the drug effects were in the same physiological and 
pathological pathways. The steps to be taken to confirm an ADR are the 
following - 
I. Confirm by the patient they had actually taken the medication that 
had been prescribed and at the dose prescribed.  
 
Characteristics 
 
 
Type "A" (Augmented) 
 
 
Type "B" ( bizarre or  
idiosyncratic) 
Dose dependency Usually shows a good relationship No simple relationship 
Predicable from known 
pharmacology 
Yes Not usually 
Host factor Genetic factor may be important Dependent on (usually uncharacterised) 
host factories 
Frequency Common Uncommon 
Severity Variable but usually mild Variable proportionately more severe 
than type A 
Morbidity High High 
Mortality Low High 
Overall proportion of 
ADRs 
80% 20% 
First detection Phases I-III Usually  phase IV, occasionally phase 
III 
  Mechanism Usually because of parent drug or 
stable metabolism 
May be because of parent drug or 
stable metabolite, but CRMs also 
implicated 
Animal models Usually reproducible in animal models Very few reproducible in animal 
models 
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II. Investigate all the observation(s)/effects mentioned by patient so 
as to ensure the onset of suspected ADRs happened after the 
drug was actually taken and not before.  
III. Determining the time interval between starting of medication and 
the onset of the occurrence. 
IV. After discounting the drug or reducing the dose, assess the 
suspected ADR by monitoring the patient status. If suitable, 
resume the Drug therapy and monitor repetition of any adverse 
events.  
V. An alternative cause for the response, other than the prescribed 
drug, is required to ensure the validity of the reaction to the drug. 
VI. Personal experience as a healthcare professional on drugs and 
their use and keeping up to date about relevant information on 
ADRs and to verify if there have been  previous conclusive reports 
on this reaction to the NPC, Drug Information Centres (DIC) and 
the manufacturer of the drug are all very important resources for 
obtaining an information about an ADR. Any person nominated for 
ADR reporting should report any suspected ADR directly to the 
National ADR Centre or hospital authorities. 
 
 The study published by Kelly, (2008) described several methods for the 
assessment and recognition of ADRs so as to be able to develop logical 
evaluation procedures, or even algorithms, for evaluating the probability of an 
ADR (Kelly, 2008). 
42 
 
  It has been suggested that one of the most straightforward algorithms in 
used is that designed by an American FDA pharmacist (Roberts, 1992) (Figure 
6). 
 Despite such suggestions the ideas formulated in the study by Naranjo et 
al. (1981) is still perhaps the most widely accepted of these instruments and is 
usually described as the Naranjo algorithm. Its purpose is to discover the 
probable cause of an ADR to drug through answering a structured series of 
questions (Table 5) so as to be able to determine a score for each question and 
of course a total score (Naranjo et al., 1981). 
 
Figure 6:  Algorithm for determining a causal link between drug and 
symptoms (after Roberts, 1992) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Are the symptoms related in 
time to use of drug? 
Was treatment stopped? 
Causal link Unlikely 
Causal link highly probable? 
Causal link possible 
Causal link possible 
Causal link possible 
Causal link possible Did the symptoms then re-
appear? 
Was the patient re-exposed to 
drug? 
Did symptoms then subside?  
NO 
NO 
NO 
NO 
NO 
yes 
yes 
yes 
yes 
yes 
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Table 5: Assessment of the relationship between a suspected ADRs using 
the Naranjo ADR probability scale (Naranjo et al., 1981). 
To assess the ADR, please answer the following 
questionnaire and give the pertinent score 
Yes NO Unknown Score 
1.  Are there previous conclusive reports on this 
reaction? 
+1 0 0  
2.  Did the adverse event occur after the suspected 
drug was administered? 
+2 -1 0  
3.  Did the adverse reaction improve when the drug 
was discontinued or a specific antagonist was 
administered? 
+1 0 0  
4.  Did the adverse reaction reappear when the drug 
was re-administered? 
+2 -1 0  
5.  Are there alternative causes (other than the drug) 
that could have on their own caused the reaction? 
-1 +2 0  
6.  Did the reaction reappear when a placebo was 
given? 
-1 +1 0  
7.  Was the blood detected in the blood (or other 
fluids) in concentrations known to be toxic? 
+1 0 0  
8.  Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
+1 0 0  
9.  Did the patient have a similar reaction to the same 
or similar drugs in any previous exposure? 
+1 0 0  
10.  Was the adverse event confirmed by any objective 
evidence? 
+1 0 0  
 
Total:     Definite = 9       Greater, Probable = 5-8,      Possible =1-4        Doubtful =0 
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 Lee, Smith and Rawlins (1990) carried out a study to investigate the level 
of agreement between experienced professionals when validating ADR reports, 
and compared their performance with a selection of algorithmic methods. The 
experienced professionals consisted of eight doctors and six pharmacists, all 
experienced in the evaluation of ADR data. 
 The result of the study showed that a group of pharmacists showed more 
internal consistency than a group of a group of doctors when validating ADRs. A 
suggested reason for this was that doctors tend to rely on their personal 
experience when making a judgment while pharmacists may depend more on 
published data. Validation of ADRs on the basis of subjective assessment by 
experienced professionals appeared to result in a significantly greater 
agreement than is obtained between several algorithmic methods.  
 The authors therefore suggested that there was no advantage in using 
structural methods in the routine diagnosis or validation of ADRs in preference 
to traditional judgmental methods. However, algorithms may be useful as 
pointers to the specific factors responsible for disagreement, or as a checklist of 
relevant points when making a final judgment on causality (Lee et al., 1990). 
 
1.2.7 Action to be taken 
        A book written by Cobert and Biron in (2002) entitled ‘Cobert's Manual of 
Drug Safety and Pharmacovigilance’  suggested that once an ADRs has been 
confirmed, urgent action needs to be taken  to care for patients who are already 
using this drug and all government organizations, health authorities and even 
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manufacturers cooperate to prevent any further extension of the ADRs 
occurring. Regulatory actions may include:  
Transmission of information (monograph or label change): 
 Changes to the information provided for health professionals and the 
patient by monographs and patients information leaflets can help to inform all 
users of the medicines. These changes to the package or bottle insert (official 
labeling) can include: 
o A reduction in the recommended dose. 
o The removal of one or more indications. 
o An absolute or relative restriction on the population being treated. 
o Additional contraindications for patients with certain medical conditions or 
diseases. 
o A restriction, contraindication or warning regarding use with other specific 
drugs or classes of drugs. 
o Use of the product as a secondary or tertiary treatment rather than a 
primary treatment. 
o Recommendation of concomitant treatment with another drug to prevent 
or correct the problem product by the drug. 
o Recommendation of periodic laboratory testing or clinical follow-up. 
 
 The changes are sometime printed in bold letters or presented in a black 
box to underline the importance of the changes and to note that they are recent 
additions to the label. Sometimes a "Dear Doctor" or "Dear Health Care 
Professional" letter is sent as well as a press release and a note published on 
the health authority website. 
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Limitation of access to the drug: 
o Alteration of availability (for example, change in its listing: narcotics, 
controlled drugs, exceptional medication). 
o Limitation on prescribers (for example, restricted to specialist) 
o Limitation on the method of prescribing (for example, limitation of number 
of tablets dispensed). 
o Limitation to hospital only dispensing. 
o Obligatory laboratory test (for example, negative pregnancy test result). 
 
Modification of the product itself: 
 Removal or substitution of active ingredients in a combination 
products. 
 Removal of one of the dosage strengths available. 
• Change in the dosage form: 
 Change or removal of excipients. 
 Change in quality in the bottle/container. 
 Change in packaging. 
• Change in storage or preparation. 
 
Withdrawal from market:  
 Temporary or definitive suspension of sales. 
 Withdrawal of particular active ingredient, a specific product or a 
specific formulation. 
 Withdrawal of stock from the wholesalers, pharmacists, or patients 
depending upon the severity of the problem. 
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 Gradual reduction in the dose, weaning off, of the drug from individual 
patients under strict medical care. 
 Cessation of manufacture and distribution. (Cobert and Biron, 2002) 
 
 The WHO updated their advice in May 2010 (Fourteenth Issue) by 
publishing lists of products with restrictions in use. The information is presented 
in Table 6 which shows the new national regulatory decisions and on voluntary 
withdrawal of products by manufactures on ground of safety from 2009, 2010 
and up to May 2010 (WHO, 2010). 
Table 6: Lists of drugs where action had been taken by regulatory 
agencies in different countries (WHO, 2010) 
Product 
Name 
Country Effectiv
e Date 
Description of action taken Ground for decision 
Aliskiren UK 2009 The Medicines and Healthcare products Regulatory Agency (MHRA) 
has warned about the risk of angioedema and renal dysfunction with the 
use of aliskiren and the risk associated with the concomitant use of 
aliskiren and non-steroidal anti-inflammatory drugs (NSAIDs). 
Aliskiren treatment may lead to renal insufficiency and acute renal 
failure in patients with renal artery stenosis. Concomitant use of 
NSAIDs may reduce the antihypertensive effect of aliskiren, which 
may result in further deterioration of renal function, including possible 
acute renal failure, which is usually reversible when treatment is 
stopped. Health-care professionals are advised not to use aliskiren in 
patients who have previously had angioedema after using it. 
 
 
Becap- 
Lermin 
 
European 
Union 
 
2010 
The EMA has recommended contraindication for becaplermin in 
patients with any pre-existing cancer, following a review of the 
available data at the Agency’s Committee for Medicinal Products for 
Human Use (CHMP) on a possible risk of cancer associated with 
becaplermin use. 
 
Benzyl 
alcohol 
Iraq July 
2008 
All intravenous injection preparations for infants containing benzyl 
alcohol have been banned 
 
Chloro- 
Quine 
Guinea-
Bissau 
Oct 
2008 
From October 2008, tablets and syrup containing chloroquine have 
been withdrawn in Guinea-Bissau. Coartem (combination of artemether 
and lumefantrine) has replaced chloroquine. 
Defer 
Asirox 
Canada 2009 Canadian Product Monograph has been changed to include a 
contraindication in high risk myelodysplastic syndrome (MDS) patients 
and in those with advanced malignancies because these patients are not 
likely to benefit from iron chelation therapy due to the expected rapid 
progression of their disease. 
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Etravirine Spain 2009 The Spanish Regulatory Agency (AEMPS) had instructed the company 
to update the data sheet about severe rash and hypersensitivity reaction. 
The AEMPS recommended that health-care professionals strictly 
follow the recommendations of the technical specifications and 
discontinue treatment in cases of severe rash or hypersensitivity 
reaction. 
 
 
Fentanyl European 
Union 
Sept. 
2008 
The EMA has recommended the suspension of the marketing 
authorization of a system (Ionsys) for the transdermal delivery of 
fentanyl. This drug delivery system has a defect that could lead to 
overdose. 
 
Goserelin Iraq January 
2008 
Gosorelin (as acetate) implant, 10.8 mg in safe system syringe 
applicator is restricted to the use in prostate and breast cancers only. 
Human 
Chorionic 
Gonadotropi
n Hormone 
Iraq January 
2008 
Registration withdrawn of non-recombinant Human Chorionic 
Gonadotropin Hormone, in the strengths 1500 and 5000 IU. 
Iron sucrose Iraq January 
2008 
The use of Iron sucrose for injection is restricted for use in hospitals, 
for in-patients only. 
 
Keto 
Profen 
France 12 Jan. 
2010 
AFSSAPS is suspending the market authorization for specialties 
containing ketoprofen gel for which the benefit/risk is now seen as 
negative because of the risk of adverse skin reactions in rare but serious 
photoallergy. 
 
Letrozole Iraq Sept. 
2009 
Letrozole 205 mg tablets is restricted to be used in endometriosis and 
advanced breast cancer only. 
 
Mefeamic 
acid 
Switz 
Erland 
 Mefenamic acid is registered in Switzerland as an analgesic and 
antipyretic agent for adults and children, but restricted to children older 
than 6 months. 
 
Norfl 
Oxacin 
European 
Union 
2008 The CHMP has advised against the use of oral norfloxacincontaining 
medicines in the treatment of acute or chronic complicated 
pyelonephritis (kidney infection) due to its poorly established efficacy 
and high risk for adverse effects. This recommendation does not apply 
to the use of oral norfloxacincontaining medicines in other types of 
infection. 
 
Orcipr 
Enaline 
UK 2009 The MHRA has annouced the withdrawal of orciprenaline sulphate due 
to its low bronchodilating efficacy (compared to salbutamol) and high 
incidence of cardiac side effects, mainly palpitations and tachycardia 
due to its non-selectivity. 
 
Indonesia   In Indonesia phenylpropanolamine (PPA) is only approved as nasal 
decongenstant in cough and cold products with a recommended dosage 
of 10 - 25 mg and a maximum dosage per day of 75 mg (adults) and 
37.5 mg (children 6 - 12 years old). 
 
Rimon 
Abant 
Ukraine 29 Jan. 
2009 
A voluntary recall has been conducted by Sanofi-Aventis. 
Sodium 
phosphate 
Canada March 
2009 
Health Canada has warned the public against using over-thecounter oral 
sodium phosphate products as bowel cleansers due to serious adverse 
effects, including electrolyte disturbances and kidney damage. 
However, these products are still considered to be safe and effective for 
laxative use. 
Tinza 
Parin 
USA 2008 The US FDA has recommended the use of alternative treatments to 
tinzaparin sodium injection in elderly patients over 70 years of age with 
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renal insufficiency and deep vein thrombosis, and/or pulmonary emboli 
due to the increased risk of death. 
 
Vinc 
Ristine 
Iraq May 
2008 
Vincristine should only be administered intravenously and not by any 
other route. 
 
Zinc-
contain ing 
intranasal 
products 
USA 2009 The US FDA has warned against the use of three zinccontaining 
intranasal products sold as over-the-counter cold remedies (Zicam 
Nasal Gel and Nasal Swab) due to their association with a long-lasting 
or permanent loss of sense of smell. These products have not been 
shown to be effective in reducing the duration or severity of cold 
symptoms. This advisory does not apply to oral zinc tablets and oral 
lozenges. 
 
 
1.2.8 Suggested solutions for ADRs 
      It is widely accepted that any substance that is capable of producing a 
beneficial therapeutic effect can also produce unwanted or adverse effects 
(Edward and Aroson, 2000). The variation in incidence of ADRs was sometimes 
expressed as being due to the use of different methods of monitoring.  To 
minimize this effect, individuals should build up a really effective personal 
reporting system so that, ADRs can be detected, recorded and reported more 
effectively (Davies, 1991).   
 As early as 1979 Martys (1979) carried out a survey of 817 patients in 
General Practice in the UK and concluded that 41% were thought to have 
"certainly" or "probably" had a reaction to the drug prescribed. All patients 
included in the survey had been given a single drug treatment for the first time. 
Adverse effects on the gastrointestinal and central nervous system were the 
most frequently reported events and very importantly, 90% of all reactions had 
occurred by the fourth day of treatment. A greater number of patients given 
drugs acting on the central nervous system or antihistamines reported reactions 
than those for other categories of drugs (Martys, 1979). 
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 Seven years later, Lumley et al (1986) conducted a study to measure the 
number of ADRs seen in General Practice and recorded how many were 
reported to Committee Safety of Medicine (CSM) via the yellow card system. 
One hundred doctors from 24 practices recorded 36 470 consultations over a 4 
week period, and 638 consultations (1.7% of the total) were suspected ADRs. 
Most involved drugs affecting the cardiovascular system, diuretics, non-steroidal 
anti-inflammatory agents, analgesics or anti-infective. Gastrointestinal effects, 
rashes or central nervous system effects were the most common adverse 
reactions which were recorded (Lumley et al., 1986). 
  A decade later Moride et al (1997) surveyed 100 General Practices 
randomly, to assess if under-reporting of ADRs occurred in the Bordeaux region 
of France by checking the data in the local Pharmacovigilance centre. They 
found ADRs effects observed were 1.99 per General Practices per day and so 
ADRs were part of any General Practices’ routine activities. According to the 
observed trend in under-reporting, there appears to be a selection process 
which indicates that spontaneous reporting in General Practice was not 
conducive to an exhaustive description of the safety profile of a drug. However, 
their findings were consistent with greater efficacy of spontaneous reporting in 
detecting serious and unlabelled effects (Moride et al., 1997).   
 Ronald (2000) carried out a study in General Practice by Prescription-
event monitoring. He studied a total of 43 363 patients to measure the reporting 
of sedation or drowsiness to obtain their frequency in post-marketing 
surveillance of four, second generation antihistamines, namely: loratadine, 
cetirizine, fexofenadine, and acrivastine. The odds ratios (adjusted for age and 
sex) for the incidence of sedation were 0.63 for fexofenadine; 2.79 for 
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acrivastine, and 3.53 for cetirizine as compared with loratadine. No increased 
risk of accident or injury was evident with any of the four drugs. Although the 
risk of sedation was low with all four drugs, fexofenadine and loratadine were 
considered to be more appropriate for people working in jobs where safety was 
a major consideration (Mann et al., 2000). 
Many suggestions have been made to avoid ADRs and these include: 
• A good awareness of the potential problem and effective education of 
all those in the process may avoid ADRs.  
• Cooperation between all the health organizations in every country, 
such as the MOH or other organizations related to drug use is 
required. Once a drug is available to the public, making a determined 
effort to ensure its safety which is the shared responsibility of all who 
are involved in the prescribing process, including patients (Zolezzi 
and Parsotam, 2005).  
• ADR reporting has a major role in the prevention of future Drug-
related problem(s). 
 
1.2.9 Historical background to ADRs reporting 
ADRs reporting systems have always depended for their success or failure of 
the active participation of the ‘reporters’. Thus: 
• In the early 19th century, the systematic reporting of adverse effects, 
particularly regarding vaccines, was noted (Van Grootheest, 2003). In  an 
article on "150 years of Pharmacovigilance"  by Philip Routledge, the 
author refers to a committee that was set up by The Lancet to collect 
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reports on mortalities resulting from anesthesia in Britain and its colonies, 
the result of which were then published (Routledge, 1998).  
• In 1950, reports of incidence of aplastic anemia associated with the use 
of chloramphenicol were received in the USA. 
• In 1960, after the thalidomide disaster, the US FDA started with the 
systematic collection of reports on all types of ADRs, through the hospital 
reporting programme (Van Grootheest, 2003).   
• In 1964, the first ADRs reporting system was established by the UK was 
the CSM (Beard and Lee, 2006). It has progressed over the years and by 
2002 had collected almost half a million reports, submitted from doctors, 
dentists and coroners on a voluntary basis, as well as from the 
pharmaceutical industry on an obligatory legal basis. (Major, 2002 , Cox 
et al., 2004a).   
• In 1968, ten countries supported a spontaneous reporting system for 
ADRs and took the decision to collaborate and, so, joined the WHO pilot 
Research Project for IDMP.  
• In 1971, a resolution of the Twentieth World Health Assembly (WHA) laid 
the foundations for the WHO IDMP (WHO, 1971 , Van Grootheest, 
2003). 
• In 1972, a report was published that formed the basis of the current 
international system of national centers collaborating in the WHO 
programme (WHO, 1972 , Van Grootheest, 2003).     
• In 1973, a resolution was passed by the WHA supporting the report and 
underlined the importance of exchange of information on ADRs (Kees 
van Grootheest et al., 2004).  
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• In relation to the monitoring of drug safety, the MOH or its equivalent in 
any country can provide reports of suspected ADRs due to healthcare 
and should ensure that professionals are aware of how to recognize and 
report such ADRs events.  
• It has been shown that ADRs management requires all the professionals 
in healthcare to be involved and ready to report. Consequently, all 
physicians, dentists, pharmacists, nurses and General Practitioners (GP) 
whether they work in government hospital or private hospitals who detect 
unwanted and unexpected ADRs should report them (WHO, 2002a).  
• All MOH or other Pharmacovigilance centres receive and accept all the 
ADR reports to build a useful ADRs database, even for  reports of 
suspected ADR, serious ADR or not.  
• Based on the awareness and a good knowledge for ADRs reporting, the 
healthcare professionals (physicians, pharmacists and nurses) require   
training as to how and what to report. Also, staff training should include 
those in the MOH, the Pharmacovigilance centre and other areas 
concerned with ADRs reports and who have experience in 
understanding, assessing and analysing reports (WHO, 2000). 
Furthermore, there are separate schemes for specialist types of ADR 
reactions, for example, in the UK, in their teratology service in Newcastle 
(UK). There is also a special scheme for children in Australia for HIV and 
birth defects for babies by specialist centres (Hughes et al., 2002).  
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1.2.10 Reporting form   
 The ADRs reporting form is considered to be a cornerstone as it plays a 
vital and essentially important role in detecting the early stages of ADRs. For 
examples of different types of ADRs forms (see Appendix 8.2).  
 These forms facilitate the accumulation of accurate data about suspected 
ADRs in Pharmacovigilance centres, MOH and drug regulatory authorities. 
Cobert and Briton (2002) suggested there were several types of forms: 
• Forms for all reactions from all products 
• Specialist forms for use in teratovigilance and maternal surveillance 
centers. 
• Specialist forms for other product categories such as: vaccines, medical 
devices and blood products. 
• Specialist forms by ‘organ system’ such as: for renal function, hepatic 
function, and dermatology and cardiology problems. 
 
1.2.11 The Yellow Card Reporting in UK 
 The thalidomide tragedy of a drug which was first marketed in Germany 
in 1956, and later, in 1958 in the UK, resulted in a number of babies being born 
with congenital malformation of limbs (Phocomelia). In 1961, the drug was 
finally withdrawn in both Germany and UK and many other countries over a nine 
month period. So, the UK established a drug regulation system to monitor the 
safety of medicines in the early 1960s (BMA, 2006).  
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 In May 1963, as a direct consequence of the thalidomide tragedy, the 
Committee on Safety of Drugs (CSD) was established. The Committee on 
Safety of Drug was superseded by CSM from September 1971. Later it became 
the Commission on Human Medicines (CHM) dedicated to collecting and 
distributing data related to suspect ADRs (Griffin, 1992 , Patel and Worell, 
1991).  
 In 1964, the then chairman of CSD, Sir Derrick Dunlop, circulated a letter 
(see Appendix 8.3), to all doctors and dentists in the UK about the introduction 
of a spontaneous reporting scheme. The letter informed them that registration of 
ADRs was a responsibility of every member of the medical/dental profession in 
the UK, asking for reports of  
 "Any untoward conditions in a patient which might be the result of drug 
treatment" 
 The letter enclosed a small supply of yellow business reply-paid 
postcards for this reporting to be sent back to the committee and these were to 
be treated with completely professional confidence. This spontaneous reporting 
scheme in the UK soon became known as "Yellow Card" (Figure 7) and is still, 
in 2012, the cornerstone of the UK's monitoring process (Davis and Raine, 2007 
, Griffin, 1987).   
 In 1967, ADR reports started to be saved in a database and doctors and 
dentists received the first confidential feedback which Medicines and Healthcare 
products Regulatory Agency (MHRA) and CSM developed into the YCS, an 
initiative based on multiple reporting.  
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  In 1971, the CSM modified the Yellow Card by requesting more 
information in this version and encouraged the reporting of ADRs. The aim of 
this scheme was to focus on certain medicines that needed intensive monitoring 
(Metters, 2004). 
 In 1980, four "Regional Monitoring Center" (RMC) were introduced to 
provide and run the YCS in Merseyside, the Northern region, Wales and the 
West Midlands. The Fife centre in Scotland was added in 2002 (Davis and 
Raine, 2007). 
 In 2003 the UK, MHRA was formed from a merger of the MCA which was 
to safeguard public health and ensure that all medicines on the UK market met 
acceptable standards of safety and efficacy (Davis and Raine, 2007).   
 
The rules of the Yellow Card Scheme by Sir Derrick: (Davis and Raine, 
2007) 
1. They should be used to report any ADRs. 
2. Responsibility reporting for all Doctors and Dentals. 
3. Immediate reporting. 
4. Confidentiality was most essential for information in all reports.  
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The MHRA, is responsible for the vigilance, risk management and monitoring of 
the safety of all licensed medicines in all UK. They also had to identify and 
investigate possible hazards and take appropriate action to minimise the risks 
and maximise the benefits to users, thus protecting public health (Waller et al., 
1998). Sir Derrick Dunlop’s ideas showed the importance of reporting any 
suspected cases or concerns regarding ADRs and examples since 1995 are 
shown in Table 7.  
Reporting ADRs via this scheme to MHRA is voluntary for all healthcare 
professionals but compulsory in the pharmaceutical industry.  
Figure 7: Yellow Card as used by the Regional Monitoring Center (MCA) 
(Source: WWW.MHRA.COM) 
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Year Medicine Adverse reaction Resulting action 
1995 Tramadol (Zydol ▼ ӿ) Psychiatric reactions Warnings 
1995 Cyproterone acetate 
 ( Cyprostat, Androcur) 
Dose-related hepatotoxicity Restricted indications, 
requirement for monitoring of 
liver function 
1995 Quinolone antibiotics Tendinitis, tendon rupture Improved warnings 
1995 Tacolimus (Prograf ▼ӿ) Hypertrophic cardiomyopathy Warnings, dose reduction and 
monitoring requirements 
1996 Alendronate (Fosamax▼ӿ) Sever oesophageal reactions Warnings, and revised dosing 
instructions 
1997 Clozapine (Clozaril) GI obstruction Improved warnings 
1997 HIV protease inhibitors hyperlipidemia and fat 
redistribution 
Improved warnings and 
monitoring recommendations 
1998 Isotretinoin (Roaccutane) Psychiatric reactions Improved warnings 
1998 Sertiondole (Serdolect ▼ӿ) Sudden cardiac death Drug withdrawal ӿ ӿ 
1999 Aristolochia in Chinese 
herbal remedies 
Renal failure Aristolochia banned 
1999 Human clottable protein 
concentrate(Quixil▼ӿ) 
Fatal neurotoxic reaction 
following unlicensed use in 
neurosurgery 
Improved warnings 
2000 Cisapride 
(Prepulsid,Alimix) 
Serious cardiovascular reactions Use of Cisapride suspended in 
the UK ӿ ӿ ӿ 
2001 Bupropion(Zyban▼ӿ) Seizures Improved warnings and 
revised dosing instructions 
2003 Kava-kava Hepatotoxicity Supply of Kava-kava 
prohibited in the UK 
  
ӿ Black Triangle (▼) drug at the time the major safety issue was identified. 
ӿӿ Sertindole was reinstated in 2002 with increased warning.  
ӿӿӿ Crisapride licenses have been cancelled. 
 
 
 
Table 7: Some major safety issue identified through the Yellow Card 
Scheme (source - Metters, 2004) 
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1.2.12 Advantages of the Yellow Card Scheme 
The main major advantages of the system are (Mann 1987): 
1. It operates for all drugs given to all patients from the first stage of 
marketing of a drug in the UK to the end of the drug's life. 
2. It is inexpensive to operate.  
 
1.2.13 The Main Uses of the Yellow Card Scheme (YCS) 
The Major uses of the YCS have been defined by (Roberts, 1992 , Anon, 1983) 
as: 
A. It has successfully provided "early warning” of a number of drug hazards. 
Examples include:  
• Oesophageal ulceration with emepronium bromide 
• Deafness with topical neomycin 
• Blood dyscrasias with mianserin. 
 
B. A Yellow Card provides information about the patient and an analysis of 
the data can lead to characterisation of iatrogenic syndromes. Examples 
of where the YCS has achieved this include nitrofurantoin induced 
esoinophillic pulmonary reactions and hepatotoxicity induced with 
ketoconazole   
C. Analysis of the YCS data can show comparative toxicity within 
therapeutic groups. 
D. Provides continuous monitoring of drug safety.   
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1.2.14  Reporting ADRs  
          Based on the WHO, (2002a) and British Medical Association (BMA), 
(2006) reports, any problem of ADRs or suspected cases resulting from 
prescriptions medicines, herbal remedies and Over the Counter (OTC) 
medications should be reported using a yellow Card. The following reasons are 
examples of what should be reported: 
“New marketing” drugs. For any new drug the healthcare professionals 
are encouraged to report all suspected ADRs which occur from use of 
this product.  
All drugs irrespective of date of introduction 
Observed reactions if a report frequency increased. 
All suspected ADRs serious or unexpected should be reported.  
 
 All suspected serious reactions for new or old drugs must be reported via 
the YCS. Any ADR, which leads to one of the following reaction, fatal, life-
threatening, disabling or incapacitating, and results in or prolonged 
hospitalisation or congenital abnormalities or medically significant, is called 
serious. There is no doubt some drugs are effective but have a low safety value; 
therefore, the relative safety of medicines in the same therapeutic class should 
always be compared by doctors. Which relate to? 
• Drug-drug interactions or drug-food interactions (including herbal 
and complementary products).  
• Special fields of interest such as drug abuse and drugs use in 
pregnancy and during lactation.  
• Drug withdrawals.  
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• Occurring from overdose or medication errors.   
• When any pharmaceutical defects are observed or when there is a 
lack of efficacy. 
 
A list of the types of serious reactions, according to the therapeutic area given 
by the CSM: 
 
ADRs in Children: 
        The monitoring of drug safety is very important for this age group. The 
reason for this is that children are rarely involved in clinical trials and many 
drugs are used on children even if they are not  licensed for this purpose.  
 Therefore, the MHRA asks that all suspected ADRs, occurring in children 
under the age of 18, should be reported regardless of whether the medications 
are licensed for use in children. In 2005, the first British National Formulary for 
Children (BNFC) was launched which gives practical information to help 
healthcare professionals who prescribe, monitor, supply and administer 
medicines for childhood disorders.    
 
ADRs in the elderly: 
        The elderly may be more susceptible to ADRs because of taking multiple 
medicines or by a poor or ineffective metabolism and/or excretion. Therefore, 
healthcare providers should be aware of reporting any ADR experienced by 
elderly. 
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Delayed drug effects: 
      The appearance of some ADRs may be delayed for months or years after 
exposure. Any suspicion of such an association should always be reported to by 
MHRA. 
 
Pregnancy and congenital abnormalities: 
         For all women who have an ADRs during pregnancy, or have a baby with 
a congenital abnormality or an aborted foetus and it is suspected to be due to 
that an ADR, a Yellow Card should be submitted including all information about 
medications taken during pregnancy.  
 
1.2.15  Who actually reports ADRs 
 At its introduction, the YCS only allowed doctors and dentists to make 
reports. Today (2012), all Health Care Professionals including; coroners, 
pharmacists and nurses working in the NHS and private health providers, 
patients and the pharmaceutical industry are  eligible and encouraged to report. 
 
1.2.16  Elements of the report form  
 A case report form should contain information on the following elements 
which need to complete (WHO, 2000) (WHO, 2002a): 
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1. Patient information: 
• Patient identifier. 
• Age at time of the event or date of birth.  
• Gender. 
• Weight.  
 
2. Adverse event or product problem:  
• Description of event or problem (nature, localization, severity, 
characteristics). 
• Date of event. 
• Date of this report. 
• Relevant tests/laboratory data (if available). 
• Other relevant patient information/history. 
• Outcomes attributed to the adverse event. 
 
3. Suspected medication(s): 
• Name (ingredient name and brand name) and manufacturer. 
• Dose, frequency & route used. 
• Therapy date. 
• Indication for use. 
• Event abated after use stopped or dose reduced. 
• Batch number. 
• Expiry date. 
• Event reappeared after reintroduction of the treatment. 
• Concomitant medical products and therapy dates. 
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4. All other drugs used (including self-medication): 
• Names. 
• Doses and routes. 
• Start and stop date. 
 
5. Risk factors: 
• Impaired renal function. 
• Previous exposure to suspected drug. 
• Previous allergies. 
• Social drug use. 
• Others. 
 
6. Reporter: 
• Name, address and telephone number (to be considered confidential and 
to be used only for data verification, completion and case follow-up). 
• Specialty and occupation. 
 
1.2.17 How to report and what happens after that: 
 Healthcare providers should complete all the information on the Yellow 
card. It is better to inform the patients after submission of a report and keep a 
copy of the report in the patient's notes. After that, the completed report should 
be submitted to either the MHRA directly or to one of five RMC(s) which will 
pass the report on the MHRA.  
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 The receivers in MHRA will send an acknowledgment to the reporter, 
remove information that identifies the patient and give the report a special 
identification number. The report will be scanned into the MHRA 
Pharmacovigilance database that facilitates the monitoring of ADRs and allows 
a rapid analysis of the report. If the MHRA needs any clarification about the 
report, the reporter may be asked for more details. 
 When the report is send by patients it will be entered on the MHRA 
databases and be considered in the context of all the other reports received 
from patients or healthcare professionals for that medicine. What is more, the 
MHRA sanctions the use Yellow Card information to detect "signaling" of 
emerging drug-safety problem.  
 They assess the causality and identify possible risk factors contributing 
to the reaction. In this period, checking data from other source(s) may also be 
referred to. These are: 
• Case reports in the literature. 
• Pre and post- marketing clinical trials. 
• Epidemiological studies. 
• Recorded-linkage databases. 
• Data from other drug regulatory authorities.  
 
 When safety hazards are recognized, the overall ADR profile for the drug 
is compared with the relevant therapeutic alternatives and its benefits in terms 
of efficacy, the therapeutic indications and the target patient populations. The 
CHM and its Pharmacovigilance Expert Advisory Group (PEAG) advise the 
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MHRA on the drug safety. After that, decisions as to, restrictions in use, 
reductions in dosage, special warning and precautions or even withdrawal of 
the product from the market when its risks are more than its benefits, can be 
made.  
 A study of 583 new active substance registered in UK between 1972 and 
1994 showed that 24 substances were withdrawn for a variety of reasons; 22 
(3.8%) of these substances were withdrawn because of safety ,one because of 
quality and another because of a lack of efficacy (BMA, 2006).  
 The accessibility of Yellow Card is easy as it is provided in many 
‘sources’. For instance, paper Yellow Cards are available by writing to either the 
MHRA or one of the RMC, and can also be found in copies of the British 
National Formulary (BNF), the Nurse Prescribers' Formulary (NPF), the Monthly 
Index of Medicine Specialties (MIMS) companion and from the Association of 
the British Pharmaceutical Industry (ABPI) Compendium of Data Sheets and 
Summaries of Product Characteristics. Electronic Yellow Cards were introduced 
in 2002 and can be downloaded from either the MHRA or the RMC websites 
www.yellowcard.gov.uk (BMN, 2006).  
 When the information from reporting is insufficient, it is referred to as 
‘reported information on a possible causal relationship between an adverse 
event and a drug, the relationship being unknown or incompletely documented 
previously’. Accordingly, more than a single report is required, based on the 
seriousness of the event and the quality of the information, to make a decision 
about the drug's future (WHO, 2002a). 
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1.2.18 The rate of reporting through the Yellow Card in the UK 
 Since the commencement of the YCS in 1964, the MHRA and the CSM 
have received over half a million reports from healthcare professionals directly 
through the scheme or indirectly via pharmaceutical companies. Some of these 
reports have been for serious ADRs that required urgent action, and others 
were less serious. Overall, the number of reports that are received annually has 
progressively increased since the introduction of the scheme. However, not all 
years have had the same level of reporting.  Notable increases in reporting 
have being seen in particular years.  
 For instance, in the mid-1970s, ADR reporting increased due to a)the 
withdrawal of practolol following its association with oculomucocoutaneous 
syndrome, b)the introduction of the CSM drug safety bulletin highlighting current 
problems in Pharmacovigilance and the inclusion of a yellow page on the GP 
prescription pads, reminding them to report ADRs. A further increase in Yellow 
Card reports is thought to have resulted from the increase in availability of 
Yellow Cards for doctors, following their inclusion in the BNF which is supplied 
to all doctors and in prescriptions pads.  
 On the other hand, in the early 1990s ADR reporting declined from over 
20,000 to approximately 17,000. The reasons for this decrease were the 
reduction in the number of Yellow Cards submitted on forms included in the GP 
prescription pads, perhaps as handwritten prescriptions were replaced by 
electronic versions due to an increased use of computerized practice systems. 
There were also the progressively increasing demands placed on doctors time 
and concerns over confidentiality which may have caused a reduction. 
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 As a result of the meningitis C vaccination campaign for all children in the 
UK under the age of 18 years, another dramatic rise in the number of ADR 
reports (over 33 000 reports) occurred in 2000.  
 In 2003 and 2004, the number of reports increased because of the formal 
introduction of midwives and health visitors and electronic reporting in 2002 
(Davis et al., 2007). 
 
1.2.19  Disadvantages of Yellow Card Scheme (YCS)  
 In 1976, Dr. Bill Inman, the pioneer the YCS, described the following 
"seven deadly sins" that may hinder the reporting of ADRs: (BMA, 2006)  
1. Ignorance - I am unsure how to report).  
2. Diffidence - I may appear foolish about reporting a suspected 
ADR. 
3. Fear - I may expose myself to legal liability by reporting an ADR. 
4. Lethargy - I am too busy to report an ADR.  
5. Guilt - I am reluctant to admit I may have caused harm. 
6. Ambition - I would rather collect cases and publish them. 
7. Complacency - Only safe drugs are marketed. 
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1.3 Major barriers for the Improvement of ADR reporting  
 The major obstacle to reporting ADRs is the lack of reporting forms 
(Lucas and Colley, 1992).  This was revealed by WHO in 2000 and 2002 and so 
all countries which try to use ADRs forms have developed special methods 
which make the process as easy as possible. For example:- 
1. Some countries have included report forms in their national formularies such 
as the BNF. In addition, some other books have a form in the reference 
section. Inclusion in prescription pads, drug safety bulletins or professional 
journals may also be effective when submitting.  
2. Technological methods for sending or replying reports using telephone, fax, 
electronic mail or the Internet (Hughes et al., 2002) have made the reporting 
of ADRs more convenient.  
3. User-friendly forms which can be submitted by freepost to the 
Pharmacovigilance centre have to lead increasing ADRs reporting. (WHO, 
2000) (WHO, 2002a).  
I mentioned previously the crucial importance of ADRs reporting for the 
reduction of morbidity and mortality rates of drugs post-marketing. Many studies 
have collected evidence that the barriers to reporting for most healthcare 
workers are very similar.  
 Lumley et al (1986) conducted a study to measure the number of ADRs 
seen by GP and which were recorded. The most common reasons given for not 
reporting were that: a) the ADR was expected b) the ADR was well known, c) 
the ADR was considered too trivial, d) the doctor was uncertain if it was a true 
ADR and e) combinations of these considerations (Lumley et al., 1986).  
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 Zoleei and Parostam (2005) and Molokhia et al. (2009) have shown how 
the barriers to an improved monitoring and reporting of ADRs have been 
analyzed in various studies and can be summarized as:    
• Fear of personal and organizational liability.   
• Lack of resources for surveillance and for reporting.   
• Labor-intensive, complex and time-consuming reporting processes.   
• Ambiguity in interpreting whether the medication was the actual cause of 
the adverse event.   
• Minimal feedback provided to reporters.    
• No incentives, rewards, or motivation to report.   
• Lack of knowledge and confidence to distinguish between significant 
ADRs and minor ones. 
• Surveillance and reporting functions without a leader.  
  
To improve ADRs reporting and achieve a more positive attitude toward 
Pharmacovigilance by pharmacists some recommendations are:  
• Motivate pharmacists to report ADRs by overcoming potential barriers to 
ADRs reporting improve their ADR detection skills and participate more 
actively in ADR prevention and management strategies.  
• Training pharmacists on how to submit ADRs reports is essential.  
• Important to provide continuous education for the  ADRs reporting 
programme so as to sustain  successful ADRs reporting  
• To improve the ADRs reporting rate; raising the availability of the ADRs 
forms and encourage the use of web-based reporting.  
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• Extracting information from questionnaires, chart reviews and patient 
interviews have proved very useful. 
• The data quality and statistical methods in ADRs reporting databases 
were other important factors found to be very useful in the detection of 
ADRs signals, hence improving ADRs reporting. 
• To improve the quality of reports by simplification of terms on the ADRs 
by improving homogenous coding.  
• To identify potential ADRs by combing patients review with computerized 
monitoring systems in hospital may lead to improvements in ADRs 
reporting. 
 
 Finally, the use of powerful computers will improve the efficiency and 
accuracy of ADRs reporting by early detection of ADRs. In addition, the use of 
electronic health data with other methods for ADRs reporting may help them not 
only to achieve better ADR reporting rates, but to improve the quality and safety 
of medication use by their patients (Molokhia et al., 2009, Zolezzi and 
Parsotam, 2005). 
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1.2.20 Aims and Objectives  
 This thesis evaluates the role of the pharmacist and other health care 
professional in Adverse Drug Reaction (ADR) Reporting in the Holy City of 
Makkah, Saudi Arabia and to assess attitude and awareness towards ADR 
reporting and factors that influences reporting by health professionals. The 
results of such finding will be utilized to initiate the improvement of healthcare 
system that promotes patient safety. The objectives of this thesis will be: 
• To determine and appraise the role of pharmacist and other health care 
professional in the Holy City of Makkah and also their present attitude 
knowledge and awareness of ADRs reporting. 
• To conduct questionnaires among health care professional in the Holy 
City of Makkah in order to assess their awareness of ADRs reporting and 
find factors that influence their reporting.  
• To conduct questionnaires among community pharmacists in the Holy 
City of Makkah in order to assess their awareness of ADRs reporting find 
factors that influence their reporting.  
• To extrapolate from results of ADR reporting a justification to implement 
safer healthcare system for the Hajj time by healthcare professionals and 
community pharmacists. 
• To find means to improve constrains of ADRs reporting that will promote 
healthcare systems and rate of ADRs reporting 
• To make interviews with 7 chief pharmacists in the Makkah 7 hospitals to 
study the sequential mixed method between the quantitative 
Questionnaires for healthcare professionals in the Makkah 7 hospitals 
and focus points extracted from reviews. 
• To focus on promoting awareness of future generation of pharmacist by 
giving questionnaire following an introductory lecture on 
Pharmacovigilance for undergraduate pharmacy student pharmacists in 
the 3rd and 4th year of the pharmacy degree to get their interest in 
introducing in introducing a course discuses pharmacovigilance concept. 
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Chapter Two 
2 Literature Review 
 The pharmaceutical literature contains many peer reviewed articles 
about how pharmacists can play a major role in making sure all medications 
they dispense are both safe and effective. In a sense, they have not been 
adequately prepared for this role as, in their undergraduate degree; the topic of 
ADRs may have received very little consideration. More should be done 
perhaps to explain to pharmacists how they can work in co-operation with 
physicians to ensure the relationship between adverse events and drugs is 
firmly established. (van Grootheest et al., 2004) 
 In contrast to the undergraduate experience there are many ways for 
pharmacists who practice both in the community and hospitals to show how 
they can positively contribute to providing a major role in the safe use drugs 
(Van Grootheest and de Jong-van den Berg, 2005 , Zolezzi and Parsotam, 
2005).  
 
2.1 The different roles of the pharmacist:  
 The modern key role of pharmacists, irrespective of where they practice 
pharmacy, is that their knowledge of drugs defines their professional activities in 
such areas as, dispensing of drugs, drug information and sometimes quality 
control, and this markedly contrasts with their traditional role of the preparation 
of drugs from raw materials which is now only a minor part of the pharmacist's 
responsibility throughout the world. (Kees van Grootheest et al., 2004).  
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 But returning to the topic of ADRs , Johnston et al., (1995) published in 
the American Society of Health System Pharmacists, an article entitled "ASHP 
guidelines on ADRs monitoring and reporting" They suggested that all 
pharmacists should exert leadership in the development, maintenance, and 
ongoing evaluation of ADR programs and work in collaboration with other 
members of the healthcare team. The suggested roles of the pharmacist should 
be such so as to facilitate: 
• analysis of each reported ADR, 
• identification of drugs and patients at high risk for being involved in 
ADRs, 
• the development of policies and procedures for the ADR-monitoring and        
reporting program, 
• a description of the responsibilities and interactions of pharmacists, 
physicians, nurses, risk managers and other health professionals in the 
ADR program, 
• using the ADR program for educational purposes, 
• development, maintenance, and evaluation of ADR records within the 
organization, 
• the organizational dissemination and use of information obtained through 
the ADR program, 
• reporting of serious ADRs to the FDA or the manufacturer (or both), and 
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• Publication and presentation of important ADRs to the medical 
community.  
• direct patient care roles for pharmacists should include patient 
counseling on ADRs,  
• identification and documentation in the patient’s medical record of high-
risk patients,  
• monitoring to ensure that serum drug concentrations remain within 
acceptable therapeutic ranges,  
• Adjusting doses in appropriate patients e.g. patients with impaired renal 
or hepatic function (Johnston et al., 1995).  
From all these points it can be seen that the pharmacist is central to the process 
of ADRs and a more comprehensive account of such roles now follows. 
 
2.2 The first role of pharmacist is: 
2.2.1 As a dispenser of drugs 
 In the recent past, the image of the traditional role of the pharmacist was 
that of someone who dispensed drugs prescribed by a physician and ensured 
that these drugs meet the required standard(s) (Kees van Grootheest et al., 
2004). Many practitioners took this view as a role befitting pharmacists.  Then, 
in 1980 (Moss et al., 1980) suggested that the traditional role should be 
supplemented with a responsibility for the prevention, identification, 
documentation and reporting of ADRs. This was thought possible as 
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pharmacists understood that no drug is absolutely safe (Van Grootheest and de 
Jong-van den Berg, 2005 , Zolezzi and Parsotam, 2005). In several countries, 
the further development of computerisation led, not only to a greater 
awareness, but also made action on ADRs a possibility (Kees van Grootheest 
et al., 2004).    
 
2.2.2 As a drug consultant 
 This role is mainly undertaken by hospital pharmacists, which have led to 
their contribution in the Pharmacotherapeutic care of patients. They are 
currently recognized, as experts on drugs and some even have consultant 
status in the NHS, showing clearly their knowledge and abilities. In some 
countries, such as USA, hospital pharmacists have an explicit coordinating role 
when hospitals wish to report adverse events. In the Netherlands, pharmacist 
status of co-consultant also facilitates such a process. 
 
2.2.3 As a "substitute doctor" 
 There are many reasons why a pharmacist could be called a "substitute 
doctor". In some parts of the world there is an acute shortage of doctors, a high 
cost of health care and large distances to be traveled by patients so they will 
consult their nearest pharmacy or pharmacist for assistance.  
 Against this background, ADR reporting has been widely discussed in 
the literature (Green et al., 1999a). The significant element of 
Pharmacovigilance is "the spontaneous reporting", and in this regard hospital 
pharmacists can play a significant role in the reporting of suspected ADRs to 
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improve overall Pharmacovigilance (Lee et al., 1997). Many ADRs happen in 
hospitals where challenging therapies stress the balance between the benefits 
and risk of medicines (Van Grootheest and de Jong-van den Berg, 2005 , 
Zolezzi and Parsotam, 2005).  
 50 years ago Annex (1965), studied the form used for the reporting of 
ADRs and there was an allowance for the pharmacist to act as a reporter. Such 
information and data provided originally by pharmacist has been considered 
elsewhere (Esch, 1972).  
 Fourteen years later Inman (1986) devoted a chapter of his book on the 
role of pharmacists in monitoring for drug safety but, in many textbooks of the 
day about Pharmacovigilance, little interest was shown to the role of the 
pharmacist (Inman and Gill, 1986). Three years later Fincham (1989), 
commented in his article "Adverse Drug Reaction Reporting and Pharmacists" 
that the exclusion of pharmacists simply did not make sense (Fincham, 1989). 
This was substantiated by Lindquist and Edwards (1993) who stated that 
“Pharmacist who advise patients directly are the most likely to detect adverse 
reactions" (Lindquist and Edwards, 1993). A year later, Roberts et al. (1994) 
concluded that pharmacists in other countries were to be encouraged to 
participate in ADR reporting , as a procedure that could only lead to better 
patient care (Olsson, 1999). 
 Ahmad et al (1996) remarked, in  his study entitled  "Quality of adverse 
drug experience reports submitted by pharmacists and physicians to the FDA", 
that the results showed essentially no difference in a subjective assessment of 
the quality of information in the Adverse Drug Event (ADE) reports submitted  
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by  physicians  or pharmacists  whether  the reports  were  submitted either 
directly or via  manufacturers. The study also showed that hospital pharmacists 
submitted high quality ADE reports to the FDA, and thereby played an important 
part in protecting public health by promptly reporting serious adverse events 
using the ADE reporting system (Ahmad et al., 1996). 
 WHO in 2000 issued a report by the UMC referring to the pharmacist in 
"Guidelines for Setting Up and Running a Pharmacovigilance Center" (WHO, 
2000). In 2002 they also issued a study entitled "Safety of Medicines. A guide to 
detecting and reporting adverse drug reactions” in which pharmacists were 
included with family medical specialists and practitioners (WHO, 2002a).  
 A further report in 2002 entitled the “Importance of Pharmacovigilance: 
Safety Monitoring of Medical Products", (subtitled "health professionals"), did 
not specifically mention pharmacists but rather commented on "inviting reports 
from all professionals involved the care of patients will it be possible to detect 
the full spectrum of complications related to pharmaceutical treatment" (WHO, 
2002a). In the world literature little information directly related to the role of 
pharmacists in ADRs reporting was found.  However the limited information 
obtained did give an overview of countries where pharmacists were involved in 
ADR reporting. 
 In a groundbreaking study by Griffin and Weber (1986), they published a 
survey of spontaneous ADR reporting systems and pharmacists' involvement in 
16 countries.  At that time, many countries had accepted pharmacists reporting 
ADRs as such: Australia, Belgium, France, West Germany, Ireland, NZ and the 
USA. In Japan, ADR reports were accepted from hospital-based pharmacists. 
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Only in Denmark, Finland, Netherlands, Sweden, and the UK, were 
pharmacists, at that time, excluded from supplying ADR reports, unless the 
reports were first funneled through physicians (Griffin, 1986), although, since 
then, all of these countries have implemented ADR reporting by pharmacists. 
 Van Groothesst et al., (2004) in their paper entitled "Pharmacists' role in 
reporting adverse drug reactions in an international perspective", the role of 
pharmacist ADRs reporting was found not to be appreciated everywhere. As an 
extreme example of this role, they showed that there were many ways the 
pharmacists could contribute immensely to drug safety and play a prominent 
role in ADR reporting. For example, in most countries that participated in the 
WHO Drug Monitoring programme pharmacists’ reports were accepted. They 
indicated that the pharmacists' reports were of substantial major significance 
and that the reports were generally highly valued.  
 In many countries such as the UK, USA and Canada, hospital 
pharmacists could also report ADRs. Pharmacists' reporting in Australia, 
Canada, the Netherlands and the USA was favourably commented on for its 
high quality which signiﬁcantly improved both the quantity and the quality of the 
reports on ADRs worldwide (Kees van Grootheest et al., 2004).  
 In Scandinavia, (i.e. Finland, Norway and Sweden) pharmacists were not 
allowed to report ADRs due to legislative restriction or lack of tradition to do so.  
But some pharmacists in Scandinavian countries were encouraged to play a 
greater role in reporting of ADRs, for example, Norwegian pharmacists whose 
roles in reporting were recognised by the Norwegian Medicines Agency and, 
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thus, have been able to report since 2005 (Kees van Grootheest et al., 2004 , 
Granas et al., 2007).  
 According to a WHO survey in 1999, ADR reporting by pharmacists was 
not practised in the following countries: Denmark, Iceland, Estonia, Indonesia, 
Vietnam, the Czech Republic, Rumania and Slovakia (Olsson, 1999). However, 
in Italy, the UK and Oman, it was stated that it was common practice to accept 
pharmacists' reports. In several countries, such as France, Italy and Spain, the 
reporting of ADRs is mandatory, including that of pharmacists (van Grootheest 
et al., 2004).  
 Intuitively, one might expect that the more highly trained and qualified a 
pharmacist was, the more likely the pharmacist would be involved in ADR 
reporting.  However, (van Grootheest et al., 2004) stated that they were unable 
to ﬁnd any relationships between the level of training or understanding of the 
profession of pharmacy and the fact whether or not pharmacists were allowed 
to report. A further complexity is found in Sweden, where nursing staff are 
permitted to report, whereas pharmacists are not (Westerlund, 2002). In 
Finland, despite pharmacists being highly trained and qualified they not are not 
allowed to report ADRs on grounds of cost effectiveness (Saarinen, 2002). 
Other countries, such as Cuba, Ireland, the Netherlands and Singapore, have 
recently initiated strategies to more closely involve pharmacists in ADR 
reporting. In Norway, pharmacists' ADR reports, particularly for OTC 
medication, are accepted, even though this does not happen in a systematic 
manner (Grootheest and Puijenbroek, 2007 , Debesa et al., 2002). 
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2.3 The Pharmacist as an ADRs reporter 
 A fundamental role of pharmacists is to ensure that medications are 
dispensed and used effectively and safely. The contribution of pharmacists to 
both the quantity and quality of ADR reports has recently been recognized and 
this could lead to important improvements in ADR reporting and hence benefit 
patients while enhancing the value of the available evidence base about trends 
in drug safety (Rouleau et al., 2011). In addition, some studies have shown the 
significant roles of hospital and community pharmacists toward ADRs reporting 
and the quality of their reports is sufficient to contribute to the system's success 
so increasing public safety (Ahmad et al., 1996 , Van Grootheest et al., 2002b).  
 However, in some countries where pharmacists are allowed to report, 
their contribution to the system is negligible or non-existent. Although there are 
differences both with respect to the attitude of the various national spontaneous 
reporting systems towards the pharmacist and to the perception of the function 
of the profession in society, it is clear that the role of the pharmacist is 
changing. Fundamental to the pharmacist’s role is to ensure that medicines are 
used safely (Van Grootheest et al., 2002a).     
 There is ample evidence that shows that the pharmacist is both willing 
and capable of fulﬁling the role of a reporter of ADRs. The traditional standard 
practice of preparing and dispensing drugs is increasingly being extended to 
also include pharmaceutical care. In this context, several countries are 
considering the possibility of authorising the pharmacist to write certain 
prescriptions such as repeat prescriptions (Ahmad et al., 1996, (Green et al., 
2001), (Kees van Grootheest et al., 2004).  
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 Evaluating the contribution of pharmacists to ADR reporting from a 
quantitative perspective reveals that, in each of those countries where ADR 
reporting by pharmacists have been established for 20 years or more, over 
1000 reports were initiated by pharmacists in 2001 (Kees van Grootheest et al., 
2004). These countries were: Australia, Canada, France, Japan, the 
Netherlands, Spain, the UK and the USA.   To this list, Chile can be added as 
having a high volume of ADR reporting initiated by pharmacists although the 
inclusion of pharmacists has been more recent.  Analysing these figures as a 
proportion of total ADR reports is not always possible, as reports are either 
received directly from health professionals or else are submitted by the 
pharmaceutical industry.  Reports from the pharmaceutical industry do not 
always reveal the original source, so pharmacist-initiated reports may be under-
represented.  Bearing this in mind, the countries with the highest proportions of 
pharmacist-initiated reports were: Canada (88.3%), Australia (40.3%), the 
Netherlands (40.2%), Japan (39%), Spain (25.9%) and Portugal (23.4%).  
 In the Netherlands, where, as mentioned above, 40.2% of ADRs 
reporting was submitted by pharmacists (Van Grootheest et al., 2002b), has led 
to the award of  pharmacists receiving the official status of co-consultant. 
Pharmacists are authorised to access patient ﬁles, which allows them the 
opportunity to become more actively involved in patient treatment and 
Pharmacovigilance. (Ahmad et al., 1996, (Green et al., 2001), (Kees van 
Grootheest et al., 2004). 
  In Australia the total number of ADR reports from pharmacists has 
increased steadily as in 1992 there were around 30% of total ADR reports from 
both hospital and community pharmacists. It is of interest to note that 75% of 
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these reports were made by hospital pharmacists The quality of reports 
submitted by hospital pharmacists has been acknowledge by Adverse Drug 
Reaction advisory committee (ADRAC). Hospital pharmacists can make a 
valuable contribution to the reporting scheme since many of the most serious 
ADRs occur in hospitals or as a result of hospitalisation (Rohan, 1992 , Low, 
1993). 
 From a qualitative perspective, it was noted in (Kees van Grootheest et 
al., 2004), that all the countries where high volumes of phamacist-initiated 
reports were recorded, high quality of reporting was also recorded.  However, 
the authors issue a note of caution about the subjective nature of both quality 
and significance ratings. The study attempted to differentiate between hospital 
based and community based pharmacists in its analysis.  It was found that most 
of the reports submitted in Japan, the Netherlands and Portugal wre initiated by 
community pharmacists, whereas hospital pharmacists were responsible for the 
majority of reporting in all other countries. Particular note was made of the 
important role played by Dutch pharmacists in the establishment of a national 
reporting system.  Finally, it was concluded that there were wide variations in 
the contribution of hospital pharmacists in different countries, whilst in the USA 
and Canada, hospital pharmacists were actually responsible for the ADR 
reporting by the hospital.  
 Against this background, the Society of Hospital Pharmacists of Australia 
(SHPA) Standards of Practice for Clinical Pharmacy now includes guidelines in 
ADR management. These guidelines state that clinical pharmacists should: 
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• Identify and monitor patients who are most susceptible to ADRs. 
• Detect ADRs as part of routine drug monitoring. 
• Encourage other health professionals and patients to report ADRs. 
• Identify patients who have experienced previous ADRs. 
 
 The collection of data and appropriate documentation should be done 
after ADRs are suspected. Subsequently, pharmacists should ensure that all 
medical staff is notified of the ADR, and the ADR report is forwarded to ADRAC. 
Minimizing ADRs can be done by monitoring patients, informing those patients 
who experienced a serious ADR, prudent use of drugs with a high rate of ADR 
and ADR documentation. This direct role and also the coordinating role, both in 
GP and in a hospital setting, can be done by pharmacists (SHPA, 1996). 
 The fact that in many countries most pharmacies are highly 
computerised is important in this context. The argument against direct reporting 
by pharmacists is that their clinical knowledge is limited. On the other hand, one 
could also argue that the knowledge doctors have about drugs is often limited, 
since this aspect is not given sufficient attention during their training (van 
Grootheest and Edwards, 2002). 
  In 1992, the FDA received over 100,000 ADE reports and pharmacists 
were major contributors to these reports. In 1993, the FDA launched 
MEDWatch, a new initiative to enhance direct reporting of adverse events by 
health professionals.  To date, the majority of reports to MEDWatch are from 
pharmacists. The results showed no substantial difference in the subjective 
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assessment of the quality of information in the reports submitted by pharmacists 
or physicians, irrespective of whether these reports were submitted directly or 
via manufacturers. This study suggests that reports from hospital pharmacists 
are valuable and of comparable quality. Ahmad et. al. (1996), stated that “We 
believe that all health professionals contribute to  the success of  FDA’s 
MEDWatch  programme  and  thereby play an important part in protecting public 
health by promptly reporting serious adverse events” (Ahmad et al., 1996). 
 The contribution a pharmacist can make will vary per country and will 
depend on the expertise and the status the profession is given within the 
different health care systems. Cooperation between doctors and pharmacists 
appears to be of vital importance, with each of the two professional groups 
contributing their respective expertise and experience to promote the rational 
and safe use of medicinal drugs (Kees van Grootheest et al., 2004). 
 Rigby, (2010) in his study "Collaboration between doctors and 
pharmacists in the community", makes a strong plea for closer collaboration and 
communication between those who prescribe medicines and pharmacists who 
dispense medication, as an essential feature of good medication therapy 
management. This implies that the traditional distinction between doctors 
(prescribers) and pharmacists (dispensers) is now outmoded and a new 
definition of the pharmacist's role has developed. This newly defined role places 
the pharmacist in a much more central position vis-à-vis the care of the patient 
and this could not be more evident than in ADR reporting by the pharmacist.   
 As the needs of patients change over time, so too, the responses of 
those who work in healthcare need to change. Pharmacists possess the very 
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skills and knowledge that such a changing responsiveness necessitates. These 
include the appropriate use of medicines, the avoidance of misuse of medicine 
and the communication skills to convey to the patient instructions on correct 
management of medication. The success of community healthcare in the future 
depends on close collaboration and communication between pharmacists and 
doctors and other professionals (Rigby, 2010).  
 Davis and Raine (2007), in their textbook entitled ‘Introduction of 
Pharmacovigilance,’ described the role of the pharmacist regarding ADRs 
reporting. They based their description on a number of countries in which 
pharmacists have been recognised as being authorized reporters to national 
reporting Schemes (Griffin, 1986). This is taken further in a study by (Roberts et 
al., 1994), who published data about the role of both hospital and community 
pharmacists in the monitoring and reporting of ADRs, and showed that their 
contributions were valuable.  
 Dr. Edmmund Major (2002), in his article "The Yellow Card Scheme and 
the role of pharmacists as reporters", demonstrated that, in both hospital and 
community settings, pharmacists were in an important and vital position as 
reporters for suspected ADRs, a finding also supported by (Sweis and Wong, 
2000). This eligibility was achieved by: 
• Increasing contact with patients which enabled them to learn of possible 
ADRs and report it, because pharmacists were considered a source of 
reliable information and advice  
• Pharmacists playing a fundamental role as healthcare professionals. 
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• In hospitals, the unique position of pharmacists in identifying and 
reporting ADRs in high volume, new drug use areas such as oncology 
was useful (Major, 2002). 
 
 Lee et al. (1997) had previously commented that RMC played a key role 
in conducting pilot studies into the potential contribution of hospital and 
community pharmacists to the YCS. A pilot scheme for hospital pharmacist 
reporting, conducted by the Northern RMC, showed that, in comparison with 
hospital doctors, hospital pharmacists submitted a higher proportion of reports 
of serious ADRs, and the reports from the two groups were of similar quality. 
Additionally, a survey of consultants whose patients had been the subject of a 
pharmacist report during the pilot study showed a high level of support for the 
continuation of the scheme (Lee et al., 1997). 
 The same study opened the way, in 1997, for extending the YCS to 
permit hospital pharmacists to submit ADR reports in all parts of the country 
(Anon, 1997). In 1999, ADR reports from the previous year were assessed and 
it was found that ADR reports made by pharmacists actually enhanced those 
made by doctors rather than simply repeating the same information (Davis et 
al., 1999).  
 By 2001, more than 4800 reports, representing 6.2% of all Yellow Cards 
received, had been submitted directly by hospital pharmacists.  
 A pilot study conducted by Davis and Coulson (1999), showed that 
reports submitted by community pharmacists equalled those submitted by 
General Practices in terms of their quality and the seriousness of the ADRs 
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reported. Additionally, it was found that community pharmacists submitted more 
reports for herbal remedies compared with General Practices (Davis and 
Coulson, 1999).  
 Houghton et al, (1999) conducted an attitudinal survey in Wales which 
provided evidence that General Practices along with community pharmacists 
were highly supportive of the view that community pharmacists had an 
important role in ADR reporting to the YCS. Accordingly, in November 1999, the 
inclusion community pharmacists in ADR reporting were extended to all parts of 
the UK, in view of their special expertise in managing over the counter products 
(Anon, 1999). 
 Another development in the role of the pharmacist took place in April 
2003 by permitting supplementary subscribing. Essentially voluntary in nature 
and always with the permission of the patient, pharmacists were empowered to 
negotiate a clinical management plan that was agreed and patient-specific.  
This is a good example of doctors and pharmacists working in close 
collaboration for the benefit of the patient.  Through the creation of Patient 
Group Direction (PGD), pharmacists and other health professionals were now 
authorised to supply and administer medicines. With these new prescribing 
powers, both Hospital and community pharmacists, now empowered to 
prescribe, have an even more important role in the YCS. In 2004, more than 
3000 ADR reports were received from pharmacists. This represented 17% of 
the total ADR reports submitted to the Agency that year (Davis and Raine, 
2007). 
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 The role of the pharmacist has been similarly enhanced in other 
countries, especially where there had been a history of involving the pharmacist 
in developing reporting systems.  In contrast, some countries do not view the 
pharmacist as being sufficiently qualified to make ADR reports.  For example, in 
some of the Nordic countries, the pharmacist is still seen primarily as one who 
simply dispenses medicine. But even in some countries where pharmacists 
have the authority to submit reports, it has been found that they seldom actually 
do submit such reports. 
 However, despite the variations in practice of ADR reporting in different 
countries and the different perceptions which exist as to the pharmacists’ role, 
the evidence clearly points to a change in understanding of the role of the 
pharmacist.  It has become less the standard practice for pharmacists to mix 
and prepare medicines as pharmaceutical manufacturing companies have 
increasingly taken on this role.  More and more, the role of the pharmacist 
moved from pharmaceutical preparation to dispensing and now pharmaceutical 
care. This implies that pharmacists will now rely less on knowledge of chemistry 
and formulae and more on the knowledge that underpins pharmacotherapy. 
 
2.4 Preventing and detecting ADRs 
 The Scottish Neonatal and Paediatric Pharmacists Group (SNAPP) and 
contributions from other pharmacists in Great Britain produced in 2010 a study 
entitled " An Introduction to Pediatric Pharmaceutical Care" as the first step 
towards the development of an accreditation scheme for pediatric pharmacists 
which has been proposed within "The Right Medicine: A Strategy For 
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Pharmaceutical Care in Scotland" which stressed the use of pharmaceutical 
care to ensure that all medicines were safely used  for  both adults and children. 
Consequently, pharmacists were asked to try to ensure that prescribing was as 
safe as reasonably possible and to be aware of the possibility of the occurrence 
of ADRs in all patients by observing any linking signs or symptoms to current or 
previous drug therapy. This new role of community pharmacists in identifying 
pediatric ADRs by providing advice to the parents or guardians of children 
taking medicines for epilepsy, depression or attention deficit disorder. The 
purpose was to develop a system to detect ‘signals’ that ADRs were occurring 
in children at an early stage so as to avoid later problems (SNAPP, 2010).  
 
2.5 ADRs Monitoring, Managing and Reporting 
 The role of both the hospital and community pharmacists in ADRs 
includes the monitoring, managing and reporting of them to the MCA/MHRA. 
Several researchers have defined the role(s) of both hospital and community 
pharmacists in ADR reporting and monitoring. Essentially these were: 
 
2.5.1 Hospital pharmacists 
 Mann (1987) commented on the Grahame-Smith working party 2nd 
report which was published in January 1986. This report made 13 
recommendations and numbers 8 and 9, shown below, dealt with the role of the 
pharmacist in ADR reporting (Mann, 1987). These were: 
"Number 8: Pharmacists play in important role in drug safety which should 
continue to be developed. We recommend that the CSM should write to health 
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authorities to ask them to encourage the participation of pharmacists in work on 
ADR in hospitals" (Mann, 1987).  
"Number 9: We do not consider that pharmacists should submit ADR reports 
direct to the CSM. If the professions can agree that a new report from is needed 
for referral by a pharmacist of a patient with an ADR to a doctor we can see no 
reason why it should not be introduced" (Mann, 1987). 
 Five years earlier, Hardman and Lloyd (1982) had carried out a detailed 
investigation into Adverse Drug Reactions in hospitals over a 5 week period. 
They concluded from this study that ward pharmacists had an active role in 
ADRs monitoring and that many of the reactions they identified would have 
passed undetected had they not been brought to the attention of the medical 
staff by the ward pharmacist. Of the reactions detected only one was 
considered suitable for reporting to CSM, but it felt that identification of the 
others improved patients' ‘comfort’. This paper concluded that hospital 
pharmacists had a role in ADRs monitoring (Hardman and Lloyd, 1982). 
  One year later, Biddolph (1983) examined the role that Australian 
hospital pharmacists played in ADR monitoring and compared this with UK 
experience. She studied the role and function of the ADRAC and the part that 
hospital pharmacists played and identified that nearly half the annual reports 
were submitted by pharmacists. She concluded that hospital pharmacists had a 
major role in ADRs monitoring and recommended that a national system be 
adopted for their contributions to the national reporting scheme (Biddolph, 1983) 
 Spencer (1985) discussed the role of some UK hospital pharmacists in 
establishing a regional ADR reporting scheme. NHS Regional ADR reporting 
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schemes were originally set up in conjunction with the CSM in the West 
Midlands and the Northern Health Authorities and in Wales (Spencer, 1985). 
One year later in 1986, the report of a Committee of Inquiry appointed by the 
Nuffield Foundation, also, acknowledged the role of the hospital pharmacist in 
ADR reporting. The report stated: 
 “We believe there is a strong case for recognizing the role of the 
pharmacist in ADR reporting. This role has sometime been 
misunderstood. The pharmacist's contribution lies, not in the diagnosis of 
adverse reactions, but in identifying possible causes, especially those 
which might be related to the formulation and its components" (Roberts, 
1992). 
In 1990 a regional reporting scheme was set up in Liverpool (Mersey ADR 
newsletter 1990). It was hoped that the Mersey Regional Reporting Scheme – 
then located in the North Western Region of the NHS would: 
• Complement and improve the region existing information services 
dealing with drug therapy and adverse ADRs. 
• Produce information that can be linked with regional prescribing figures, 
enabling the incidence of ADRs to be calculated more accurately than 
has usually been possibly in the past. 
• Facilitate research on particular ADRs. 
• Increase local reporting of ADRs by publication schemes via existing 
lines of communication established for the distribution of what was to be 
termed a ‘Drug Information Letter’. This was designed to improve 
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communication with the reporting and also providing all prescribers 
information on the local reporting of ADRs (Roberts, 1992).  
 In 1991, a pilot scheme allowing hospital pharmacists to submit yellow 
cards to the CSM was set up in the Northern Region of the NHS.  This was the 
first time pharmacists were allow to sign yellow cards for submission (Anon, 
1990) 
 In a  later study on a national basis "Reporting of ADRs by hospital 
pharmacists: pilot scheme"  (Lee et al., 1997), the suggestion was made that  
direct reporting of suspected ADRs by hospital pharmacists would enhance the 
YCS and improve Pharmacovigilance within the UK. When the pilot scheme 
finished, direct reports from hospital pharmacists in the former Northern region 
continued to be registered, but without any positive reporting the scheme had 
encouraged, the numbers reported decreased.  
There were two further studies assessing the ADR reporting system in 
pharmacy departments within the UK. 
 Ferguson and Dhillon (1999) surveyed Drug Information Centres 
attached to hospital pharmacies listed in the Drug information Pharmacists 
Group (DIPG); a year after the YCS for hospital pharmacists was launched. The 
aims were a) to identify how the hospital pharmacy managed ADR reporting, b) 
the existence of education for pharmacy personnel, c) the existence of 
designated pharmacists for ADR reporting and d) the number of ADR reports 
sent to CSM. A response rate of 74% (n=185/250) was obtained by sending a 
follow-up questionnaire. The results were very informative: 
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• In-house procedures in ADR reporting were available in 35% of the 
pharmacy departments. 
• Education for hospital pharmacists was provided by 54% of 
respondents in the form of training within the pharmacy department 
and 20% in a form training given by external organizations. 
• A designated person for the collection of data existed in 32% of 
pharmacy departments. 
 
 Factors associated with higher reporting rates by pharmacy departments 
included the existence of an ADR procedure, promotion, education and a 
designated ADR person. The reporting rate used in the analysis was actually 
the number of reports submitted by the pharmacy department to the CSM. The 
authors did not take into account the number of pharmacists from each 
pharmacy department or the size of the hospital when assessing the 
association between number of reports and contributing factor, making it difficult 
to judge the magnitude of the reports (Ferguson and Dhillon, 1999). Therefore, 
factors found to be associated with the reporting rate were problematic. Another 
limitation was the number of ADR reports submitted to CSM, which was based 
on the recollection of hospital pharmacy respondents. Therefore hospital 
pharmacists with a designated ADR pharmacist might have better records on 
the number of reports submitted to CSM. Reviewing the number of reports 
received by CSM could have been used to confirm the departments reporting 
rate but this was not carried out (Ferguson and Dhillon, 1999). 
 
95 
 
 Green et al. (1999) surveyed 100 hospital pharmacy departments 
selected from the DIPG and a further 100 selected from the Chemist & Druggist 
Directory (C&DD). The aim was to assess the impact of the involvement of 
pharmacists in YCS. The response rate obtained was 76.5% (153/200), 
achieved by sending a follow up questionnaire.  The results included: 
• A formal hospital ADR reporting scheme existed in 18.9% of pharmacy 
departments. 
• Education was provided to pharmacists by 62.3% of hospital pharmacies, 
and it was found that departments with a greater number of pharmacists 
were more likely to provide education or training in ADRs. 
• A designated ADR specialist pharmacist existed in 9.3% of pharmacy 
departments. 
• The median number of ADR reports sent to the CSM was 6 (range 3-
100) reports.  
 
 Factors found to have increased the number of reports were: the number 
of methods available, the number of professionals available to report ADRs and 
the promotion of ADRs. However, the factors relative to the reporting rate was 
not found to be statistically significant. The selection criteria of pharmacies 
surveyed were not explained; consequently, it is difficult to assess whether or 
not the results of the study were representative of UK hospital pharmacies 
(Green et al., 1999b).    
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2.5.2 Community pharmacists 
 In 1983, the Royal Pharmaceutical Society (RPS) and CSM were 
interested in investigating the role of community pharmacists in the reporting of 
ADRs. The Nuffield Report supported the investigation of the ADR reporting role 
of the community pharmacist. In 1990, the report of the Joint Working Party on 
the Role of Community Pharmaceutical Services recommended that the 
community pharmacist should directly report any ADRs of which he/she was 
aware. Similar criteria were suggested by Grahame-Smith for assessing 
community pharmacist roles in ADR reporting (Roberts, 1992). 
 That community pharmacists can make observations, detection, 
evaluation, documenting and reporting ADRs is now well established. Their 
unique position in interacting with patients allows them to ask about ADRs, 
more so than perhaps any other healthcare professional (McCloskey, 1996 , 
Kees van Grootheest et al., 2004). An example, of this interaction is that 
community pharmacists in Australia effectively identified problems associated 
with OTC medicines (Hughes et al., 2002).  
 This is against the background of the study by Volans (1987), who 
suggested that under reporting of ADRs is likely since, in the case of OTC 
products, minor reactions may be ignored by both patient and doctor or wrongly 
ascribed to prescription medicines. He, therefore, recommended that particular 
consideration should be given to developing the potential for pharmacists to 
collect and report ADRs caused by OTC products. Four years later, Roscoe et 
al., (1991), showed in a study in a small community pharmacy that interactions 
occurred with prescribed drugs and other drugs including alcohol, tobacco, 
caffeine and herbal products. They recorded 61 interactions with some patients 
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presenting with more than one potential problem. Analysis of the interactions 
indicated that many were of major, potentially harmful and had clinical 
significance (Roscoe et al., 1991).   
 At the same time, Spencer and Edward (1992) conducted a survey of GP 
for their attitudes to an extended role for community pharmacists specifically 
reporting ADRs. Most of the GP believed that community pharmacists should be 
involved in reporting ADRs (Spencer and Edwards, 1992).  
 Numerous studies have reported the potential contributions pharmacists 
can make to national reporting systems. The practical experience of countries 
such as Australia, Canada, the Netherlands and the USA has shown a 
significant improvement to both the quantity and quality of the reports on ADRs 
worldwide (Kees van Grootheest et al., 2004). 
  In the Netherlands the community pharmacist plays an important role in 
the detection and reporting of suspected ADRs. Community pharmacists in the 
Netherlands displayed a positive attitude towards ADRs reporting and were 
knowledgeable and highly motivated to ADRs reporting based on an 
established tradition of pharmacists reporting such events (Van Grootheest et 
al., 2002a) see Table 8. 
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2.6 Attitude and awareness of Hospital and Community Pharmacists to 
ADR reporting: 
 The available literature shows the fundamental role of pharmacists in 
contributing to ADRs reporting to either a) new drugs, or b) any serious 
reactions not well known or associated to an established drug which also need 
to be reported. However, there still remains the problem of under reporting.  
Many factors that might encourage or discourage health care professionals from 
reporting ADRs have been examined in a number of studies.   
 The first two of these (Li et al, 2004 , Bäckström et al., 2000) assessed 
the level of attitude and awareness of pharmacists to ADR reporting parallel 
those reported by other healthcare professionals (Lee et al., 1994, Bawazir and 
Al-Sultan, 2009).  
 In the UK, Green et al.(1999), conducted studies to elicit the views or 
attitudes towards hospital pharmacists’ role in reporting ADRs, as part of their 
professional role. Reports which had been submitted made a valuable 
contribution to the YCS. Their knowledge of drugs and awareness to report 
Country % Hospital 
 pharmacists 
Community 
pharmacists 
Canada 88.3 + - 
USA 68 + - 
Australia 40.3 + +/- 
Netherlands 40.2 - + 
Japan 39 ? + 
Spain 25.9 + + 
Table 8: Percentage of professional ADR reports originating from pharmacists 
by country (Van Grootheest and Berg, 2005) 
"+" indicates that is primarily pharmacists from this setting who originate the reports;"_" indicates that 
pharmacists do not typically originate the reports,"+/-" indicates that some but infrequent reports originate from 
pharmacists practicing in this setting;"?" indicates unknown data.  
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reactions plus suitable education and training were responsible for successful 
ADRs reporting (Green et al., 1999a).  
 In 2000, the study on ADRs by Sweis et al. (2000), reported that Hospital 
Pharmacists in UK were more likely to report serious and rare ADRs and ADRs 
associated with newly marketed drugs. The pressure of work, lack of confidence 
in recognizing ADRs and the fear of breaching patient confidentiality, made 
them more likely to report the more serious effects but to ignore effects that they 
regarded as trivial. Suggestions as to how to minimize such problems included 
training, meetings and a hospital written policy (Sweis and Wong, 2000). 
 A further study by Green et al., (2001) investigated the attitude and 
knowledge of 600 hospital pharmacists toward ADR reporting. They concluded 
that pharmacists’ knowledge regarding the Yellow Card spontaneous ADR 
reporting scheme should be supported. Furthermore, they found that hospital 
pharmacists were significantly more like to report serious reactions to new 
drugs and reactions not well known to be associated with a particular drug. 
They suggested that enhanced education and training was vital to increase and 
maintain ADRs reporting (Green et al., 2001). Further studies by this group, 
Green et al., (1999, 2001), and also Sweis et al. (2000) have discussed 
common denominators for factors to both encourage and discourage reports by 
hospital pharmacists.  
The factors which encouraged the reporting ADRs were (Li et al, 2004 , 
Bäckström et al., 2000) 
• A serious reaction. 
• Unusual reactions. 
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• Reactions associated with new drug marketing. 
• The confidence in the diagnosis of the ADRs. 
• Well known reaction associated to a drug.  
• Active support. 
 
  In contrast, the factors which discouraged to the reporting ADRs were: 
• A lack of awareness of reporting ADRs. [Considered one of the most 
important factors by which a failing therapy can be made safe]. 
• Ignorance of the actual reporting requirements.  
• Fear of involvement in litigation. 
 
 In Canada, Taras-Zasowski and Einarson (1989) in a study entitled 
"Review of Canadian pharmacist involvement in ADRs reporting". ADR 
recognition, evaluation and reporting were considered to be important aspects 
of modern pharmacy practice. A total of eight studies have reported the 
incidence of ADRs in Canadian hospitals. On average one in every six patients 
(17 percent) developed an ADR. This may prolong hospital stay, increasing the 
cost of hospitalization by millions of Canadian dollars annually. Although ADR 
programmes can be time consuming, their potential for reducing the financial 
burden of ADRs would be a positive outcome. The authors concluded that ‘a 
great opportunity existed for pharmacists to contribute in this area of patient 
care’ (Taras-Zasowski and Einarson, 1989). 
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 In Hong Kong, Lee et al. (1994) published a study about the attitudes 
and knowledge of pharmacists working in community pharmacies in Hong Kong 
towards the reporting of ADRs. Using questionnaires they found that most 
community pharmacists approved the compulsory reporting of ADRs and they 
suggested that their knowledge about ADR reporting should be actively 
promoted (Lee et al., 1994). 
 
 In Rhode Island (USA), Generali et al, (1995) surveyed 793 pharmacists 
to assess their knowledge of the ADR reporting process and the nature and 
seriousness of ADRs observed by pharmacists. They also were interested in 
determining how pharmacists perceived their role in monitoring and reporting 
suspected adverse drug reactions. Almost all pharmacists (97%) believed that 
action should be taken when a serious ADR was suspected. Hospital 
pharmacists were more likely to receive ADR information from physicians. 
Younger pharmacists (< 45 y) were more willing to contact the physician and 
refer the patient to medical attention. The study concluded with fewer than half 
of the respondents (41%) claiming to have observed a serious ADR (potentially 
life-threatening or requiring hospitalization), although almost all (97%) believed 
that pharmacists should take some action when a serious ADR is suspected. 
The influence of the practice setting, the number of years in practice, and the 
number of hours worked per week influenced the reporting practices and 
attitudes (Generali et al., 1995). 
 In NZ, Zolezzi and Parsotam, (2005) concluded from the data they had 
obtained in their study entitled, "ADR Reporting in New Zealand: implications for 
pharmacists" with the suggestion that ‘The pharmacy profession considers that 
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ADR surveillance is a priority and a professional responsibility. It is essential 
that programs aimed at increasing ADR surveillance include processes that are 
user friendly and lack negative associations or stigma’ (Zolezzi and Parsotam, 
2005).  
 In India, Chandra (2006), conducted a study "Design and Implementation 
of ADR system in Community Pharmacies" in trained Community pharmacists 
which showed an interest toward reporting ADRs after an ADR workshop which 
improved their rates of reporting (Chandra, 2006).  
 In Portugal, Herdeiro et al.(2006) and Ribeiro Vaz et al.(2009) conducted 
two studies in northern Portugal to identify attitudes of pharmacists' ADR 
reporting and strategies for increasing ADRs reporting rates among Portuguese 
pharmacists.  Most attitudes were found to be based on Inman's `seven deadly 
sins' and the factors that affect underreporting among these professionals. ADR 
under-reporting is strongly associated with certain attitudes, possibly indicating 
that under-reporting could be minimised through educational interventions 
targeted at changing such attitudes. They suggested that Pharmacists' ADR 
education must be improved and educational programmes should be focused to 
address the problem. Educational interventions were efficient in increasing the 
ADR spontaneous reporting rate, among Portuguese pharmacists. Among this 
professional group, workshops are as efficient as telephone interviews to 
improve ADR spontaneous reporting. Also indicate that community pharmacists 
must be a priority target for this intervention (Herdeiro et al., 2006 , Ribeiro Vaz 
et al., 2009). 
 In Norway, Geddea Dahl et al. (2007) and Granas et al. (2007) in two 
studies considered the attitude, characteristics and quality of  pharmacist ADRs 
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reporting and their role was found to be indispensable since their ADRs reports 
provided valuable data to health professionals (Geddeâ Dahl et al., 2007). 
 In Turkey, Toklu and Uysal (2008) published similar studies that were 
carried out in community pharmacists which showed by studying investigation 
attitude and knowledge toward Pharmacovigilance and ADR reporting in the 
Kadikoy district of Istanbul the pharmacists had insufficient knowledge about 
Pharmacovigilance and ADRs reporting (Toklu and Uysal, 2008). 
 In Nepal, Subish et al. (2008) analyzed the knowledge, attitudes and 
practices of healthcare professionals including pharmacists regarding ADRs 
and Pharmacovigilance.  They found that Pharmacists played a great role in 
educating other healthcare professionals regarding prevention, detection and 
reporting of ADRs (Subish et al., 2008). 
 In Sudan, the Elnour et al. (2009) study emphasised the importance of 
raising the awareness of pharmacists towards ADRs reporting. So, a low level 
of ADRs awareness might stem from a lack of basic knowledge and lack of 
vigilance. Education and training in relation to ADRs among healthcare 
professionals was suggested to be warranted (Elnour et al., 2009). 
 In China, two studies by Su et al. (2009) and Xu et al. (2009) in two 
different geographical regions of China assessed the knowledge and 
awareness of pharmacists of ADR reporting. They found that hospital 
pharmacists exhibited a positive attitude toward Pharmacovigilance and these 
studies showed that the pharmacists were competent in reporting ADRs. These 
Chinese studies were used to support further studies designed to provide 
guidelines for future work in Pharmacovigilance (Xu et al., 2009 , Su et al., 
2009). 
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 In Thailand, the study by Jarernsiripornkul et al. (2009) assessed the 
knowledge, attitudes and practices of 414 Thai hospital pharmacists concerning 
the safety monitoring programme and reporting of ADRs to the Thai Food and 
Drug Administration. The main barriers affecting ADRs reporting were found to 
be a lack of co-operation between health professionals and staff shortages. The 
Thai hospital pharmacists had a positive attitude towards reporting of ADRs, but 
not all were aware of the Safety Monitoring Programme for new drugs 
(Jarernsiripornkul et al., 2009). 
 In Malaysia, a paper by Ting et al. (2010) published a pilot study 
designed to assess the community pharmacist's knowledge, attitude and views 
on ADRs reporting. Their findings showed that they played an important role in 
reporting ADRs although Malaysian patients were still perceived to be ill-
informed of their medications (Ting et al., 2010). 
 In Nigeria, Oreagba et al (2010) published a survey of community 
pharmacist which investigated the knowledge, perception and practice of 
Pharmacovigilance in South West Nigeria. Half of the respondents had not 
heard of the word ‘Pharmacovigilance’ although 90% believed in the importance 
of the role of pharmacist reporting ADRs. For the majority of community of 
pharmacist in Lagos South West Nigeria the reporting rate for ADRs was poor 
as was their knowledge regarding Pharmacovigilance. A need for an 
educational programme to train community pharmacists regarding the concept 
of Pharmacovigilance and ADR reporting were considered to be urgently 
needed (Oreagba et al., 2010). 
 In two recent studies in Iran, Khalili et al. (2012) and Vessal (2009) 
related the knowledge, attitude and perception of clinical pharmacists towards 
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ADRs. One study found that the pharmacists in Iran had little knowledge about 
both Pharmacovigilance and the usefulness of a ADRs spontaneous reporting 
system. The other study investigated 100 participants before and after 
intervention, which consisted of presentations and workshops. Knowledge 
about an awareness of the Iranian Pharmacovigilance Center at the Ministry of 
Health and the detection of ADRs in patients was rudimentary and only seven 
(8.5%) pharmacists had reported ADRs before the educational/intervention 
phase. This increased significantly to 18 (22%) after the intervention. The study 
concluded that Clinical pharmacists' interventions were successful in improving 
healthcare workers' knowledge, attitude and perception about ADRs and 
spontaneous reporting in hospitals (Khalili et al., 2012).   
 Against this background  of all of the previous diverse studies we can say 
there is a general global consensus that there needs to be adequate training 
and education programmes about Pharmacovigilance and ADR reporting so as 
to improve the health of patients and to maintain the safe use of drugs. 
 
2.7 Saudi Arabian perspective    
 In Saudi Arabia, the MOH has shown great interest and concern about 
patient treatment. The KSA has established many programmes for health care, 
and, for the purposes of this thesis, the most important programme was for 
Post-Marketing Surveillance established in 1998 to assist in the study of ADRs 
so that by early detection of unexpected or serious ADRs, or any increase in 
frequency of known ADR plus the detection of quality defect of registered 
products, reports could be published and distributed to all those who would find 
such information important. This programme was quickly established and 
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allowed all healthcare professionals to report and even for patients to report 
problems, but unfortunately participation was very low (Bawazir and Al-Sultan, 
2009 , Bawazir, 2006). 
 In the last two studies, Professor Dr. Saleh Bawazir published data in 
2006 regarding community pharmacists in Riyadh, the capital city of Saudi 
Arabia, which assessed the attitude and behaviour of community pharmacists in 
Saudi Arabia towards ADRs reporting. His paper in 2006, was aimed at 
examining the attitude and behaviour of hospital pharmacists in several 
hospitals of Saudi Arabia regarding the reporting of ADRs (Bawazir, 2006).  
 The methodology used descriptive questionnaires for both studies, in a 
sample taken from 240 community pharmacists and 510 hospital pharmacists. 
There were two main sections in the questionnaire. The first section dealt with 
the demographics of the participants and covered their educational status and 
awareness about the system of ADRs in KSA and their behaviour towards it. 
The second section of the questionnaire was the attitude of hospital pharmacist 
in reporting and what potential barriers might affect their attitude to reporting.  
 In the 2006 study, the rate of response was 71.7% for hospital 
pharmacists and in the second study it was 67.1%. An awareness of ADRs 
reporting was only found in 21 community pharmacists (13.2%) but the other 
study showed 45.6% of hospital pharmacists were aware of the ADR reporting 
programme in KSA. This is still a relatively low awareness rate (Bawazir, 2006). 
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2.7.1 Degree of Awareness in Community Pharmacist and Hospital 
Pharmacist in the KSA 
 Community pharmacists were found to have acquired their knowledge 
about ADR reporting in different ways. For example, 33% of community 
pharmacists had learnt about ADRs programme from colleagues, 14.3% of 
them had read about it in the pharmaceutical literature and 9.5% knew about 
the programme from employees in the MOH. In the past, all Pharmacists in the 
KSA reported an ADR to the MOH. But now, after establishing the new centre, 
management of Pharmacovigilance of all pharmacists reports ADRs is carried 
out by the Saudi Food & Drug Authority (SFDA). However, only 29% of 
pharmacists were aware of the change of reporting responsibilities.  
 Moreover, Dr. Bawazer indicated in his study that 4% and 6.3% of 
community pharmacist claimed they had submitted an ADR report to the MOH 
or a pharmaceutical company, respectively, and 18% of pharmacists indicated 
that they did not know where they had to report to in terms of the MOH or the 
Drug Company. In contrast, hospital pharmacists had a greater feeling of 
responsibility toward ADRs reporting and they considered it an essential part of 
their duties and obligations. The percentage of hospital pharmacists in his study 
who submitted an ADR report to the MOH was only 7%. However, 23.1% of 
hospital pharmacists claimed they had carried out an ADR report to their own 
hospitals.  
 This study also showed many barriers existed which affected ADR 
reporting for community pharmacists. For example, 67.7% of them did not know 
where their reports should be sent. Additionally, 62.8% found the necessary 
paper work for ADRs was unavailable and 41.7% did not to know how to report 
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the ADRs. Other findings (83.7%) from community pharmacists indicated that 
the publication of ADRs reports was an important stimulation for further reports 
and these could be collected together in an ADR Bulletin. In addition, 29% 
emphasised that education and training were required to improve pharmacists' 
knowledge toward ADRs reporting.  
 A second study found that one of the barriers experienced by hospital 
pharmacists was an insufficient clinical knowledge about the drugs (42.7%).  As 
a group, some hospital pharmacists (33.3%) did not know the address of the 
reporting agency, and the form for ADRs reporting was unavailable. Some, 
(22.6%) were unaware as to how to report ADRs and furthermore, 17.3% 
indicated that the ADRs forms were very complicated to fill out. 64.3% 
emphasized that ADR reporting in a publication such as an ADR bulletin was 
very helpful and the study showed 64.1% of them indicated the importance of 
receiving feedback from the programme.  
 Finally, the conclusions made from these studies were that the majority 
of community pharmacists (86.8%) surveyed was unaware of the ADR reporting 
programme in Saudi Arabia. In contrast, hospital pharmacists had a much better 
awareness towards the ADR reporting system in KSA but they still considered 
under-reporting a problem as 71% of pharmacists were not aware that 
pharmacists in KSA could report an ADR to the MOH or SFDA (Bawazir, 2006, 
Bawazir and Al-Sultan, 2009).  
 None of these studies on ADRs reports included any data from the Holy 
City of Makkah. This was of great interest as it was at this city that this PhD 
study was to be carried out. This city has a population of 1.7 million people 
which increases to 4 million pilgrims during the religious period such as the Holy 
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month of Ramadan and Hajj. There is an urgent need to investigate ADR 
reporting in the context of a city which receives over 3 million pilgrims during the 
Ramadan and Hajj seasons. Apart from its normal functioning throughout the 
year, additional strains are placed on the health service when there is such a 
large influx of people from many different parts of the world and this has special 
implications for ADR reporting.  So there is a need to investigate the problem of 
reporting of ADRs in the Holy City of Makkah by pharmacists due to the vital 
role pharmacists play in the Holy City of Makkah during the Hajj time.  Because 
no previous study has been carried out into ADR reporting in the Holy City of 
Makkah, this thesis was designed to make an original contribution to the 
knowledge about ADRs relevant to the Holy City of Makkah and the views and 
perceptions of the pharmacists involved in hospital and community settings 
about the topic of ADRs and their reporting. 
 
Important note to the reader 
It should be noted that although the title of the city in Arabic is usually translated 
as ‘the Holy City of Makkah’ in the next paragraph and subsequent chapters this 
title will be shortened to ‘Makkah’. No disrespect for the full title of the city is 
either implied or meant but it is a means whereby the text can be suitably 
shortened. But before Makkah is considered it may be useful to provide the 
reader with a brief synopsis of the health care system currently used by Saudi 
Arabia.  
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Chapter Three 
3 The Kingdom of Saudi Arabia (KSA) 
3.1 Background 
 The Arabian Peninsula has played an important role in history since the 
earliest civilizations as an ancient trade centre and the centre of one of the 
principal monotheistic religions of the world, namely Islam (Figure 8) (Embassy, 
2009). 
 
 
 (Sources: www.theodora/maps.com) 
Figure 8: Saudi Arabia Map 
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 The KSA is the one of largest Arab countries in the Middle East. It 
comprises 13 administrative provinces and is considered as a major Islamic 
country because it contains the ‘Two Holy Mosques’ one in Makkah and the 
other in Medina (see Figure 9).  Consequently, the other name for the KSA is 
"The Lands of The Two Holy Mosques" which are Islam's two holiest places. In 
1932, King Abdul-Aziz established the formal foundation of the KSA when a 
majority of the world powers recognized his sovereignty of the new nation (see 
Figure 10).   
 
 
 
 
 
  
 
 
 
 
 
 
 
(Sources: www.aqarcity.com) 
Figure 9: Makkah and Medina the two Holy mosques in the 
Kingdom of Saudi Arabia 
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 (Sources: www.cambridgeforecast.wordpress.com) 
 
 
3.2 Location and Size of the Kingdom 
        Geographically, the KSA is strategically located between Asia, Africa and 
Europe and occupies around fourth-fifths of the Arabian Peninsula. It is divided 
into four important administrative areas known as ‘Provinces’. The first Province 
is central and is considered to be the ‘heart province’. The second is the 
‘western province’, the third is simply called the ‘southern province’ and the final 
province is known as the ‘eastern province’ which is a very important region due 
to having the oil resources and petroleum industries. Confusingly, it is also 
called the ‘fourth region’ in some documents. The KSA is surrounded by three 
Seas; to the south, by the Indian Ocean, to the west, by the Red Sea and to the 
east, by the Arabian Gulf. It occupies 2,250,000 square kilometers (868,730 
square miles).  
Figure 10: King Abdul Aziz Bin Saud attending official dinner with Sir W. 
Churchill, Lake Qaroun, Egypt in 1945 
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       The KSA is bounded in the North by Jordan, Iraq and Kuwait; on the east, 
by the Arabian Gulf, Bahrain, Qatar and the United Arab Emirates; in the south, 
by the Sultanate of Oman and Yemen; and on the west, by the Red Sea as 
illustrated in (Figure 11).  Furthermore, the KSA has three main sand deserts. 
The first is the northern one is called Al-Nafud which borders onto the second 
one, another large sandy desert called “Rub Al-Khali” meaning the “empty 
quarter”, and is one the largest desert regions of the world. The third, to the east 
is the known as the “Al-Dahna” desert. The KSA has no rivers or lakes although 
it does have some annual rainfall. 
 
 
 (Sources: KSA image) 
 
 
Figure 11: Location of KSA in world 
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3.3 Population 
 In 2009, according to the central department of statistics and information, 
which is the most recent data available, the KSA had an estimated population of 
25 million, including about 6,830,266 million foreign residents (Sambidge, 
2010).  
 
3.4 Healthcare System 
        The organisation responsible for healthcare in the KSA is the MOH. It 
provides a comprehensive system of healthcare for everybody who lives in 
Saudi Arabia, free of charge. The overall concept includes individuals, family 
and visitors plus, in addition, all elderly and disabled people. The MOH is 
always trying to increase and improve the quality and ‘quantity’ of healthcare 
provide to its subjects. The MOH is responsible for the supervision of all 
healthcare issues whether this is in the government or the private sector.  
       The MOH in Saudi Arabia is a member state of WHO and classifies the 
healthcare system into two tiers. The first tier is the private sector which 
contributes (40%) of the provision of healthcare systems in Saudi Arabia. The 
other tier (60%) is based upon the provision by government of national 
healthcare centres and other clinical centres which provide a wide range of 
medical facilities including preventative, emergency, rehabilitative, curative and 
basic services through a diverse range of government agencies. 
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3.5 Government Agencies  
3.5.1 The Ministry of Health (MOH)  
 This is one of the most important Government agencies and is 
considered to be a very comprehensive system. It provides healthcare for the 
population and is under continuous development by providing all the health 
services in hospitals and Primary Health Care (PHC). In each of these, they 
provide both generalists and specialists to maintain a high quality of medical 
care using high numbers of well qualified staff and excellent modern facilities. 
The number of all hospitals in Saudi Arabia still continues to increase reflecting 
the progressive growth in the population of the country.  
 The MOH has regional health organizations distributed in each province 
and areas of the country (see above Figures 8 and 11) including Riyadh, 
Makkah, Gassim, Assir, Gizan, Medina, North Border, Eastern Region, Hail, 
Tabuk, Baha, AlJouf and Najran. The MOH contributes to the maintenance of all 
healthcare facilities in each province. In addition, all the smaller towns are 
provided with some type of healthcare provision. The MOH considers the 
hospitals as the cornerstone for the increased level of healthcare provision in 
the country and by such provision achieves a greater degree of patient 
satisfaction in the service to the whole country. The increase in both the number 
of hospitals and number of hospital beds from 1970-2008 can be seen in (Table 
9) Data about the Primary Healthcare Centres in the KSA is shown in (Table 10)  
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Table 9: The total number of hospitals supported by the MOH and total 
number of hospital beds for the respective years 1970 - 2008 
Year Number of MOH 
hospitals  
No. of beds 
1970 74   9 039 
1999 114 15 729 
2002 195 28 522 
2003 200 29 000 
2004 213 30 020 
2005 218 30 489 
2006 220 31 877 
2007 225 31 420 
2008 231 31 720 
 
Table 10: The total number of primary health care centres in the KSA for 
the years 1999-2009. 
     
 
 
 
 
 
 
  
Year Number of MOH primary Healthcare 
centres in the  KSA 
1999 1756 
2000 1766 
2001 1786 
2002 1792 
2003 1804 
2004 1858 
2005 1905 
2006 1925 
2007 1925 
2008 1986 
2009 2191 
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3.5.2 Military Hospitals   
 The military hospitals of the KSA constitute: those of the Saudi Arabian 
National Guard (SANG) and the Saudi Arabian Ministry of Defense and Aviation 
(MODA). All military hospitals provide services for members of the armed forces 
and their families throughout Saudi Arabia. Furthermore, and relevant to this 
thesis, these medical facilities provide their services for the benefit of pilgrims 
during the Hajj and which are provided free of charge (see next sub-section). 
 
1. Saudi Arabian National Guard (SANG) 
There are four hospitals with a total of 1400 beds in addition to which there are 
many mobile clinics (see Figure 12) in both the capital city and also near to 
Makkah.  
 
 
 
 
 
 
 
 
 
(Source: Saudi press agency. www.spa.gov.sa) 
 
 
Figure 12: Mobile clinics forming a military Hospital in Makkah 
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2. Saudi Arabian Ministry of Defense and Aviation (MODA) 
 There are 10 hospitals with a total number of 3454 beds in all parts of the 
country and they contribute their services as additional resources each year 
during the Hajj season with both temporary hospitals and polyclinics. 
 
3. Ministry of Interior 
 The Ministry of Interior healthcare system is for serving policeman and 
their family members and is located at the Security Forces Hospital (SFH), 
Riyadh (500 beds). During the Hajj season, in a co-operative venture, provision 
is made by the SFH to support the existing health care system in Makkah by 
meeting the additional demands on the healthcare system arising from the influx 
of the millions of pilgrims. In 2010, they started building a new hospital in 
Makkah city which actually opened early in 2012. 
 
3.5.3 Referral Hospitals 
      There are four referral hospitals, which are also teaching and medical 
research centres. Each of these 4 hospitals has 1610 beds for specialized care 
such as cancer and organ transplantation and even surgical facilities so 
specialties that the separation of congenitally joined twins can be achieved. 
There are also specialist genetics advisory centres.  
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3.5.4 Private Health Sector 
      The MOH supervises all the private providers of health in Saudi Arabia and 
these, together with the provision of public facilities, have ensured that a very 
comprehensive system exists. The private clinics range from those providing 
basic health care to highly specialised hospitals with highly successful medical 
facilities and services.  To use such facilities people have to either pay 
themselves or be covered by some form of a patients insurance plan (MOH, 
2010 , Ziegler, 2010 , Arabi and Al Shimemeri, 2006). 
 
3.5.5 Saudi Red Crescent Society (SRCS) 
  A major component of the healthcare system in Saudi Arabia is provided 
by the ‘’Saudi Red Crescent Society’’ (SRCS). It effectively provides fast 
medical services ranging from first aid and so provides emergency care prior to 
the individual being admitted to a hospital.  It also provides relief during natural 
disasters and works both inside the KSA and abroad (SRCS, 2009). Although 
the SRCS exist in the country at all times it is perhaps in the time of the Hajj 
when they make a major contribution. It provides for the needs of the Pilgrims 
by many staff, ambulances and comprehensive facilities in orders to help 
pilgrims (see Figure 13). 
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Figure 13: The staff of Saudi Red Crescent Society "SRCS" serving in the 
Holy city of Makkah during the Hajj. 
(Source: www.islam-love.com) 
 
3.6 Pharmacovigilance in KSA 
3.6.1 The Saudi Food and Drug Authority (SFDA) 
 The Saudi Food and Drug Authority (SFDA) was established to function 
as an independent body not directly linked to the MOH. This organization has 
the responsibility of foods, drugs and medical devices in Saudi Arabia under a 
resolution of the Council of Ministers of the KSA. This authority aims to protect 
all citizens and consumers in Saudi Arabia and guarantees the control and 
regulation of foods, drugs and any other chemical and/or biological products. 
Additionally, medical devices are checked so as to ensure that they are safe 
and reliable. All drugs and foods which are imported into the KSA or even those 
produced locally have to comply with mandatory standards.  
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I. The aim and objectives of the SFDA are as follows: 
• To inspect drugs and foods for both humans and animal consumption for 
safety, security, and effectiveness. That inspection includes: 
• Safety of complementary biological and chemical substances, 
cosmetics and pesticides. 
• Safety and efficacy of medical devices and their impact on the public 
health. 
• Setting the policy and procedures for food and drugs by ensuring plans exist 
to achieve and implement these policies.  
• Continuous monitoring and control of licenses for drugs, foods and medical 
devices.  
• Sharing scientific data for food and drugs by using an established database 
for both research and distribution of information, both locally and 
internationally. 
 From this brief description it can be seen that the SFDA has three 
sectors namely, Foods, Drugs and Medical devices. The main SFDA provides 
information about the drug sector which is specifically related to medicines. This 
is outlined in the following sub-sections. 
 
3.6.2 Drug sector  
 One significant purpose of the drug sector branch of the Saudi FDA is to 
manage and develop efficient pharmaceutical registration and monitoring 
systems in the KSA. The registration of drugs, it was hoped, would avoid drugs 
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producing harmful or even toxic effect due to low quality or of non-registered 
quality. To achieve these aims, the SFDA collected a wide range of professional 
opinions and these were formulated into a policy. These regulations and 
guidelines have provided improvements and protection for public health in the 
KSA and include: 
• Guidelines about biological drugs :  
- Blood products 
- Vaccines 
- Allergenic products 
• Post-marketing surveillance (PSM) guidelines. 
• Cosmetic pharmaceuticals products. 
• Veterinary medicines. 
 
I. Responsibility and classification of drug sector in SFDA 
The drug sector has a series of responsibilities including: 
• licensing of the manufacture, import, export, distribution, promotion and 
advertising of medicines;  
• assessing the safety, efficacy and quality of medicines and issuing 
marketing authorization;  
• inspecting and surveillance of manufacturers, importers, wholesalers and 
dispensers of medicines;  
• controlling promotion and advertising of medicines;  
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• Providing independent information on medicines to professionals and the 
public. 
 The Drug sector has many departments and sections concerned about 
relevant issues relating to healthcare for both professionals and patients which 
are divided into the following structures (see Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Structural organization departments of drugs 
sectors in SFDA (source: www.sfda.gov.sa). 
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3.6.3 National Pharmacovigilance Centre (NPC)  
 In 2009, Saudi Arabia acquired membership of the WHO-UMC 
international drug organization and established a National Pharmacovigilance 
Centre (NPC) under the organization of SFDA (Figure 15). This centre monitors 
ADRs and drug related problems in all healthcare centres in Saudi Arabia. The 
transfer of ADRs to the NPC centre was completed by 2010. The NPC, under 
the umbrella of the SFDA centre, is concerned with detection, assessment and 
prevention of ADR or other drug related risks. The new logo of the NPC 
contains two languages; Arabic and English, (Figure 16) meaning to the 
concept of Pharmacovigilance.  
 
 
 
 
Figure 15: Saudi Arabia established membership with UMC  
(Source: www.sfda.gov.sa). 
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 In 2011, Ghazi Seed, the director of the NPC in SFDA gave a lecture in 
Riyadh which provided a detailed background about the ‘Rules and 
Responsibilities of Pharmacovigilance in Saudi Arabia which were essentially: 
• To detect ADRs as early as possible.  
• Calculation of the increase disease risk frequency of (known) 
adverse reactions.  
• Identification of risk factors and possible mechanisms underlying 
adverse reactions.  
• Estimation of quantitative aspects of benefit/risk analysis and 
dissemination of information needed to improve drug prescribing 
and regulation.  
• If possible – prevent  ADEs  
• Drug quality surveillance.  
• Encourage rational and more effective use of medicines.  
Figure 16: Logo of the National Pharmacovigilance Centre in 
the KSA (Saudi Vigilance) (source: www.sfda.gov.sa). 
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• Communication with international institutions working in 
Pharmacovigilance. 
• Promoting of understanding, education and training in 
Pharmacovigilance. 
 
Also it was stated the classifications within the NPC and the importance of  
other departments working with others to protect patients and use medicines 
safely (Ghazi, 2011).   
 
1. Classification of NPC in SFDA: The NPC is divided into many 
departments as shown in Figure 17 below:  
  
 
 Figure 17: Organization structure of NPC in SFDA 
(Source: www.sfda.gov.sa). 
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 The SFDA has an official, descriptive website (see Figure 18) where 
much useful and relevant information is both displayed and updated and is a 
valuable source for both healthcare professionals and the public. Published in 
both Arabic and English, its aim is to increase knowledge and awareness of 
foods, drugs and medical devices. Reporting of ADRs is possible online but, as 
yet, little actual data have been obtained [see Appendix8.2].   
 The strategic plan of the NPC includes building an infrastructure for NPC 
by using a ‘reporting channel’ connecting large hospitals in five different Saudi 
Arabian regions to a reporting system of 62 Pharmacovigilance coordinators 
who have been recruited (Figure 19). There is also an Advisory Committee 
which can enhance the awareness of reporting by both professionals and the 
public (Ghazi, 2011). 
Figure 18: Official website of the SFDA 
(Source: www.sfda.gov.sa). 
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2. NPC Processing for ADRs 
1. NPC receives potential ADRs report via many different ways;- e mail, 
FAX, by the SFDA website via reporting online or by post 
2. Analysis of information from the ADRs reported by the 
Pharmacovigilance centre can be entered into their database. 
3. Scientific  evaluation of the information and an investigation and possible 
opinions about the best and safe use of the relevant drugs 
4. Advisory committees can be contacted if something needs to be reported 
to them or if more investigations or recommendations are required. 
Figure 19: 62 Offices in different regions in Saudi Arabia 
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5. Such recommendations, if approved, can be saved as shown in Figure 
20  (Ghazi, 2011).  
 
 
 
 
 
   
 
 
 
  
  
 Dr Saeed (2011) remarked, in his lecture, that ADRs reporting is 
necessary by all health care professionals (Physicians, pharmacists and 
nurses), the public (citizens and residents), and qualified persons in 
Pharmacovigilance departments within the drug industries (Figure 21).  
 
 
 
 
 
Figure 20: NPC processing under SFDA 
(Source: www.sfda.gov.sa). 
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 In addition, all suspected ADRs that happen during any of Therapeutics 
failure, Counterfeiting, Medication errors, Quality issues and Packing & labeling 
errors can be classed as "TCMQP" reports.  All such events can be reported to 
NPC as a consequence of the use of medicines, herbal products and cosmetics 
(see Figure 22) (Ghazi, 2011). 
 
 
Figure 21: Who should report to NPC?  
(Source: www.sfda.gov.sa). 
131 
 
 
 
 
Furthermore, between October-2009 to April-2011 the NPC received 1486 
reports from different regions of Saudi Arabia of which 85%, (n=1266) were 
ADRs reports and the lowest reports were for herbal products (1%) and 
cosmetics (1%) (See Table 11) (Ghazi, 2011). 
 
Table 11: Reports were received by NPC from the different regions of the 
       KSA (source: www.sfda.gov.sa). 
 
 
 
 
 
 
 
Report types Numbers % 
ADRs 1266 85% 
Herbal products 17 1% 
Cosmetics 16 1% 
Medications errors 63 4.5% 
Products quality 123 8.5% 
Total 1486 100% 
Figure 22: Types of effects which should be reported to 
the NPC (source: www.sfda.gov.sa). 
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 In 2011, Saudi Arabian pharmacists played a significant and vital role in 
ADRs reporting similar to that in others countries. For example, ADRs reports 
by pharmacists were 286, whilst the physician’s 172 reports and for all other 
health care professionals numbered 228 reports to NPC (See Figure 23).  
 Of these reports received by NPC, 39% were classified as serious and 
61% as non-serious. The total ADRs reports by System Organ Class (SOC) 
were 3133 (Figure 24). The highest proportion of these (n= 498) were for 
general disorders and administration, whilst congenital, familial and genetic 
disorders were only of the order of 1%. 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 23: Number of reports received by the NPC allocated to the 
different groups of ‘reporters’ (source: www.sfda.gov.sa).  
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 The NPC and the Pharmacovigilance Advisory Committee (PAC) 
analysed and classified these reports by multidisciplinary teams and provided 
independent evaluation of safety concerns which had to be taken. Decisions 
and actions ranged from labeling updates to revoking a drug marketing 
authorization, for example, the withdrawal of Sibutramine and the suspension 
and then the withdrawal of Rosiglitazone.  As the NPC in Saudi Arabia is 
currently established, it has achieved both national and regional success  which 
has led to  actions such as the withdrawal of medications, announcement in 
many news websites such as the Middle East business news (MEED) and 
(REUTERS) and SFDA website ( see Figure 25 ) below. In the editions of the 
Figure 24: ADR reports by System Organ Class 
(source: www.sfda.gov.sa). 
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‘safety news’ that were issued during 2010-2011,’ 18 medications were 
withdrawn from the market, suspended or placed under review.  
 
  
 
 To help the process, several organized events were conducted about the 
awareness and education, using suitable training and workshops, for health 
care professionals (HCPs) and the general public. It was considered that all 
these groups were important and were the key that could lead to an increase in 
ADRs reporting. The NPC conducted 45 workshops and more than 5000 
healthcare professionals received training about Pharmacovigilance and ADRs 
reporting (see Figure 26). Furthermore, the NPC encouraged healthcare 
professionals to provide 10 reports by using the motivation of giving them a 
Figure 25: Medications Alerts by SFDA in local and international websites 
(source: www.sfda.gov.sa). 
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"reporting award" which was equivalent to one hour accreditation in the 
Continuous Medical Education programme (CME) by Saudi Commission for 
Health Specialties (SCHS). 
 
Figure 26: Awareness of Healthcare professionals and Public  
(Source: www.sfda.gov.sa). 
 
3. Basic Steps in Setting up the NPC: 
 According to generally accepted guidelines for the safety monitoring of 
medicinal products, and the setting up and running a Pharmacovigilance centre 
by WHO-UMC 2000, some individual choices remained in the country to decide 
what it would like a NPC need to do? Some considerations and requirements to 
be effective included the following points:- 
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1. Make contact with the health authorities and with local, regional or 
national institutions and experts in the fields of clinical medicine, 
pharmacology and toxicology outlining the importance of the project and 
its purposes.  
2. Create the centre with suitable staffing, accommodation, telephones, 
word processors, database management capabilities, and bibliography 
and library facilities.  
3. Produce printed material to inform health professionals about definitions, 
aims and methods of the Pharmacovigilance system.  
4. Provide education and training of the Pharmacovigilance staff with regard 
to: 
• Data collection and verification.   
• Interpreting and coding of adverse reaction descriptions.   
• Coding of drugs.  
• Case causality assessment.  
• Signal detection.  
• Risk management.  
 
5. Design a reporting form and start collecting data by distributing it to 
hospital departments, family practitioners, etc.  
6. Establish a database.   
7. Organize meetings in hospitals, academia and professional associations, 
explaining the principles and demands of Pharmacovigilance and the 
importance of reporting.  
137 
 
8. Promote the importance of reporting adverse drug reactions through 
medical journals, other professional publications and communications 
activities.  
9. Maintain contacts with international institutions working in 
Pharmacovigilance; for example, the WHO Department of Essential 
Drugs and Medicines Policy (Geneva) and the UMC, Sweden (WHO, 
2000). 
 
 One of the important targets of the establishment of the SFDA was to 
increase the awareness and knowledge of healthcare professionals and the 
public regarding the safety of drugs. It was considered a major role of the NPC 
was to educate and raise awareness for healthcare professionals, companies, 
scientific offices, patients and the public by using announcements in different 
ways.  These can include all the media outlets such as TV, radio, newspapers, 
internet and textbooks. 
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3.7 The Holy City of Makkah  
3.7.1 Background  
 Makkah is not only the Holy capital of the KSA but is the Holy capital of 
the Islamic world. Many pilgrims come to the city of Makkah during Ummrah 
and Hajj. The geographical location of Makkah; surrounded by volcano-derived 
mountains, is rather unusual. One Holy site is known as the Kabha which is 
located in the middle town of Makkah. All Muslim pilgrims pray facing towards 
the Kabha five times daily for prayers being held there at the Kabha (see Figure 
27). 
 
 
Figure 27: The Holy Kabah in the Holy City of Makkah 
(Source: www.islamwallpaperz.blogspot.co.uk) 
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3.7.2 Locations  
 The Holy city of Makkah is the capital of ‘Makkah Province’, which 
includes neighbouring Jeddah (see above Figure 8). It is found in the western 
part of KSA. 
3.7.3 Government 
 The governor of the Holy city of Makkah has full responsibility for 
everything about his province and, during the Hajj season, he is appointed by 
the King of Saudi Arabia (Saudi Arabia government) and has great powers to 
authorize and organize the Hajj season. In 2007, the Prince Khalid al Faisal was 
appointed as governor where he remains to this day. 
3.7.4 Language 
 Arabic is the official and main language of Saudi Arabia. In addition, 
many other languages are spoken due to the variety of Muslim people visiting 
Makkah, many of whom come from non-Arabic speaking countries.  These 
languages include:  English, Urdu (Indian-Pakistan), French, Tagalog 
(Philippine language), African languages and many more. 
3.7.5 Population 
       In 2008, the Population of Makkah, during Hajj, was estimated to be around 
5,448,773 including both Saudi and Non -Saudi residents. More recent statistics 
produced by the Government Statistics Centre are shown in Table 12: The 
population of Makkah in 2008 broken down into age groups and Saudi and non-
Saudi origin. 
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Table 12: Population of Makkah in 2008 broken down into age groups and 
Saudi and non-Saudi origin (Source: www.MOH.com). 
Age Groups 
Saudi Non Saudi Total 
Male Female Total Male Female Total Male Female Total 
≤1 56088 50350 106438 21685 24126 45811 77773 74476 152249 
1-4 234518 225114 459632 88751 86769 175520 323269 311883 635152 
5 -9 281827 257748 539575 101162 115771 216933 382989 373519 756508 
10-14 233106 229988 463094 89617 87982 177599 322723 317970 640693 
15-19 195951 185481 381432 60260 61152 121412 256211 246633 502844 
20-24 142348 167094 309442 77919 48073 125992 220267 215167 435434 
25-29 116214 141368 257582 124990 59836 184826 241204 201204 442408 
30-34 112514 105247 217761 162295 71650 233945 274809 176897 451706 
35-39 95341 101249 196590 155489 71184 226673 250830 172433 423263 
40-44 78761 79116 157877 114656 38111 152767 193417 117227 310644 
45-49 57433 58628 116061 74325 20584 94909 131758 79212 210970 
50-54 40689 45876 86565 40070 14949 55019 80759 60825 141584 
55-59 35923 34156 70079 22978 9544 32522 58901 43700 102601 
60-64 27121 33502 60623 13723 6197 19920 40844 39699 80543 
65-69 25775 15959 41734 7414 3569 10983 33189 19528 52717 
70-74 21160 17543 38703 4133 5275 9408 25293 22818 48111 
75-79 11360 9984 21344 2528 1604 4132 13888 11588 25476 
80-84 7441 7514 14955 1430 976 2406 8871 8490 17361 
85+ 8608 7465 16073 590 1846 2436 9198 9311 18509 
Total 1782178 1773382 3555560 1164015 729198 1893213 2946193 2502580 5448773 
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3.7.6 Description of Hajj  
       The Hajj is considered a fifth pillar of Islam and during the annual 
pilgrimage, there are more than 3 million people from all around the world 
visiting Makkah. It is suggested that each Muslim should visit Makkah at least 
once in a lifetime. So every adult, man or woman healthy, black or white, rich or 
poor, can perform the Hajj once in their lifetime. The Hajj is an intensive period 
of activity and lasts for 4 days. All the male pilgrims’ only need to wear the same 
simple white clothing, which represents human equality, so as to avoid any 
distinction between the different nationalities.  
       The pilgrims gather to perform rites dating back to the time of Abraham. 
The Hajj journey occurs in fixed Arabic Month called (Dull-Hajah) on 8th-12th of 
the same month of the Islamic calendar.  This will occur at different times of the 
year according to the Gregorian calendar in different years with the same route 
of pilgrims to be taken during Hajj every year (see Figure 28). The 8th of Dull-
Hajah is considered the first official day of Hajj so that all pilgrims after they 
arrive at Makkah have to reside in the area called the Mina area, three miles 
from Makkah. They stay at night in a city made from ‘tents’. The 9th of the 
month is the most important day for all pilgrims.  In the morning of the 9th, all 
pilgrims travel east to the Plain of area called ‘Arafat area’, where Muslims 
believe Adam and Eve were reunited after leaving Eden.  They remain there 
until sunset. 
       A daylong group vigil, in which pilgrims stand in the presence of God, 
marks the zenith of the hajj. At sundown, the Hajj loops back toward Makkah, 
halting at a patch of hills called ‘Muzdalifah area’, where pilgrims stop for the 
night, to participate in a nightlong vigil, and collect small pebble stones for the 
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next day. At dawn, pilgrims cast pebbles at the ‘Jamraat’, three stone pillars that 
symbolize temptation - places where Satan tried to tempt Abraham from the 
path of God. Firstly, they throw seven stones at the largest pillar, and then stone 
the other two over the course of two or three days. 
 Finally, back in Makkah, pilgrims perform the ‘’seven turns around the 
Kabah’’ one last time before heading home. The end of the Hajj is celebrated 
with a three-day feast (BBC, 2006 , Wikipedia, 2010). 
  
 
 
 
 
 
 
 
                                   (www.wikipedia.org/wiki/Hajj) 
For the 2009 Hajj, it has been estimated that 2,511,000 people attended and 
participated in the celebration. These included:-  
• 154,000 pilgrims coming from domestic areas within the KSA. 
• 1,613,000 were overseas pilgrims. 
But when all the data had been processed the corrected number of actual 
pilgrims was, in fact, 2,313,278 as shown in Table 13. 
Figure 28: Route of Pilgrims to be taken during the Hajj 
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Table 13: Total number of Pilgrims who took part in the Hajj between 1995-
2009 (Source: www.MOH.com). 
Year From Inside  The Kingdom 
From Outside the 
Kingdom Total 
1995 784769 1080465 1865234 
1996 774260 1168591 1942851 
1997 699770 1132344 1832114 
1998 775268 1056730 1831998 
1999 571599 1267555 1839154 
2000 549271 1363992 1913263 
2001 590576 1354184 1944760 
2002 610117 1431012 2041129 
2003 592368 1419706 2012074 
2004 629710 1534769 2164479 
2005 700603 1557447 2258050 
2006 724229 1654407 2378636 
2007 746511 1707814 2454325 
2008 679008 1729841 2408849 
2009 699313 1613965 2313278 
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 These numbers are more complex than first appears because some 
pilgrims do not follow the official policy and procedures in the Hajj rules and so it 
has been estimated that 753,000 more people took part as these were without 
valid Hajj permits but still participated in the Hajj (Embassy, 2009). 
 The Governor of Makakh province set up many workshops prior to Hajj to 
reduce such ‘improper conduct’ and to follow the Hajj instructions. They sent the 
instruction and regulations to all who were concerned with or had responsibility 
for pilgrims, agencies and all Saudi embassies worldwide. Furthermore, 
information for pilgrims was transmitted on all types of media; by television, 
radio, newspapers, films, etc., with the aim of increasing the awareness of the 
pilgrim’s knowledge about the Hajj.  
The most important points that were included can be summarized as:-   
1. The Saudi government will try its best to clamp down on violations and 
negative phenomena, such as selling fake products and begging 
2. The pilgrims must understand the importance of having licenses to 
perform the Hajj 
3. Another important issue is for buses not to carry more than 25 pilgrims. 
"all vehicles must be licensed by the Municipality” this is to ensure the 
safety of pilgrims 
4. All police authorities through their officers and officials will work 24 hours 
a day to eradicate the begging phenomenon, 
5.  The Ministry of Hajj will issue severe sentences and fines for those who 
violate the rules,  
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6. Local Hajj companies should not accept more than their official quota of 
pilgrims. 
  
Finally it was stressed that: 
‘Pilgrims should not think that they can break the rules.  
Being a pilgrim is not an excuse that allows you to break the rules of 
Islam and the Kingdom (Al-Jassem, 2009).  
 
 The Saudi Gazette, the newspaper found in all the Saudi embassies 
throughout the world reported that more than 1.6 million Hajj visas were issued 
in 2009. However, Ambassador Al-Salloom said that Saudi Arabia had deployed 
temporary Hajj missions to issue visas in countries where the KSA does not 
have embassies, including: Benin, Comoros, Gabon, Gambia, Kosovo, 
Kyrgyzstan, Macedonia, Mauritius, Sierra Leone, Tajikistan, Togo, and Trinidad 
and Tobago (saudiGazette, 2009) and so the numbers may have been higher 
than actually recorded. 
 According to the WHO the Saudi Arabian Government via the MOH lists 
some of vaccine requirements all pilgrims must have before the Hajj season 
and they must have a valid certificate for the following:- 
- Yellow Fever. 
- Meningococcal Meningitis. 
- Poliomyelitis. 
- Seasonal Influenza. 
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 Saudi health authorities may take precautionary measures in addition to 
the above-mentioned requirements in coordination with the WHO. These 
measures would be taken in a timely manner in order to avoid the spread of 
infection among pilgrims and Ummrah performers or the forward transmission of 
diseases to their home-countries. 
 
3.7.7 Healthcare in the Holy City of Makkah: 
 Makkah currently has 7 hospitals and many polyclinics staffed and active 
for these periods of the pilgrimage. They employ more than 50 pharmacists and 
300 assistant pharmacists. This study will explore the attitude and awareness of 
ADRs reporting amongst hospital pharmacists and health professionals.  
1. Hospitals in Makkah 
 The diagram below shows all hospitals supported by the MOH in Makkah 
and the number of beds each of these hospitals contains (see Figure 29 and 
Table 14): 
• King Abdulaziz Hospital. 
• King Fasial Hospital. 
• General Ajiad Hospital. 
• Al-Noor specialist Hospital. 
• General Hira specialist Hospital. 
• Children and Delivery Hospital. 
• Abin- Sina Hospital. 
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Figure 29: Hospitals of the Holy city of Makkah 
(Source: www.MOH.com) 
 
 
 
 
 
 
 
148 
 
 
Table 14: The number of hospital beds per hospital in Makkah 
(Source: www.MOH.com) 
During the time of the Hajj, the MOH provides different healthcare services and 
facilities to all pilgrims from the time the pilgrims arrive in Makkah until they 
depart to their own country. The provision is made in three main phases: 
A. Phase One   
 Healthcare is provided for pilgrims when they arrive in Makkah, 
irrespective of their route of arrival which can include: airports, ships, railway 
stations and motor cars as shown in (Figure 30). This service has three major 
types of provision as follows: 
• Treatments services. 
• Precautionary services.  
• Emergency services.  
NO Hospital 
Beds 
ICU 
Emergency Total 
Basic Extra 
1 King Abdulaziz  12 27 24 245 
2 King Fasial  12 10 22 159 
3 General Ajid  18 - 29 120 
4 Children and delivery  - 2 - 252 
5 Al Noor Hospital specialist 52 - 60 500 
6 Hira Hospital specialist 12 36 10 261 
7 Abin Sina  9 - 7 104 
- Total 115 75 152 1641 
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Figure 30: The Medical Services available to all pilgrims by different 
facilities in Makkah (Source: www.MOH.com). 
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B. Phase Two 
      In Makkah, the planning of healthcare during the Hajj seasons is more 
critical and concentrated due to the very high number of pilgrims being collected 
together in a relatively small area. So, the MOH inside Makkah has planned 
(see Figure 31) a system of cooperation with all the hospitals and many primary 
care centres, to provide a high level of healthcare for pilgrims by 6 polyclinics 
staffed by physicians from General Practice inside the Holy Harm mosque (Holy 
Kabah) and provides a comprehensive service available for 24 hours a day 
emergency cases. Also, the cooperation between all the hospitals in Makkah is 
made more effective by the extremely good co-ordination and co-operation (see 
Figure 32) shown for all the MOH hospitals, National Guard hospital, Ministry of 
Defense hospital, SFH, King Fasial specialist hospital and private hospitals. 
Therefore, in all parts of Makkah city had been distributed accurately and 
precisely, hospitals and primary care centers with international symbols easy to 
find it the location (see Figure 33).  
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Figure 31: Healthcare during Hajj in different places of Holy Makkah 
(Source: www.MOH.com). 
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Figure 32: Hospitals which co-operate together during Hajj period 
(Source: www.MOH.com). 
Figure 33: Map of Makkah showing all the hospitals and medical centres. 
The hospitals are shown as red squares with an included white letter H. 
The Red Crescent symbol shows the location of the primary care centres 
(Source: www.MOH.com). 
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C. Phase Three  
        During the Hajj, pilgrims stay in a tented ‘city’ known as Al-Mashar al 
Mokadasa. They usually stay there for a period of 12 days. Consequently, the 
government of the KSA has built comprehensive facilities to provide all pilgrims 
with access to hospitals and primary care centres by the MOH in co-operation 
with hospitals as shown in figure 34.  
       The MOH, in the countryside of Makkah, ‘Al-Mashar al Mokadasa’, provides 
96 polyclinics and 7 hospitals and an emergency compound in case of a 
disaster such as a fire, earthquake, flooding or volcano see Figure 33. The 
provision of services is divided into two major types of treatment services like:  
• Firstly, emergency cases, admission hospital intensive care unit (ICU) 
and operations.  
• The second, services which are precautionary including those for any 
infectious diseases, isolation and their treatment. The MOH plan of how 
they deal with healthcare services and providing services for pilgrims at 
Holy Sacred Places of Makkah during the Hajj.  
• The total of the healthcare medical staff is 11725, including: consultants 
(825), specialists (1876), in general practice (2132), technicians, (4266) 
nursing staff (2626) and non- technicians.  
 
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The total number of beds in all the hospitals which are located in Makkah is 
1080. Divided into:-  
1. Arafat area which has three hospitals (see Figures 35 and 36): 
A. General Arafat Hospital which has 300 beds. 
B. Arahma Mountain Hospital which has 140 beds. 
C. Namira Hospital which has 140 beds. 
2. Mina area which has four hospitals (see Figure 37): 
A.  Mina Hospital which has 50 beds. 
B. Mina Village Hospital which has 160 beds. 
C. Mina Bridge Hospital which has 150 beds. 
D. Mina Emergency Hospital which has 190 beds. 
Figure 34: Healthcare services provided for pilgrims in Makakh 
during the Hajj period (Source: www.MOH.com). 
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Figure 35: Location of the three major hospitals - shown by a red square 
containing a white H - and 49 medical centres (shown by Red Crescent) in 
the Arafat area (Source: www.MOH.com). 
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Figure 36: The Medical centres (shown by a red crescent) between the Arafat and 
Muzdalifa areas (Source: www.MOH.com). 
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Figure 37: The Hospitals (shown by a red square containing a white letter H) and 
Medical centres which are (shown by a Red crescent) distributed in the Mina area 
(Source: www.MOH.com). 
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Chapter Four 
4 Data Collection and Methodology for this thesis 
4.1 General Introduction 
This chapter presents the methodology for the data collected for this thesis.  
• The first data set was collected in the period - July, August and 
September 2010. The data was obtained by a sequential mixture of 
methods: beginning with a quantitative analysis of a close-ended 
questionnaire which included statements for measuring the strength of 
attitudes on a number of issues, related to ADR reporting, previously 
identified in the literature review.  These findings after analysis identified 
issues that required further exploration which became the basis for the 
second stage of the methods.  
• The second stage used semi-structured interviews with senior 
Pharmacists.  
• The third and final stage of the methods was to combine and analyze the 
findings from both the quantitative and qualitative stages, noting 
especially any important convergences or divergences.  Consequently, 
the key findings of this research were identified and then discussed, 
resulting in a number of recommendations.   
 
4.2 Research Question 
 As previously stated, ADR reporting is a relatively new process for the 
KSA, having been initiated as recently as 2009-10 with the setting up of the 
NPC and the transfer of ADR reporting being completed by 2010 
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(www.sfda.gov.sa).  In the literature review, many examples were given of 
countries that had a longer tradition of ADR reporting, which experienced in 
their earlier years, a low rate of reporting by health professionals for a variety of 
reasons. This research wished to build on the previous finding in other countries 
and to benefit from lessons learned from them.  Research previously conducted 
in KSA, has not included Makkah. Thus, it was of interest to discover whether 
findings would reveal any special implications for ADR reporting in Makkah.   
 Pharmacists are in a good position to detect ADRs and report them 
during their work at either hospital or community pharmacy.  It was of interest to 
the researcher to discover the efficiency of the current systems and practices 
for ADR reporting by pharmacists. Such an interest led to formulation of the 
following research question: 
 
"How efficient are pharmacists, in the Holy City of Makkah, in using the 
Pharmacovigilance system to detect and report ADRs?" 
 
Addressing this main research question was achieved after a comprehensive 
analysis of the literature (see Chapter Two above) which found that  the main 
research question also had a number of possible ‘sub-questions’ which arose 
from the  key issues in the many works published on ADR reporting.  These 
included: 
• Were pharmacists aware of the ADR reporting system? 
• Did pharmacists understand how to use the ADR reporting system? 
• Are we reporting systems available to pharmacists? 
• What are the attitudes of pharmacists to ADR reporting? 
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• What were the perceived barriers to ADR reporting on the part of 
pharmacists? 
• Was the knowledge of the ADR reporting system enhanced by the 
availability of training, library and internet access? 
• Did pharmacists consider that they have a role in ADR reporting? 
• Did pharmacists understand why ADR reporting is important?  
 
 All these ‘sub-questions’ helped the researcher to formulate the number 
and range of actual questions and attitudinal statements for the questionnaires 
as well as identifying issues for exploration during the semi-structured 
interviews.   
 
4.3 ADRs Reporting Survey  
 Studying ADRs reporting for this thesis in Makkah consisted of four 
studies: 
• The first were interviews with chief pharmacists in Makkah hospitals   
• The second was a questionnaire for healthcare professionals - doctors, 
dentists, nurses and hospital pharmacists employed by the MOH. 
• The third was a questionnaire for community pharmacists employed in 
the private sector. 
• The fourth was a questionnaire following an introductory lecture on 
Pharmacovigilance for student pharmacists in the 3rd and 4th year of 
the pharmacy degree of the department of Pharmacy, Umm Al-Qura 
University, and Makkah.  
161 
 
4.4 Ethical Approval and Confidentiality  
 Ethical approval was obtained from the MOH in Saudi Arabia, the Saudi 
Cultural Bureau Attaché at the Royal Saudi Embassy London, the University of 
Bradford, the SFH in Makkah, which when submitted  by the researcher to the 
Director of Hospitals MOH in Makkah enabled them to  grant official approval for 
the research. 
 
4.5 Confidentiality, informed Consent and Right to withdraw 
 The questionnaire which was sent to both hospital and community 
pharmacists and other healthcare professionals - doctors, dentist and nurses 
was designed to produce data which could not be attributed to a specific 
individual. Consequently, it was anonymous and was only coded for each 
hospital and each health care professional group. Respondents were made 
aware of this in the invitation letter, but were assured of the confidentiality of the 
answers they gave. To ensure respondents anonymity in the database, codes 
and hospital details were kept separately during entry and data analysis. 
Participation was on an entirely voluntary basis and without any incentives 
whatsoever. Respondents had been informed, through the invitation letter that 
returning the completed questionnaires would be deemed to be an indication of 
consent to participate in the study under the conditions of the study.  
 In these conditions, participants were informed that they had the right to 
have their data withdrawn from the study by a request to the researcher.  There 
may be a number of reasons why a particular participant might have second 
thoughts about the inclusion of their data and the literature contains suggestions 
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that it is sometimes not reassuring enough to simply state that the study will be 
anonymous.  This is because there could be situations where the participant 
might fear that somehow their data could be identified and might fear the 
possible consequences e.g. from their employer and the answers they have 
given to specific questions.  These fears were respected by the researcher and 
steps were taken to minimize any potential problems. 
 Accordingly, each participant was informed that they had the right to 
have their data and responses removed from the survey.  Although statistical 
packages allow for the removal of one set of responses from the dataset once it 
has been produced, and they will adjust graphics and statistical test results 
accordingly, it was not feasible that the right of withdrawal should be protracted, 
as results and findings may be significantly affected by a number of subsequent 
withdrawals. Therefore, the researcher allowed a three week period during 
which there was a right to withdraw.  Participants were advised that agreement 
to participate implied a commitment on their part to contribute to the research 
and that their right to withdraw would cease after three weeks. In the event, this 
precautionary step was found to be unnecessary as the researcher did not 
receive any request for withdrawal. 
 
4.6 Study Design 
 The quantitative study of health care professional was by using a self-
administered questionnaire (survey), distributed on a person to person basis by 
hand by the researcher.  The qualitative stage consisted of semi-structured 
interviews with 7 chief pharmacists, again by the researcher, and was carried 
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out following the full analysis of the questionnaire responses so ensure the most 
effective use of such a technique. The interviews which were used were 
designed on a thematic approach which could it was thought establish both 
commonalities as well as divergences of the relevant topic areas.  
 
4.6.1 Methodological Issues 
  The major advantage of any quantitative method used for experimental 
analysis is that it generates large amounts of data in an efficient way as the 
format is the relatively ‘easy to answer format’ through multiple choice 
responses or selecting a score on a rating scale. The major disadvantages 
include the fact that exploring issues in depth is simply not possible.  To 
strengthen the validity of the data, the questionnaire was first conducted in a 
pilot study to identify errors, ambiguities and possible sources of bias in the way 
the questions were framed.  A small number of points needed further 
clarification and this resulted in some questions being reworded, although not 
many changes were actually required.  Details of the pilot study are presented 
in section 4.6.5  
 In contrast, the qualitative methods  which were used did allow for a 
more in-depth probing of issues but were more time consuming to conduct and 
analyse and as a consequence usually only a relatively small number, but 
highly selected subjects, were are involved.  This is normal for this type of 
research. 
 So, whereas the quantitative methods give an analysis of the breadth of 
knowledge of the subjects and can be expressed in terms of numbers, the 
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qualitative methods tend to give a greater depth to the data, can express 
nuances and interpretations and sometimes probe the human meaning of a 
phenomenon. Sometimes because both the breadth and depth are sought in 
answering research questions, a mixed method is employed, combining both 
quantitative and a qualitative methods. There is an obvious advantage in having 
both breadth and depth in the findings of the research, but there may also be 
some disadvantages.  These include the additional resources of time, travel and 
costs (Denscombe, 2007). Another disadvantage is that the researcher may be 
knowledgeable and experienced with one type of method but may have to learn 
about and develop the skills necessary for the other method.  But, more 
fundamentally, there can also be problems when the findings of one method fail 
to corroborate the findings of the other method.  There can also be fundamental 
epistemological problems in a mixed method and because this is important for 
the studies carried out in this thesis this will now be addressed. 
It is admitted that a mixed method approach can result in a situation where the 
results from one stage are not supported or corroborated in the other stage.  
Such a situation would be difficult, if not impossible to resolve and would 
present a major defect in the mixed method.  The researcher was confident 
that, in this study, the risk of lack of corroboration was minimal and that there 
would be internal consistency in the research design.  The reason for this was 
the particular type of mixed method being utilised, that is a sequential mixed 
method.  The sequential mixed method implies that the findings of the first stage 
are used to formulate questions and issues to act as guidelines for the 
interviews.  Thus, it was expected that there would be internal consistency as 
the interviews were designed to probe in greater depth the important issues 
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which emerged from the questionnaires.  The analysis of the interviews was 
carefully conducted with a view to establishing the fact that issues raised in the 
questionnaire were corroborated by responses from the interviewees and that 
nothing contradictory to those findings was to be found in the responses to the 
interview questions.  In essence, one of the aims of the interviews was to take 
up issues from the questionnaire responses and to probe these in greater 
depth. Thus, the researcher was confident that there would be internal 
consistency within the mixed method, despite the conflicting epistemologies 
inherent in a mixed method approach.  
 
4.6.2 Epistemological Issues 
 The lack of corroboration in the findings obtained when these two 
methods are used is an obvious difficulty but rather than being a problem it may 
be considered an advantage and viewed as a better reflection of the real world 
situation(s) where matters are often quite complex and not capable of simplistic 
solutions. Of more crucial importance, though, are problems of mixed 
epistemologies inherent in a mixed method approach.  Epistemology refers to 
the truth claims being made by a research method and the underlying 
philosophical assumptions.  Quantitative methods are most often considered to 
be based in positivistic or scientific realism.  This assumption is based on taking 
any data which reflects an individual’s sense of experience as being a true 
reflection of the real world. This can be problematic. In contrast,   qualitative 
methods are often based on the assumption that the individuals mind interprets 
phenomena and searches out the human meaning of experiences.  Put more 
simply, the claims of quantitative methods are based on an objective, mind-
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independent reality, whilst qualitative methods are more subjective, viewing 
reality as the human meaning or interpretation of what is perceived.   Both types 
have an established role in research protocols. 
 This established role was recently commented on by Robson, (2011) 
who suggested a resolution of the mixed epistemologies could be achieved by 
using/ adopting a pragmatic approach. He suggested that, underlying 
quantitative studies are the assumptions of scientific realism; underlying 
qualitative methods are the interpretive, hermeneutical or phenomenological 
assumptions which require the adoption of pragmatism.  Robson (2011) sees 
no problem in having conflicting philosophical underpinnings for each stage of 
the mixed method.  He declares in fact that because the ‘mixed methods’ work 
in practice this is sufficient justification for their use. Pragmatism indeed! 
 More recently, Bryman (2012) has commented that the conflicting 
epistemologies inherent in mixed methods simply mean that each stage 
employs distinctive epistemological assumptions but that "these connections 
are not viewed as fixed ineluctably" (Bryman, 2012).  In my thesis I have taken 
the view that irreconcilable epistemologies in the stages of a mixed method 
should be frankly admitted, and the section above tries to outline such 
procedures, but despite this difficulty, valuable insights may be gained using 
both methods and so this is what was used. 
 Finally, this problem is not as simple as the mixing of two distinct 
methods.  Choosing one particular method implies not just a commitment to 
certain epistemological assumptions but a paradigm choice as recently 
described by Bryman (2012). The author sees the conflicting paradigms as 
167 
 
incompatible because the researcher, using a mixed method, still remains 
committed to a single paradigm and cannot consistently commit to both.   
 Personally, coming from a pharmaceutical background, I remain 
committed to a scientific realist paradigm and so opted for a mixed method 
approach in the hope that the qualitative method would in some way enhance 
the findings of the quantitative method.     
 
4.6.3 Research Methods  
 Having opted for a mixed method approach decisions were needed 
about the particular type of mixed method appropriate for this study.  Three 
distinct types of mixed methods were proposed by Cresswell (2009) depending 
on whether the methods were to be conducted at the same time and 
independent of each other, or whether one method follows the other 
sequentially and the second method does not commence until the first has been 
conducted and analysed.  Issues arising from the analysis of the findings of the 
first method are used to frame the second method.  Thus, the options here are 
either quantitative followed by qualitative, or else, the qualitative method is 
conducted first and is followed by the quantitative. 
 This thesis has opted for a sequential mixed method in which the 
quantitative stage is conducted and analysed, and, in the light of the findings, 
only then is the qualitative phase conducted. The quantitative phase is based 
on a questionnaire consisting of close-ended questions and attitudinal 
statements.  These incorporate the various research sub-questions designed to 
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measure the extent of respondent's knowledge, to gauge their attitudes and to 
discover their actual behaviour vis-à-vis ADR reporting. 
 The questionnaire was conducted based on a random, representative 
sample of groups of healthcare professionals (doctors, dentists, and nurses) 
and pharmacists (hospital pharmacists, community pharmacists, student’s 
pharmacists and Chief Hospital Pharmacists). In total 470 people were used in 
this study which was based exclusively in Makkah. Questionnaires were used to 
establish the knowledge, attitudes, behaviour, understanding of ADR and 
barriers about the multiple variables associated in ADRs reporting [see 
Appendix 8.4]. 
  
4.6.4 Questionnaire Development 
 Questionnaire design was based on many previous ADR studies from 
across the world reported in the literature. These included in chronological 
order: Lee et al. (1994), Ferguson & Dhillon (1999), Green et al (1999), Sweis & 
Wong (2000), Van Grootheest (2002a), Bawazir (2006), Toklu & Uysal (2008), 
Al-Sultan & Bawazir (2009), Su et al. (2009), Vessal et al.(2009), Oreagba et 
al.(2010), Ting et al.(2010). The final questionnaire for this study was designed 
to collect data relating to Makkah as previous studies in Saudi Arabia were 
focused on Riyadh and other cities but not including Makkah. It was of interest 
to the researcher to discover any similarities with those previous studies as well 
as any phenomena which were unique to Makkah. The design of the 
questionnaire included comprehensive consideration of question format (close-
ended question). Close-ended questions simply asked for either 'Yes' or 'No' or 
the selection of an answer from a ‘multiple choice’ type of possible responses 
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by ticking the appropriate box.  This made it as user-friendly as possible for the 
respondents and facilitated the collection of numerical data and its collation 
prior to be examined for comparative purposes. Coding for data entry also was 
considered as part of the questionnaire development.  A list of the variables 
prepared for loading into SPSS is to be found in (Appendix 8.6)   
The questionnaire had 38 questions arranged in 5 sections.  The first of these 
sections was designed to collect data on respondents' sex, age, professional 
status, education and nationality.  These would become independent variables 
for analysis to discover any trends based on these factors.  The remaining 
questions and attitudinal statements were designed to measure extent of 
knowledge and attitudes towards ADR reporting.  Data has been presented in 
tables and graphs using Microsoft Excel and the SPSS analytical tool.  The 
researcher was guided in using SPSS by following Greasley (2008).  It was 
proposed to target a sample of size 470, drawn from the seven hospitals.  
 
4.6.5 Pilot questionnaire  
A pilot questionnaire was given to five pharmacists who were not participants in 
the study proper and they were informed that their role was to assess the 
questionnaire to ensure that it was fit for purpose and to indicate where there 
were ambiguities or bias through loaded questions.  In the light of feedback 
received, modifications were made to two questions which were considered 
ambiguous relating to "attitude toward ADRs reporting system".  Question A7 
asked about continuing education and training. Three of the respondents in the 
pilot study noted that access to internet facilities was an important factor in 
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continuing education and it had not been included in the questionnaire.  
Accordingly, in section A, question 8 was added asking whether internet 
facilities were available (See Appendix 8.4). 
• Do you have an internet facility in your work place?  
A. Yes   
B. NO 
Section D, question 2 was about attitude towards ADR and which bodies should 
be included in the reporting.  The original questionnaire had only four options 
but two of the participants alerted the researcher to the need for including the 
newly established SFDA.  Accordingly, a fifth option was included in this 
question in the final version (See Appendix 8.4): 
• Submitting ADR Reports to : 
A. MOH     
B. Pharmaceutical Industry     
 C.SFDA      
D. Others       
E. don’t know  
Following these revisions, they were pre-tested in another pilot group of five 
academic postgraduate pharmacy students at the University of Bradford.  Once 
again, the participants were briefed about the purpose of the pilot which was to 
identify any errors or ambiguities. No further problems were identified and thus 
the researcher was confident that the questionnaire was free of ambiguities and 
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biases and was therefore fit for purpose as an instrument for collecting the 
required data. 
 
4.7 The Qualitative Phase:  Semi-structured Interviews  
 Semi-structured interviews were conducted with 7 chief hospital 
pharmacists in Makkah to determine their awareness and knowledge of ADRs 
reporting and to explore issues from the findings of the questionnaire (see 
appendix 8.7). The questions focused on: 
• General information related to the ADRs reporting system in the hospital 
and their roles. 
• Attitude and behaviour toward ADRs reporting. 
• Availability of and barriers to ADRs reporting.  
Semi structured interviews contain open ended questions that invite discussion 
and reflection rather than "yes" or "no" responses which are more typically 
found in questionnaires or structured interviews.  The interviewer aims to 
prompt the interviewee to greater in-depth discussion rather than simple short 
answers.  Following the analysis of the questionnaire (Ch 5) some issues were 
identified that would be explored further in the interviews.  The following is a list 
of those questions and issues.  The interviewer is free to pose these questions 
in a natural way as they come up during the interview so the questions need not 
be asked in the order shown here.  Rather this list is to serve as a guide for the 
interviewer who will be expected to ensure that they are all explored naturally 
within the flow of the interview. 
List of questions and issues for the semi structured interviews: 
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1.  General background questions related to the interviewees' roles as they see 
them, their qualifications and experience, especially the length of time they have 
spent in more senior supervisory and managerial roles. 
2. Knowledge of ADR reporting, what it entails, its purpose and where the report 
should be sent.   
3.  Is ADR reporting consistently carried out in your organisation?  Why or why 
not?  Is there a clear policy and procedure in place?  If there is no policy, is 
there some system of reporting that is carried out in practice?    How effective is 
this system or practice? 
4.  Who is responsible for ADR reporting in your organisation?     
5.  How important is ADR reporting? Why/why not?  What is your personal 
attitude towards ADR reporting?  Do you view it as helpful?  Or is it seen as a 
bureaucratic system - another form to be filled out? 
6.  Have you had any training in ADR reporting?  If not, would you be open to 
undertaking some training? Would your staff members be open to receiving this 
training? 
7.  What problems do you think would occur in trying to implement and embed 
an ADR reporting system in your hospital?  Would there be resistance?  How 
could you deal with such resistance?  
8. What technical support would be required?  Do you have sufficient IT 
systems in place?  Do staff members have sufficient access to computers and 
the internet?  What measures will need to be taken to ensure internet security 
and backup systems?  
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9. Would you be open to introducing an ADR reporting system?  How would you 
motivate your staff members to accept such a system and to ensure that it is 
effective?  Would you be willing to promote it among your staff members? 
10.  Do you think an ADR reporting system can work in practice?  What steps 
can be taken to ensure that it works properly?  How would you monitor its 
effectiveness? 
11.  What impacts do you think ADR reporting would have on patients?  What 
benefits do you think it could bring to your hospital?  Would it add to the 
workload of staff members?  Could it possibly reduce their workload in the 
longer term? 
12.  Do you have any questions on ADR reporting?  Do you have any 
suggestions?  Would you be willing to keep in contact with me by phone or 
email, if you have questions or suggestions in the future? 
These questions and issues are to be explored in the interview.  This list is not 
meant to be prescriptive and the questions need not be addressed in the order 
above.  However, all of them need to be included in the semi structured 
interview.  Assurances of confidentiality and anonymity will be given. 
 The interviews were held in the chief pharmacists’ own offices as it was 
felt that they would be more likely to participate if they were not required to 
travel to some other venue.  The original interviews were in Arabic (see sample 
in Appendix 8.7) and transcripts were prepared in English (see sample in 
Appendix 8.7)  The researcher felt that the interviewees were more likely to feel 
relaxed being interviewed in their native tongue and the environment of their 
own offices would be perceived as non-threatening. The respondents were 
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most cooperative and it was easy to negotiate a mutually convenient time to 
meet for the interview. The timing of the interviews ranged from 35 minutes to 
55 minutes. The responses were recorded by the researcher by writing notes in 
shorthand during the interviews and writing them up in greater detail later the 
same day.  This method was felt to be more appropriate in the context than tape 
recordings which might have been felt by the respondents to be rather intrusive. 
 The responses in the transcripts were read 3 times each and notes were made 
in the margin on the second and third readings. Common themes which 
emerged were used for analytical purposes but equally important, divergent 
views were also noted.  A process of thematic encoding was followed leading to 
the stage of exile coding where the themes were isolated from their original 
contexts.  Finally, the themes were closed down to a number of broad 
categories through which the totality of the responses could be viewed.  These 
categories are presented in chapter 5 and discussed in chapter 6. 
 The researcher feels that the responses were honest and frank as it was 
possible to carry out as the interviewees accepted responsibility for contributing 
to the enhancement of healthcare by giving simple, straightforward and honest 
responses.   
Following the guidelines given by (Robson, 2011, p.467), a thematic coding 
approach was utilised to analyse the qualitative data from the interview 
sessions.  The approach was to allow the themes to emerge quite freely even, 
where appropriate, using ‘hunches’ as is commented on in (Foss and Williams, 
2003).   By this method, the data was processed by reducing the emergent 
themes further and encoding them.  
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Each transcript was read thoroughly, then  a second reading with the purpose of 
extracting themes and subthemes. The researcher kept the coding as open as 
possible. The researcher found it useful to keep a memo as recommended by 
many authors [e.g. Fielding (2008), and Strauss and Corbin (1998)] so that 
insights gained in the process would not be lost or forgotten.    
Recognising recurring patterns enabled the researcher to select a smaller 
number of key themes as recommended in Creswell (2009) and Silverman 
(2011) and many other writers in the field. 
A list of themes and open type questions used to guide the interviews is 
presented in Appendix 8.7                                                                                                                                                                                          
 
4.8 The sequential mixed method 
 This part of the study used the findings of both the quantitative and 
qualitative stages.  In a sequential mixed method, the central aim was to focus 
on issues derived from the questionnaire and to probe these in greater depth to 
discover subtleties and nuances.  The issue of corroboration, then, did not arise 
as the first phase was used to inform the second.  It was found at the mixing 
stage that the interviews actually enhanced the main findings of the quantitative 
phase. 
 
4.9 Pharmacy student questionnaire post Pharmacovigilance lecture 
 An interesting aspect to the sequential mixed method was a short open 
ended questionnaire given to pharmacy students to address their knowledge 
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and deficiencies of Pharmacovigilance and ADR reporting.  A lecture on 
Pharmacovigilance and ADR reporting was given by the researcher.  At the end 
of the lecture, the students were to respond to two open ended questions and to 
email their responses to the researcher. Assurances of anonymity and 
confidentiality were given. There was a total of 180 students divided into 
classes of 25 or 26 and a total of 136 students submitted their responses by 
email and handwriting (some samples of responses are included in Appendix 
8.7).  Verbal feedbacks at the end of the lecture as well as the email responses 
were generally positive in their attitudes to the importance of Pharmacovigilance 
and ADR reporting. None of the responses were negative towards ADR 
reporting and respondents either saw it as "important" (64 respondents = 47%) 
or very important (72 respondents = 53%). The response rate of 136 from 180 
students (76%) was excellent, though it is not possible to speculate why the 
remaining 24% did not respond and what their attitudes might have been.  
Suffice it to say that these students are engaged on a very busy training 
programme.  Thus a response rate of 76% must be viewed as a very positive 
and representative response. These results provided an interesting and 
contrasting insight from those obtained in the mixed method, from the 
perspective of education and training. This is more fully considered in Chapter 
5, where comparisons are also drawn from the literature on the inclusion of 
Pharmacovigilance in pharmacy curricula and training programmes. 
 
4.10 Evaluation of the Method 
 Although the mixed method approach offers the advantage of both 
breadth and depth, many authors point out inherent difficulties in such an 
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approach. Conducting both quantitative and qualitative methods calls for 
additional resources of time travel and costs (Denscombe, 2007). Since in the 
sequential mixed method the second phase cannot be conducted until the first 
has been completed and analysed, it is obvious that this adds considerably to 
the time involved in the collection and analysis of the data (Creswell, 2009). 
 There is also the problem that may arise when one study fails to 
corroborate the findings of the other.  This is a real risk, especially when the 
same research questions underlie both methods. However, this is not 
necessarily the case with sequential mixed models.  In this current study, the 
subject matter of the qualitative stage arose from the findings of the quantitative 
stage.  The main purpose of the interviews was not primarily to confirm the 
findings of the questionnaires but to focus deeply into issues arising from the 
questionnaires. What was primarily being sought in Phase 2 was an 
enhancement and deeper exploration of issues rather than confirmation.  Of 
course, it would be a desirable outcome if one method did corroborate the 
other.  But even where there is a lack of corroboration, the mixed method is still 
worthwhile in providing both breadth and depth to the research. 
 A more serious issue in this research design is the problem of conflicting 
epistemological assumptions underlying the two methods.  This problem has 
already been discussed earlier in this Methodology chapter (see section 4.1.3).  
It has already been mentioned that using a quantitative method followed by a 
qualitative one involves a paradigmatic shift on the part of the researcher.  
However, it has also been commented on that this is impossibility for the 
researcher due to the paradigm commitment involved.  
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  The researcher, coming from a scientific background, remains 
committed to a scientific realist stance.  Attempts to reconcile conflicting 
epistemologies appear unconvincing to the researcher who also tends to view a 
pragmatic solution as untenable. The researcher views the problem of 
conflicting epistemologies as a real one, but one which can be accepted as a 
reflection of the complexities of real life situations. This, seemingly intractable 
problem is frankly admitted.   Nevertheless, this study has been worthwhile and 
will hopefully add to the scholarly discourse on the subject of ADR reporting.   
 Finally, there is the issue of language.  English is well recognised as the 
"lingua franca" of trade, commerce and higher education.  Third level colleges, 
in the Middle East, frequently deliver their lectures in English, or at least 
bilingually, in both Arabic and English.  There are two reasons for this; firstly, 
much of the scholarly work and research has been conducted through the 
English language and, secondly, students, after graduating, are likely to be 
working in a global context where English is commonly used in global 
communication. 
 The questionnaires were presented using the English language since the 
participants were practitioners in healthcare and were reasonably proficient in 
reading English texts.  The use of English facilitated the analysis and discussion 
of the data for a thesis which was to be presented in the English language. 
 In contrast, the face to face interviews were conducted in Arabic and the 
notes taken during the interview were in Arabic. These were then written up fully 
in Arabic immediately after the actual interviews. The final transcripts were then 
translated into English.  
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Chapter Five 
5   Data Analysis and Results 
5.1 Data Analysis 
5.1.1 Part 1: Questionnaire for Health Professionals 
 The researcher visited all the 7 hospitals used in this study namely; 5 
general and 2 specialists’ hospitals.  The following hospitals were included: the 
King Abdul-Aziz Hospital, King Faisal Hospital, General Ajiad Hospital, Children 
and Delivery Hospital, Abin-Sina Hospital, Al-Noor Specialist Hospital and 
General Hira Specialist Hospital. In all these hospital health professionals were 
invited to participate in the study. The study was fully explained to the 
participating health professional by a face -to- face meeting and by a covering 
page letter in both English and Arabic. They were assured about the anonymity 
and confidentiality of the data. The responses of the health professionals to the 
survey were either obtained at the same time as the distribution or collected 
over the next 12 weeks.  
 Of the 470 questionnaires which were circulated, 310 were completed by 
205 doctors, 25 dentists, 49 pharmacists and 31 nurses.  With respect to the 
pharmacists in July 2010, just before this part of the study was carried out, the 
register of the Health Affairs Directorate listed 64 hospital pharmacists (45 were 
Saudi hospital pharmacists and 19 non-Saudi hospital pharmacist) in Makkah 
hospitals. The response rate of the pharmacists group was 76.5 %.   
The questionnaire comprised 5 sections, namely A, B, C, D and E: In brief (see 
Appendix for the full questionnaire 8.4). 
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Section A, ten questions covering the health professional demographics, 
reference texts availability and continuing education activity.  
Section B contained general questions aimed at establishing the extent of the 
respondents’ knowledge about the Saudi ADR reporting system.  
Section C was designed to find out the extent of the participants' knowledge as 
to the purpose of an ADR system.  
Section D consisted of thirteen items exploring the health professionals' attitude 
to reporting and the factors that either positively or negatively affected their 
attitude and behavior toward ADRs reporting system.  
Section E questions were designed to investigate the barriers of ADRs system 
in Makkah. 
 All items were a series of statements and the health professionals were 
asked to indicate the strength of their agreement or disagreement on a 5 point 
Likert scale from ‘strongly agree’ to ‘strongly disagree’. A 4 point scale does not 
contain a middle option of neither agreeing nor disagreeing as this avoids a 
"sitting on the fence" response and so forces the respondent to register some 
view.  Some authors are critical of using a 4 point scale as a neutral response to 
some questions might actually be the correct position of the respondent.  Thus 
to avoid the risk of bias the researcher has used a 5 point scale to allow for 
genuinely neutral positions on some issues. 
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1.  Statistics 
Statistics are presented in tables which can be found in Appendix 8.6.  
Graphical representations of these tables will be presented in the text.  The full 
list of variables prepared for loading into SPSS is to be found at the beginning 
of (Appendix 8.6). 
Responses to each question and their percentage values were calculated. In 
the analysis of all the questions, the total number of respondents to the 
questionnaire survey was used to calculate this value. This was considered 
acceptable as so few questionnaire forms contained a zero answer. 
The raw data was loaded into SPSS and a table was created with 38 variables 
across the 310 cases.  Summary statistics from SPSS for the demographic 
variables sex, age, nationality, specialism, educational qualification and 
professional experience are presented in Table 32 in Appendix 8.6.  Frequency 
tables for these variables are in Tables 33 - 38 in Appendix 8.6. 
 
2. Results 
Section A. Demographic Information of Health professionals (n = 310) 
 A total number of 470 questionnaires were distributed and 310 were completed 
and collected, a response rate of 65.9%. The major reasons for non-participation 
(34.1%) were being too busy and/or unwilling to participate. The demographic 
statements for all the respondents will be presented below. The majority (70%) were 
male (See Table15 and Figure 38) There were 217 (70%) males and 93 (30%) 
females in the sample. Women are better represented in the medical profession 
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than within employment as a whole in Saudi Arabia which is estimated to be 
below 22% (Al-Arabiya, 2012). 
Figure 38: Bar chart showing Sex distribution  
 
 
 
 
 
 
 
        
      Table 15: Gender of health professionals 
 
Variable Number (%)* 
Sex 
Male 217 (70 %) 
Female 93 (30%) 
 
 
Age distribution  
46.8% were in the Age range 31-40 years (see Figure 38). The median age in 
Saudi Arabia is 25.7 years (index mundi 2013) so these figures suggest that our 
sample might be slightly skewed in the direction of the oldest age group.  
However, the age range begins at 23 which is the youngest age to work in the 
medical profession due to the level of qualifications required. 
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30% 
46.80% 
23.20% 
From 23 to 30
From 31 to 40
Average 40
 
 
 
 
 
 
 
 
 
 
 
Nationality: 
 
The majority of the health professionals were non-Saudi 64.8% (n=201) (shown 
in Table 16 and Figure 40) all of whom have to be Muslim for eligibility to work 
in Makkah.  This is due to the shortage of qualified Saudi medical professionals.   
 
Table 16: The Nationality of health professionals 
 
 
 
 
 
Figure 40: Nationality  
 
 
 
 
 
 
 
Nationality 
Saudi 109 (35.2%) 
Non-Saudi 201 (64.8%) 
Figure 39: Age groups (years) of the health professionals in this study 
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Specialist: 
The majority of respondents were physicians 66.8% (n=207) (see Figure 41) 
and (in Appendix 8.6 see Table 35) almost half of which held a master degree 
qualification 46.5% (n=144) (see Figure 42). Thirty-five percent of the health 
professionals had between 11 to 20 years of experience (see Figure 43), the 
modal time spent on continuing education was found to be 6-10 hours for 34.2% 
of the group (see Figure 44). Commonly the health professionals stated they did 
not have appropriate library references available to check for ADRs (see Figure 
45). Only 39.1 % of health professionals had internet access (shown in Table 
17). Finally, 64.8% (n=201) had not been trained as to how to report ADRs 
(shown in Table 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Response rates of health professionals 
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Figure 42: Highest qualification of health professionals 
Figure 43: Number of year’s professional experience of health 
professionals.  (Median= 20.0 years) 
Figure 44: Number of hours per month spent in "training" by 
health professionals  
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 Table 17: Internet facility availability for health professionals in workplace 
Internet facility in work place 
Yes 121 (39.1%) 
No 189 (60.9%) 
 
 
 
 
 
Table 18: Health professionals trained in reporting methods 
 
 
 
 
 
 
Trained how to report ADRs 
Yes 109 (35. 2%) 
No 201 (64.8%) 
Figure 45: Reference books available to health professionals 
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Section B. Familiarity with the ADR reporting system 
 47.1% (n=146) of the respondents were aware of existence of ADR 
reporting and monitoring system in Makkah (shown in Table 19). 51.9% (n=161) 
of the respondents considered that this system was being implemented in their 
hospital (see Figure 46).  59% of the health professionals were not aware of the 
existence of National Pharmacovigilance Center (NPC) in the Saudi Food and 
Drug Authority (SFDA) (shown in Table 20). This is due to the fact that the 
SFDA is newly established having opened in 2009 and there is a lack of 
knowledge about its function. 55.5% had learnt about the ADRs programme 
from an official at work (see Figure 47) and this fact is of interest to the 
researcher in devising a strategy for disseminating information. 36% of 
respondents thought the MOH was the department which was responsible for 
receiving the ADRs reports and interpreting them (see Figure 48). 
 
Table 19: Familiarity with the ADR reporting system  
% Number Are you aware of the ADRs reporting 
47.1% 146 Yes 
31.6% 98 No 
21.3% 66 Not sure 
100% 310 Total 
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     Figure 46: Have you an ADRs reporting programme in your hospital 
 
Table 20: Awareness level of the of the NPC in SFDA  
Percentage Number   Are you aware of the existence of  NPC in SFDA 
40.9% 127 Yes 
59% 183 No 
100% 310 Sum 
 
 
 
Figure 47: How did you become aware of the ADR reporting system 
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Figure 48: Department responsible for receiving and interpreting ADRs 
reporting. 
 
 
Section C: The purpose of the ADRs reporting system 
 50% of the health professionals opined that this system had benefited 
patients by identifying safe drug use. 46.1 % considered it would be useful to 
calculate the rate of incidence of ADRs and 54.2% of health professionals 
considered the purpose of the reporting system was to identify ADR within the 
same pharmaceutical class and 48.4% of respondents considered the purpose 
of the ADR reporting was to detect potential ADRs. 42.9% of respondents 
thought the system served as a source of information about the characteristics 
of ADRs (shown in Table 21). 
 
35.80% 
23.90% 
18.10% 
22.20% Ministry of Health (MOH)
Saudi Food and Drug
authority (SFDA)
Pharmaceutical Company
Don’t know 
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Table 21: The purpose of ADRs reporting system 
Not sure No Yes  
Statement % No. % No. % No. 
28.7 89 21.3 66 50 155 The ADR reporting will identify safe drug 
24.5 76 29.4 91 46.1 143 The ADR reporting will identify rate of 
incidence 
26.1 81 19.7 61 54.2 168 The reporting system will identify ADRs 
variations with the same therapeutics 
class 
22.2 69 29.4 91 48.4 150 The ADR reporting will detect potential 
ADRs 
30.6 95 26.5 82 42.9 133 To serve as a source of information about 
the characteristics of ADRs 
 
 
 
Section D: Attitude towards the ADR reporting system 
       Perhaps the results of major importance were that 70% of respondents 
agreed that pharmacist assistance - in detection, reporting and management of 
ADR was very useful and was part of a professional's role. This was far more 
than just the Pharmacists responding in a positive way. More than 70% 
reporting that it was an integral part of a normal task (see Figure 49). 34.20% 
(n=106) of respondents were only reporting of ADRs based on "a life 
threatening situation" (see Figure 50). They indicated by ADR reporting 
responsibility of pharmacist, physician and patient being 42.6%, 30.6% and 
7.1% respectively (See Figure 52). From the group 62.6% believed that ADRs 
reporting facilitated the science of monitoring drug safety and was important. 
The majority also thought 79.4%, it was essential to be sure of the causality 
relationship between the drug and an ADR before reporting it. Of great interest 
was that 70% of the health professionals had experienced ADRs in their normal 
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professional practice and 73.5% thought that ADR reporting was an indication 
of taking patients' complaints seriously (see Figure 49). Perhaps surprisingly, 
47.1% stated that they had come across a patient(s) with an ADR during the 
previous month and they had wished to report it (shown in Table 22). In fact 
33.2% (n=103) were submitting an ADRs report to Ministry of Health (MOH) 
located in Makkah, Saudi Arabia for such an event (see Figure 51), 71.3% of 
the respondents felt the need to discuss the report with the prescriber before 
reporting the effect. Finally, the study provided results which suggested that the 
vast majority of the health professionals, 67.1%, thought that ADRs reporting 
should be a mandatory programme (see in Figure 49).  
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Figure 49: Health professional attitude toward ADRs reporting 
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1- ‘I would report an ADRs that causes: 
 
 
 
Figure 50: Reporting of ADRs based on causal effects 
 
 
2- Submitting ADRs reported to: 
 
 
Figure 51: Submitting ADRs reported to 
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3- Have you come across patient(s) with an ADRs during the last month 
and wished to report it? 
 
Table 22: Proportion of the respondents to the survey who had 
encountered patient(s) with ADRs during previous month and had wished 
to report it. 
 
Percentage Number   Have you come across patient(s) with ADRs during last month and wished to report it? 
47.1% 146 Yes 
52.2% 162 No 
0.64% 2 I don’t know 
100% 310 Sum 
 
 
 
 
Figure 52: Responsibility to report ADRs 
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Section E: Constraints on ADRs reporting 
 The main factors which discouraged ADR reporting is shown in (Figure 
53) where 66.8% of the respondents did not report ADRs because reporting 
forms were simply not available.  
 However, when ADRs forms were available then 55% of the respondents 
could not complete them as they were not sure how to use them and 63% did 
not report ADRs simply because they did not know the address to which these 
reports should be sent.  
 More than 50% of health professionals did not report ADRs because they 
described the reporting form as simply too complicated to fill in and in a similar 
way 58% of respondents mentioned that the ADRs reporting was time 
consuming.  Furthermore, 65% said they were reluctant to complete the form 
due to insufficient clinical knowledge and 52% believed that all serious ADRs 
were already detected and known for a newly marketed drug.  This wrong 
perception is a major cause for concern. Finally, 57% of health professionals 
stated that the lack of ADRs reporting may reflect the fear to report such events 
(see Figure 53) as it may cause problems to themselves, their department of 
their hospitals. 
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Figure 53: Constraints of the study 
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3- Statistical Tests (SPSS) 
Cross tabulation for the importance of reporting ADR against gender showed 
that there was little difference based on gender with 71% of males agreeing or 
strongly agreeing and 66% of females (Table 39 Appendix 8.6).  Similar results 
were also found for gender against agreeing or strongly agreeing being 60% for 
both male and female (Table 40 Appendix 8.6) 
 A more significant cross tabulation result was that found for age against 
agreeing or strongly agreeing about the importance of ADR reporting.  The 
figures show a downward trend from the 23-30 age group which returned 
agreeing or strongly agreeing at 93%.  The corresponding figure for the 31-40 
age group was 74.2% and for the 40+ age group 53% (Table 41 Appendix 8.6).  
Why this trend exists would be worth exploring during the next stage of the 
mixed method in the semi structured interviews.  Cross tabulation for 
importance of ADR reporting in monitoring patients' health, however showed 
very little difference across the age groups (Table 42, Appendix 8.6). 
Another interesting cross tabulation result was found for nationality against 
agreeing about the importance of ADR reporting.  The results showed that 85% 
of Saudi nationals were in agreement while only 61% of non nationals were in 
agreement (Table 43, Appendix 8.6).  
Similarly, the importance of monitoring for ADR’s in Saudi nationals was at 78% 
whereas this was only 50% for non Saudi’s. 
A t-test of the mean response rates on the question of awareness of the 
importance of ADR reporting for the Saudi and non Saudi group revealed a very 
significant difference with p = 0.02.  This shows that the higher reported 
awareness of the importance of reporting among Saudis as compared to non 
Saudis is highly significant and not attributable to natural variation in the data 
(Table 46 Appendix 8.6).   
This is strengthened by the 95% confidence interval for the mean difference 
which ranges from – 0.268 to – 0.023.  This interval does not contain 0 
therefore with 95% confidence, the mean difference is significant. 
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Cross tabulating insufficient clinical knowledge against agreeing or strongly 
agreeing on the importance of ADR reporting revealed that 72% agreed that 
reporting was important despite their lack of clinical knowledge (Table 44 
Appendix 8.6).  Cross tabulating insufficient clinical knowledge against agreeing 
or strongly agreeing on the importance of ADR reporting for monitoring patients’ 
progress revealed that only 55% were in agreement that it was important 
(Table45, Appendix 8.6). 
Correlating specialism against agreement on reporting responsibility revealed a 
weak negative correlation (r= -0.328).  However, a very high significance level 
was returned at 0.000. (Table 47 Appendix 8.6)  This indicates that as the level 
of specialism increases the degree of agreement on the importance of ADR 
reporting decreases.  A scatterplot of this correlation is presented in Figure 54. 
 
Figure 54:  Scatterplot reporting responsibility and Specialism level 
 
199 
 
5.1.2 Part 2: Semi-structured Interviews with Chief Pharmacists. 
The semi structured interviews were held with seven senior pharmacists, one 
from each hospital, each of whom held directorship positions.  A sample of 
notes taken during interview in Arabic is to be found in (Exhibit 1 Appendix 8.7) 
and a full transcript of the second interview translated into English is presented 
as (Exhibit 2 Appendix 8.7).   
The aim of the interviews was to probe a number of issues which emerged from 
the quantitative stage of the study. Five of the interviewees were aged 40 or 
over and the remaining two were in the 30 - 40 age range.  Five were male; two 
were female.  All of the interviewees were Saudi nationals.  
Five of the chief pharmacists interviewed admitted that they did not have a 
sufficient background in clinical pharmacy nor were clinical pharmacists 
available in their hospital. Because of this, they felt that they lacked the 
qualifications or experience necessary to carry out ADR reporting.  They also 
mentioned time constraints on acquiring the requisite skills for ADR reporting.  
These were mostly older chief pharmacists whose experience had been based 
on an older model of pharmacy and had not been able to adapt to the current 
changing role of the pharmacist.  This finding clearly underscores the value of a 
mixed method of analysis as these issues might not have emerged from a 
simple questionnaire. Furthermore, some chief pharmacists remarked that the 
ADRs reporting policy of some hospitals had not yet been written and 
circulated, as this new system had been so recently established in Saudi 
Arabia. They felt that written ADRs policies were important for the management 
of ADRs and that without these policies there were no clear guidelines to follow.   
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An extensive discussion with two of the interviewees, in the light of there 
being no formal policies in place, focused on the Australian policy on ADRs 
previously discussed in Section 3.3 of SHPA and their standard guidelines for 
ADR management were discussed as a good example of a formal policy in 
place.  Features of the Australian formal policy included: 
• The procedure for detection and prevention of ADRs. 
• The type of data collected as part of the assessment of the ADRs 
• The criteria to define the correlation of the ADRs and the suspected drug. 
• The documentation and prevention of ADRs (SHPA, 1996).  
 Moreover, based on previous studies Green et al., (1999b) and (Nita et 
al., 2004) carried out in Makkah only two hospitals have ADRs policies and the 
chief pharmacists of those hospitals were included in the interviews. The above 
studies found no association between hospital size and the existence of the 
ADR reporting policies and no association between the number of pharmacists 
and the existence of the ADR reporting policies and that this was due to the fact 
of the ADR reporting system having been so recently introduced into the 
country.  Clearly, this was another in-depth insight which only emerged from the 
interviews and indicated the need for education and training for staff on the new 
ADR reporting system.  
 Five of the chief pharmacists commented that their hospital did not 
encourage health professionals to report ADRs to SFDA through the ADRs 
reporting forms which could be submitted by fax, post, by hand or online. Again 
it emerged that this was due to the lack of knowledge and training of pharmacist 
staff. Furthermore, they reported the lack of availability of some facilities such 
201 
 
as: online access, direct phone line and ADRs report form availability.  An 
example of this came from the fourth interview: 
Respondent 4:  We do not have internet access here so it would not be possible 
to introduce the ADR system you're talking about because how would we 
submit a report ….in writing? Filling out a form 
I:  Yes you could it that 
R4:  But forms are not always available …..and then I guess, it just doesn't get 
done.  
 All chief pharmacists commented on the importance of screening for 
ADRs by doctors and nurses due to their having first contact with patients and, 
therefore, were tasked with first notifications of ADRs and reporting and to also 
inform pharmacists and then return the form to the pharmacy department in the 
hospital to be followed up as a check point for all details recorded on the ADRs 
reporting form. Consequently, reporting ADRs was seen as part of the 
professional role of a pharmacist, even though there were no clear policies in 
place in five of the hospitals. Therefore, the significant communication between 
doctors and pharmacists would be more effective to report ADRs and so lead to 
reports being sent to the SFDA, were policies and clear guidelines better 
articulated by formal written policies. It was thought that nurses should also take 
more responsibility for the detection and reporting of ADRs.  
 The comparison between this system and the previous study done in UK 
and  Australia by Smith et al. (1996) and Nita et al. (2004) respectively,  
emphasised that pharmacists were more likely to detect ADRs and report ADRs 
than doctors (shown in Table 23) . Based on these studies, we would suggest 
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that increasing the quantity of ADR reports also demands co-operation between 
health professionals and, where possible, the use of a designated person to 
screen the reports prior to submission to a national reporting centre (Smith et 
al., 1996 , Nita et al., 2004). 
Table 23: A comparison between doctors and pharmacists in UK and 
Australia regarding personal responsibility for ADRs reporting. 
Personal UK Australia 
Doctors 58% (48/83) reports 23% (10/44) reports 
Pharmacists 38% (240/635) reports 91% (72/79) reports 
 
 
The analysis revealed a number of themes that were repeated in most of the 
interviews.  These included: lack of internet facilities, lack of forms, work 
overload, time constraints, staff shortages, resistance to change, lack of 
knowledge of ADR's, role responsibilities and ADR being of low priority.  Six 
overriding themes were chosen as representative of the qualitative data.  These 
are presented in Figure 55 below supported by extracts from the various 
interviews: 
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already 
overburdened 
R5; Fine...but there just 
isn't enough time.  
R2: my staff is already 
have a heavy workload. 
R7:  We are constantly 
short of staff through 
illness 
 
 
 
No internet 
 
R1: we dont have facilities 
to to check drugs or 
report ADRs 
R2:  Physicians should 
have a safer computerised 
physician order entry 
(CPOE) 
R3MOH needs to provide 
us with internet and IT 
facilities 
R4Look we don't need 
more form filling here and 
also we don't have 
internet  
 
responsibility 
R1  Its not my 
responsibilty its the 
physician's 
R3:  All staff are 
responsible 
R7 The nurse...they 
have first point of 
contact with patient 
but pharmacy is also 
involved 
Encourage 
R2: I'll try but I bet they call 
in sick or take a holiday for 
training day 
R3:  Its hard to motivate staff 
to take on a new system 
R5. 
I can tell you now they wont 
be interested 
R6. 
I think its a great idea to try 
to get the staff to 
communicte and work 
together 
 
Training and 
Education 
R2; They're already 
booked in for diabetes 
training...I don't think we 
can fit in ADR reporting 
R4 I am sure that it would 
increase ADR reporting in 
our hospital 
R6  We would need 
training events to 
understand it but I would 
be in favour of that 
Barriers 
R1 I do not have enough  
knowledge of clinical 
pharmacy 
R2  No forms available so 
reporting just doesn't get 
done 
R6The problem is time 
We're already overloaded 
R7I don't consider ADR 
reporting to be a 
priority...we've got lots of 
more pressing issues 
 
Figure 55: Representative themes from data analysis of interviews 
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These themes were further examined and reflected on by the researcher and 
eventually they were reduced to three categories which embraced the entire 
qualitative data obtained through the semi structured interviews. the three 
categories were: Technology, Internalisation and motivation. These three 
categories embrace the data.  They are not totally exhaustive but they express 
the key points that arise from a thematic analysis.  Technology includes all 
modern means of supporting and implementing a project and principally 
involves the design and implementation of IT solutions to the task of installing a 
robust ADR reporting and storage system. Issues of data protection and 
Internet security are involved. 
Internalisation refers to how an ADR reporting system can be effectively 
embedded in hospitals and pharmacies. It also refers to how knowledge of ADR 
and practice I n reporting becomes internalised in individuals through education 
and training.  This includes all staff members but also patients whose 
awareness of self reporting should also be considered. 
Finally, motivation refers to the processes involved in leading people to 
overcome resistance and to embrace a new system conscious of the benefits it 
will bring. The psychology of motivation needs to inform this process.  People 
can be extrinsically motivated by rewards and gifts.  It is desirable that they 
become more intrinsically motivated by recognition of their knowledge and 
expertise through certification.  These are presented in Table 24.  
Table 24:  Final Categories from Qualitative Analysis 
Categories Application 
 
TECHNOLOGY 
Internet facilities.  Safer Computerised Physician Order Entry 
(CPOE).  Secure drug database. Electronic Health Record (EHR).  
Data protection.  Internet Security and Backup systems 
Internalisation Staff training and development.  Workshops.  Knowledge of ADR.  
Training method appropriate in an adult context. 
Motivation Overcoming resistance.  Psychology and change management.  
Rewards and Incentives for extrinsic motivation.  Certification for 
intrinsic motivation. 
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5.1.3 Part 3: Community pharmacists 
 In 2010, the Health Affairs Directorate register listed 339 private 
community pharmacies in Makkah as being authorized by the MOH. Using a 
random sample of 170 community pharmacists registered with different places 
in Makkah, the researcher visited each pharmacy during; July, August and 
September 2010. The community pharmacist on duty at each of these locations 
was invited to participate in this study.  
 The study was explained to the potential participants both verbally and 
by a covering letter written in both English and Arabic. They were assured that 
the data would be treated confidentially and any results published would be 
anonymised. Their responses were either obtained at the same time as the visit 
or collected at a later time if the pharmacist was too busy to complete the 
questionnaire. The questionnaire which was eventually used was modified from 
the previous example used in the first part of this thesis but which had to be 
modified in a limited number of ways to make it suitable for community 
pharmacists in Saudi Arabia.  
 The questionnaire comprised 5 sections of questions. (A, B, C, D and E) 
The first section A consisted of ten questions covering the community 
Pharmacists demographics, reference source availability and continuing 
education activity. Section B had general questions to establish the extent of the 
respondents’ knowledge about the Saudi ADR reporting system and section C 
was designed to find out the extent of the participants' awareness of and the 
purpose of ADRs system. Section D consisted of thirteen items exploring the 
community pharmacists’ attitudes to reporting and the factors that either 
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positively or negatively affected their attitude and behaviour toward the ADRs 
reporting system.  
 Finally, section E dealt with the perceived barriers of the ADRs system in 
Makkah. Pharmacists were asked to indicate their agreement or disagreement 
on a 4 point Likert scale from ‘strongly agree’ to ‘strongly disagree’.  
 
Results - Section A: Demographic information   
i. Gender  
 It is pertinent to note that all the 339 authorised community pharmacists 
in Makkah are male because they have to deal with both male and female 
customers. However, it should be emphasized that there are female 
pharmacists in Makkah and in KSA who as a group tend to be employed as 
clinical pharmacists in hospitals and in other roles in academia and in research 
and development. All the values shown in the charts and tables below are 
expressed in percentage terms of the group studied i.e.170 male community 
pharmacists. 
ii. Age range  
Based on the question above the survey of the age groupings 21-30, 31-40 and 
>40 years, of the 170 pharmacists studied are shown in Figure 56. 
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iii. Nationality 
 Among the 170 community pharmacists surveyed most of respondents 
were Egyptian nationals and of Arabic origin (56%), Saudi nationals were 25% 
and the remainders were expatriates from the Sudan, India and the Philippines 
(19%).  
 The dominance of foreign educated pharmacists is expected in the near 
future to change since the Umm Al-Qura University in Makkah will produce its 
first mainly indigenous pharmacy graduates in 2012. The increase in Saudi 
nationals in all spheres of employment is a topical issue in all industries in the 
KSA and it is the government’s desire to substantially reduce the reliance on 
expatriate workers. (See Figure 57) shows the percentage of Nationalities of the 
170 community pharmacists who completed the questionnaires.  
 
Figure 56: Percentage totals of community pharmacists in the three 
age group ranges: 21-30, 31-40 and >40 years (n=170) 
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iv. Educational qualifications          
 In terms of educational qualifications -Bachelor and post graduates this 
study found that most of the community pharmacists 82.3% (n=140) held a 
Bachelor degree in Pharmacy, although 11.7% (n=20) had a Master’s degree. 
None had a PhD and 10 had other qualifications as shown in Table 25. 
Table 25: Educational qualifications of the community pharmacists 
surveyed in Makkah 
Educational qualification Number (%) 
Bachelor degree 140 (82.3%) 
Masters degree 20 (11.7%) 
PhD degree 0 
Other qualifications 10 (0.56%) 
 
 
 
Figure 57: Percentage distribution into the three nationality groups 
of the 170 community pharmacists who took part in this survey 
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v. Professional Experience in years 
 The majority of the community pharmacists (62%) had less than 5 years’ 
experience while 17.6% had between 6-10 years of experience. This reflects 
the situation in the whole of the KSA, so the community pharmacists in this 
study were representative of the community pharmacists in the whole country in 
terms of their pharmaceutical professional experience (shown in Table 26). 
 
Table 26: The numbers of years and percentage of community 
pharmacists' experience 
 
Number of years Number (%) 
1 – 5 110 (62%) 
6 – 10 30 (17.64%) 
11 – 20 30 (17.64%) 
20+ 0 
 
 
vi. Training and continuing education which community pharmacists 
spent per month. 
 The survey found that 47% of the community pharmacists working in 
community pharmacy had received some training on how to report ADRs. 
Consequently, it was found that 52.9% of the community pharmacists had not 
been trained on ADRs procedure.  
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 As far as individual continuing education was concerned, 76% carried out 
between 1 to 5 hours per month and 24% of community pharmacists spent 6-10 
hours on such educational activities per month (see Figure 58).  
 
 
 
 
 
 
 
 
 
 
 
vii. Internet facilities in community pharmacists workplace 
 One of the important working tools to provide a strategic level of 
knowledge for the community pharmacist in Makkah is internet access. The 
majority of the community pharmacists (88%) had no access to the internet at 
the workplace and so could not report ADRs online (Table 27).  
 
 
  Hours 
% staff 
Figure 58:Hours of continuing education spent per month by 
community pharmacists in Makkah 
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Table 27: Internet facility for community pharmacists in workplace 
 
Internet facility in work place 
Yes 20 (12%) 
No 150 (88%) 
 
viii.  Reference books available 
  The majority of the community pharmacists (64.7%) relied mostly 
on the British National Formulary (BNF) as a reference manual used in the 
workplace, followed by 29% for the Middle East Index (MIMS) and the least 
commonly used reference for community pharmacist was the Saudi National 
Formulary (SNF) (see Figure 59). 
 
Figure 59: Reference books available for community pharmacists to use in 
their place of work. 
 
 
65% 
29% 
6% 
Reference books available  
BNF MEI SNF
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Section B: Familiarity with the reporting system 
i. Awareness of the ADRs Reporting System:   
In this part of the study regarding ‘awarness and attitude of community 
pharmacists’ it is used  to gauge the extent of their knowledge of the ADRs 
reporting system. It was found that 82.4% (n=140) were not aware of the 
system so indicating that only 17.7% were aware of the system (shown in Table 
28).  
Table 28: Awareness of the ADRs Reporting 
Yes No 
17.7% (n=30) 82.4% (n=140) 
 
ii. ADRs reporting program system available:      
In Figure 60,  below, 65% of community pharmacists had no available systems 
in place for an ADRs reporting programme in the workplace. In contrast, 35%  
had suitable facilities available to them. 
 
 
 
 
 
 
 
Figure 60: The percentage of availability for community pharmacists of an 
ADR reporting system. 
213 
 
iii. Awareness of the existence of the National Pharmacovigilance 
Centre (NPC) in the Saudi Food and Drug Authority (SFDA): 
This survey found that in Makkah Community Pharmacists 59% (n=100) were 
unaware of the existence of the NPC, the remainder 41% (n=70) had an   
awareness of the SFDA (shown in Table 29).  
 
Table 29: Awareness of the existence of the NPC in the SFDA by 
community pharmacists in Makkah. 
Percentage Number   Are you aware of the existence of  NPC in SFDA 
41% 70 Yes 
59% 100 No 
100% 170 Sum 
 
 The next question considered the effectiveness and the respondents’ 
extent of knowledge about the Saudi ADR reporting system. It found that only 
18% community pharmacists were aware of the ADRs reporting programme or 
had learnt about the programme from colleagues; 53% had read about it and 
29% knew about the program from MOH officials. Only 5.8% were aware that 
pharmacists in Makkah could report an ADR to the MOH (see Figure 61). 
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iv. Which department do you think is responsible for receiving and 
interpreting ADRs reports? 
 The majority commented about which department was responsible for 
receiving and interpreting ADR reporting and 65% considered it to be the MOH. 
In contrast only 29% claimed that they would submit the ADR report to the 
SFDA. Interestingly, 6% thought that ADR reports were to be submitted directly 
to a pharmaceutical company. None of community pharmacists in Makkah 
indicated that during the last month they had come across an ADR they wished 
to report to the MOH or drug company (see Figure 62).   
  
Figure 61: The main sources of community pharmacists’ awareness 
of the ADR procedures. 
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Figure 62: Community pharmacists' beliefs regarding which department 
was responsible for receiving and interpreting ADR reports 
 
 
 Section C :The purpose of the ADR reporting system 
 
 53.2 % of surveyed community pharmacists considered that the main 
purpose of ADR reporting was to enable "safe drugs" to be used in clinical 
practice, whereas 29 % considered it would be useful to simply calculate the 
"rate of the incidence" of ADRs. A group which measured 6% of the total 
considered the purpose of the reporting system was to identify ADR within the 
same "pharmaceutical class" and considered the purpose of the ADR reporting 
was to detect potential ADRs. Finally, 12% thought the system would serve as a 
"source of information" about the characteristics of ADRs (see Figure 63).  
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             Figure 63: The purpose of ADR reporting system as adjudged by 
the community pharmacists of Makkah. 
 
Section D: Community pharmacists’ attitude towards the ADR reporting 
system. 
 The community pharmacists thought that reporting of ADRs was the 
responsibility of the pharmacist; physician and patient with the figures being 
38.8%, 32.9% and 5.9% respectively (shown in Figure 66). 65% (n=110) of 
respondents considered the reporting of ADRs to be an integral part of the 
professional roles of the pharmacist’s duties. All community pharmacists 
decided to report any ADRs after the researcher had explained the importance 
of such reporting (see table 30). A significant number of respondents, 40% 
(n=68), commented, that the effect which would cause them to send in a report 
had to be when "a life threatening situation" developed (see Figure 64).This was 
against a background where 29.4% (n=50) of the community pharmacists 
53% 
29% 
6% 
12% 
The purpose of ADR reporting system     
‘safe drugs’ 
rate of incidence
pharmaceutical class
source of information
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believed that ADRs reporting to facilitate the science of monitoring drug safety 
was important.  
 One important aspect of the results was that 94% (n=160) responded they 
indicated that they must be sure of the causality between the drug and ADR it 
was essential to be certain about an effect before reporting. Nevertheless, 
88.2% (n=150) of community pharmacists saw reporting as an integral part of 
the pharmaceutical task and 70.5% (n=120) said that ADR reporting was an 
indication of taking patients' complaints seriously. 35.3% (n=60) of respondents 
believed to get more information about ADRs that they may come across during 
their professional practice. 76.5% (n=130) of respondents felt the need to 
discuss the report with the prescriber before reporting (see Table 30). Maybe 
astonishingly, many of the community pharmacists 45.2 % (n=77) stated they 
had come across a patient in their pharmacy with an ADRs during the last 
month and had wished to report it (see Table 31). Actually, 47% (n=80) were 
submitting an ADRs report to MOH in Makkah (see Figure 65). 
 Finally the vast majority of the community pharmacists 94.1% decided 
that  the ADRs reporting should be a role for all community pharmacist due to 
prevent any risk patient also, can community pharmacists provider to the public 
safe medication (see table 30).  
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Table 30: Attitudes of community pharmacists in Makkah towards the 
ADRs reporting system. 
% Statement 
65%  (n=110) Reporting ADRs is part of the professional role of a 
pharmacist 
29.4%  (n=50) I believe that the science of monitoring drug safety is 
important 
94% (n=160) I want to be sure that the ADRs is related to the drug before 
reporting 
35.3% (n=60) I report for getting more information about ADRs questions 
that I come across in my profession practice 
70.5% (n=120) I report to show the patient that their concerns are being taken 
seriously 
 
88.2% (n=150) I always report ADRs because it is part of tasks 
 
76.5% (n=130) Consulting the physicians is important before reporting ADRs 
 
94.1% (n=160) ADRs reporting should be compulsory 
5.9% (n=10) ADRs reporting should be voluntary 
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1- I would report an ADRs that causes: 
 
 
 
Figure 64: Reasons which would encorage a community pharmacist in 
Makkah to report an ADR.  
 
 
2- Submitting ADRs reported to: 
 
 
Figure 65: ADRs reported by community pharmacists to the selected 
authorities 
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3- Have you come across patient(s) with ADRs during last month and 
wished to report it? 
 
 
Table 31: Proportion who encountered patient(s) with ADRs during 
previous month and had wished to report it. 
 
Percentage Number   Have you come across patient(s) with ADRs 
during last month and wished to report it? 
45.2% 77 Yes 
30.5% 52 No 
24.1% 41 I don’t know 
100% 170 Sum 
 
 
 
 
Figure 66: Responsibility to report ADRs 
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Section E: Limiting factors and/or constraints of the study 
 The results of this study would suggest that a number of factors can 
affect community pharmacists, who were employed in Makkah, reporting ADRs. 
Although the majorities were enthusiastic about making reports, 58.8% of 
pharmacists did not report and such effects simply because the reporting forms 
were not available in the workplace. A further 29.4% of the respondents did not 
report because they did not know the address where the reports should be sent 
to and 23.5% (n=40) of respondents described the reporting form as just too 
complicated to complete. The 17.6%, who thought they had insufficient clinical 
knowledge to make such reports and 41.2% of respondents did not do so 
because they thought it was only for newly marketed drugs. Finally, 52% of 
community pharmacists were not really too concerned about reporting such 
events (see Figure 67). See more correlation in appendix 8.6 
 
Figure 67: Constraints which reduce the effectiveness of reporting ADRs 
by the Community Pharmacists of Makkah. 
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5.1.4 Part four: Students pharmacists 
        The fourth participating group were undergraduate students, A total 
numbers of 180 students in the 3rd and 4th years of the pharmacy degree of the 
School of Pharmacy, Umm Al-Qura University, Makkah, KSA, were required to 
partake in hospital placements as part of their studies. This was done by 
dividing the total number of students into groups of 20 students. They undertook 
a one month training placement period during the summer months of July, 
August and September 2010. Here they were under the supervision of a 
qualified pharmacist in the three main hospitals recognised as providing an high 
quality educational experience. These were the Al-Noor specialist hospital, 
General Hera specialist hospital and King Abdulaziz Hospital in Makkah.  
 These students were gaining practical and clinical experience within a 
hospital setting where ADR reporting would soon be introduced. The 
researcher, realising that Pharmacovigilance was much neglected in the 
University curriculum, decided that these students would benefit from a lecture, 
delivered by the researcher to each group to raise their awareness of the 
importance of Pharmacovigilance, especially in view of the fact that it would 
become a feature of their responsibilities in their future roles in pharmacy.  In 
fact, many of these students would be graduating from Umm Al Qurah 
University, Makkah in 2012.   
 Following each lecture, I presented each student with two open 
questions to assess their views and attitudes towards the importance of 
Pharmacovigilance and whether or not this was important enough to be 
included in their University curriculum as a discrete module.  The researcher 
also wished to gauge the students' knowledge of and attitudes towards ADRs 
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reporting.  This was the first time that many of them even heard of the term 
Pharmacovigilance and actually saw a typical ADR reporting form. 
 During the lecture, the researcher explained about this research project 
and asked if they, the students, would give their views on the importance of 
Pharmacovigilance by answering two brief questions at the end of the lecture as 
a form of feedback.  They were informed that a summary of their feedback 
would be included in his research report (see Figure 68 and Figure 69). The 
questions were presented in both English and Arabic and students were not 
required to add their names or personal data. They were assured of 
confidentiality and anonymity and that reporting, in the final thesis would be 
generalised.  The students were informed that their responses would only be 
used for academic purposes and they were thanked, in anticipation, for their 
cooperation (see the comment of students in appendix 8.8). 
 
The open questions were: 
 
A. How did you find the lesson about Pharmacovigilance and ADRs 
reporting and have you any comments?  
B. Do you think that Pharmacovigilance and ADRs reporting should be 
included in your pharmacy programme at the University as a 
separate module? 
 
 The responses of student pharmacists were either obtained at the same 
time in the class (mostly) or, collected at a later lecture (seldom). All 180 
students, 100% response, submitted their responses and the researcher 
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received many emails from them stating that they had found the lecture most 
interesting and informative. Many of these students have subsequently changed 
their final chosen project to "Pharmacovigilance".  
 
Results and Conclusions 
 Earlier in the thesis the knowledge of Pharmacovigilance currently held 
among medical students and practitioners was given. The conclusion of these 
studies is that there is an important need to provide teaching and practice of 
Pharmacovigilance as a basic requirement for undergraduate programmes in 
Medical Schools generally, and in pharmacy schools, in particular.  From my 
own questions to the Makkah students is that Pharmacovigilance if suitably 
explained they found the topic both important and interesting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: A lecture for undergraduate pharmacy students during 
training in their hospital placement.  
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Shankar et al. (2006), has suggested in his study entitled “Teaching 
Pharmacovigilance to medical students and doctors "that the 
Pharmacovigilance programme could be covered in two pathways, (theory and 
activity)". The information (theory) is to be covered in two lectures of 1 h 
duration each. The first of the two activity sessions was designing a reporting 
form and the second, carrying out a severity and causality assessment of the 
given ADR report which lasted for duration of 2½ hours.   
They considered that a total of 6-7 hours may be required, with a 
minimum of 6 hours should be spent on Pharmacovigilance. But they were 
flexible and suggested that colleges can modify the time component according 
to their own requirements. A visit to a real the Pharmacovigilance centre and 
the presentation and discussion of findings could be done in the second 
Figure 69: Practical workshop session based on Pharmacovigilance 
and ADRs reporting for undergraduate pharmacy students during 
training in their hospital placement. 
226 
 
session. The lectures could be organised around the aims and needs for 
Pharmacovigilance in particular regions in the country following the setup of the 
Pharmacovigilance programme. Also, the practice of spontaneous reporting 
should be included. . All further learning should be activity-based and carried 
out in small groups. In conclusion, teaching Pharmacovigilance to medical 
students will make them aware of their responsibility to report ADRs. Doctors, 
from other specialities, have an important role in reporting ADRs and sensitising 
medical students to the importance of Pharmacovigilance (Shankar et al., 
2006). 
More recently, Smith and Webley (2012) remarked in their study 
"Pharmacovigilance teaching in UK undergraduate pharmacy programmes", 
that the level of reporting by UK pharmacists remained low. This may reflect the 
finding that the amount of time dedicated to the teaching of pharmacovigilance 
in UK pharmacy undergraduate degree programmes was low. Therefore, more 
time may be required to be devoted to the teaching Pharmacovigilance on 
pharmacy undergraduate courses. Thus, there is a significant need to make 
pharmacists aware of their need to enhance their level of ADRs reporting in UK 
(Smith and Webley, 2012).     
 
1. Objectives of a pharmacovigilance teaching programme  
It is thought that an outline of ADRs is covered in most undergraduate 
pharmacology textbooks and curricula throughout the world. Though the 
present academic curricula mention ADRs, they do not train students to apply 
pharmacovigilance in their future practice. The objective of the programme 
should be to create an awareness of pharmacovigilance among medical 
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students. In their future practice, they should be able to report ADRs using the 
spontaneous ADR reporting form. They need to be aware of the reporting 
system in their area or region.  
In Malaysia, a study by Elkalmi et al. (2011) used a questionnaire on 510 
final years of underdratuated student’s pharmacists at 5 Malaysian public 
universities to evaluate current knowledge and perceptions about 
Pharmacovigilance and ADRs reporting. The study concluded that the majority 
of final-year pharmacy students in Malaysian public universities had insufficient 
knowledge about pharmacovigilance and ADR reporting. (Elkalmi et al., 2011) 
In UK, Cox. et al. (2004), in a study entitled “Adverse drug reaction 
teaching in UK undergraduate medical and pharmacy programmes”. 57% of 
medical school students had knowledge of the Yellow card scheme and the 
scheme featured in the majority of undergraduate syllabi. The supply of an 
information pack, targeted at undergraduate health professionals, they thought 
might improve awareness of the MHRA and the Yellow Card Scheme. Changes 
in the teaching of therapeutics are being seen in pharmacy courses, and an 
emphasis on the practical application of skills and clinical knowledge is 
becoming more common (Cox et al., 2004b).  
 In France, Zenut M. et al. (1998) presented a systematic collection of 
ADRs, over a period of nearly 20 years. Educational interest resulted from (1) 
discussion about some ADRs frequently leading to hospitalization or 
consultation; (2) information about recent drugs and new and/or not well known 
ADRs; (3) which helped to educate doctors on  the rational prescription of drugs 
and increasing awareness of Pharmacovigilance (Zenut et al., 1998). A survey 
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among medical residents in France showed that the majority lacked knowledge 
of Pharmacovigilance (Graille et al., 1994).  
In India, studies by Rehan et al. (2002) "Adverse drug reaction 
monitoring: Knowledge, attitude and practices of medical students and 
prescribers" in a medical college in New Delhi found that the knowledge, 
attitudes and practices (KAP) regarding ADR monitoring was comparable 
among undergraduates students and prescribers, but overall, the scores 
needed improvement and need to change in the undergraduate teaching 
curriculum (Rehan et al., 2002).  
A second more recent study in India by Vora et al. (2012), entitled 
"Knowledge of Adverse Drug Reactions and Pharmacovigilance activity among 
the undergraduate medical students of Gujarat" similar problems were 
experienced and future doctors in society many had deficiencies in their 
knowledge regarding ADRs and Pharmacovigilance. Urgent attention on a 
priority basis, not only for the success of the Pharmacovigilance program, but 
for the better clinical management of the patients in general was also stressed 
(Vora et al., 2012).  
 
2. Teaching pharmacovigilance to postgraduate students  
 Consequently, perhaps all postgraduate (PG) medical and pharmacy 
students should, develop their knowledge and awareness of pharmacovigilance 
programmes and importance of reporting ADRs. Subish et al. (2009) conducted 
a study for "Introducing Pharmacovigilance to Postgraduate Pharmacy Students 
in Nepal" by sessions and surveys to emphasize the importance of 
pharmacovigilance programs in developing countries similar to those in the 
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developed countries that have incorporated pharmacovigilance teaching in the 
pharmacy curriculum. Pharmacovigilance programs have an important role in 
the early detection and prevention of ADRs, and Healthcare professionals 
should increase their awareness of the existing pharmacovigilance programs in 
developing countries and should report ADRs as a part of their professional 
obligation (Subish et al., 2009). 
 
3. Advantages of teaching pharmacovigilance to medical/pharmacy 
students: 
1. Teaching pharmacovigilance to medical/pharmacy students makes them 
realise that all medicines can cause ADRs.  
2. It emphasises their responsibility to participate in the national pharmaco-
vigilance system. 
3. Spontaneous reporting schemes have been a major source of 
information in pharmacovigilance.  
4. The knowledge of drug safety issues can improve the manner in which a 
doctor takes the clinical history of a patient, with more emphasis on the 
medication history, and can help to understand the behaviour of drugs 
better.  
5. It can decrease the irrational use of medicines, adverse drug-drug 
interactions and inappropriate poly-pharmacy. 
 
 The feedback from the pharmacy students in Makkah after the sessions 
was very positive.  They said they found the sessions educative, informative 
and interesting. They now believe that knowledge of the spontaneous ADR 
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reporting form has emphasised to them to the importance of reporting ADRs. 
The students now have more knowledge about pharmacovigilance, assessed 
during informal discussions of workshop and in conversations were found to be 
satisfactory. We are working on an assessment framework for the other 
activities which were carried out and found to be very valuble.  
 
4. More positive results of this teaching showed that: 
1. Academics are currently undertaking significant changes in terms of both 
the structure and curriculum of the pharmacy undergraduate programme 
in Makkah. 
2. A high proportion of pharmacy students mentioned the importance of 
“Pharmacovigilance” as a discrete science in the undergraduate 
programme. 
3. The students were very interested in the inclusion of ADRs and reporting 
in their syllabus or including it in the mandatory therapeutic module.  
4. They encouraged the practice of ADRs reporting during training in 
hospitals. 
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Chapter Six 
 
6 Discussion, Conclusion and Recommendations  
6.1 The Makkah hospitals health professional’s experience of ADRs 
 
 In contrast to many countries in the developed world, the literature 
concerning health professionals’ awareness and attitudes towards 
Pharmacovigilance and ADRs in the KSA is rudimentary. To date, only two 
studies have been undertaken and published which are relevant to this topic, 
namely those of Rockville (2001) and Bawazir (2006). One problem with 
assessing the awareness and attitudes to ADRs and their reporting is the 
problem of it being under-reported not only by pharmacists, which were the 
focus of these two studies, but by other health professionals as well. This 
reluctance to report ADRs  has been a feature of medicine for many years as 
the results in the studies of Davis & Coulson, (1999), Bäckström et al., (2000), 
and even more recently by Toklu & Uysal, (2008) all showed. This reluctance to 
report ADRs, is usually explained as being attributed to a simple lack of 
awareness of a specified medication being able to cause an ADR. If this reason 
is accepted then it may suggest either a basic lack of knowledge about the 
potential of a drug or a group of drugs being able to cause problems or simply 
not keeping up to date about the findings which have been made about ADR 
and which can be found in published sources. 
 In this thesis, the detailed analysis made on a random sample of 310 
health professionals - 205 doctors, 25 dentists, 49 pharmacists and 31 nurses, 
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in seven different hospitals, all located in Makkah produced some interesting 
findings.  The nature of the participants was that the majority (70%) were male, 
of non-Saudi origin (65.2%), middle aged (45.8%) and had a degree at Master’s 
level (46.5%) may have influenced the results in terms of their previous 
experience of ADRs in their country of origin. Of this group, 15.8% were 
pharmaceutically qualified with the majority being medically qualified (66.1%).  
 The major findings showed that the majority of all the different groups of 
health professionals expressed an inadequate knowledge and awareness of the 
ADRs reporting program in Makkah. It is obvious that if people do not know the 
existence of such a system then making reports to it is clearly impossible. 
These findings suggested a lack of knowledge and co-operation between the 
health professionals in Makkah hospitals and the ‘central authorities’, such as 
the Saudi MOH, so as to ensure that an awareness of ADR reporting exists and 
so can be actually carried out. This may require specific programmes being 
developed for the long term development of health professionals in Makkah 
specifically related to matters concerning ADRs. Pharmacovigilance is not a 
single ‘one off education lecture’ but rather a continuous process of developing 
and maintaining awareness and encouraging its reporting.  The correct use of 
appropriate reporting ‘systems’ is very important since the continued use of 
medications which have been found to have problems in use if not reported 
could lead to serious consequences for both the patient, the health care system 
and the individual members of staff. 
 In 2012 the major way regulatory authorities use to communicate with 
their ‘sources of information’ is to use the Internet. This process of reporting is 
vital on a global scale as it allows knowledge about any drug problems to be 
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rapidly shared with other health care workers who are located anywhere in the 
system. In this thesis the finding that 61% of the respondents were not able to 
access drug information using the Internet system is a cause for serious 
concern.  
 But the problem was more complicated and was not simply that of poor 
availability of access to the Internet as many of the respondents were simply 
unsure as to what the definition of Pharmacovigilance and ADR actually were.  
Consequently, when the researcher asked them to participate in a study about 
Pharmacovigilance, one reason for declining to participate (n=160) may be 
simply due to a poor understanding of the concept and/or little interest in the 
matter.  
 Despite these problems the majority of the health professionals from 
those requested to take part did so and all the respondents showed a positive 
attitude towards ADR reporting. The vast majority of respondents, 67.1%, 
regarded reporting any suspected ADR as a professional obligation and 
considered ADR reporting the responsibility of the pharmacist, the physician, 
and patients. The majority of the respondents (70%) considered ADR reporting 
an integral part of pharmaceutical care. The finding that despite such 
expectations 65% of health professional had been not trained on how to report 
ADRs was unexpected and needs to be addressed by suitable training. It is an 
interesting finding from the questionnaires that even though 72% of 
respondents admitted to having insufficient knowledge of ADR and how to 
report, they nevertheless, agreed that it was important.  This is a good starting 
point for raising motivation.  Resistance to change is mostly at the chief 
pharmacist level which emerged in the interviews where five of the seven 
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interviewees displayed reluctance or even resistance to this innovation.  This is 
further supported in cross tabulations against age where the 23-30 age group 
showed a 93% rate of agreement about the importance of ADR reporting.  The 
same rate for the >40 age group was only 53%. 
The study also points towards the inclusion of non Saudi personnel in training 
programmes who only showed a 61% agreement rate as opposed to Saudis of 
whom 85% viewed ADR reporting as important. 
 How this training could be carried out is matter for speculation.  One 
simple solution could be for relevant courses, including ‘hands on workshop 
sessions’, to be organised and carried out by the NPC in the SFDA and so 
create a workforce which are qualified and trained ADRs reporters. The finding 
that fifty-nine percent of health professionals were not aware of the existence of 
NPC in the SFDA and were also unaware of the system of reporting ADR 
through the appropriate channels and filling in the forms to report suggests the 
task will not be a either simple and/or quick task but will require a considerable 
investment in both time and the provision of relevant courses for existing and 
future staff to make sure everybody is aware of the systems that currently exist 
and any changes which are made to them over the years to come. It is 
consequently a continuous process of updating which is required. 
         One factor which emerged from this part of the study and was also found 
in the community setting (see below) was that 71.3% of the health professionals 
thought it was absolutely essential to consult with the prescriber before actually 
submitting an ADR report. This has potential advantages and disadvantages.  
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 The reluctance to report without contacting the prescriber may indicate 
two things. Firstly, there may be a lack of confidence in the nurse or pharmacist  
and secondly, they may anticipate that reporting without checking may have 
legal consequences because the completed the reporting form and this 
responsibility they are extremely worried to take. The situation is not however 
without promise and there are signs that some positive elements exist since 
33.2% (n=103) of the respondents had submitted some type of an ADRs report 
to MOH located in Makkah. In addition, 36 % of respondents made comments 
regarding the confusion about which department was actually responsible for 
receiving and interpreting ADR reporting for the MOH.  Confusion over role 
responsibility for ADR reporting was also in evidence from the semi structured 
interviews.  
 The finding that 47.1% of the group stated they had come across 
patient(s) with an ADRs during the last month and they wished to report this 
ADR was most unexpected. This is worrying as it suggests the problem of 
ADRs is widespread but it is also very promising since if this attitude continues, 
then, when, the 3 million visitors or pilgrims come in to Makkah as well as its 
residents report the occurrence of ADR then the overall reporting rate may be 
improved. It is interesting to speculate does this high level of coming across 
ADRs reflect the fact that pilgrims bring with them problems which their 
countries of organ have not be told about or actually detected. This may reflect 
that fact, discussed at length in the literature review, that ADRs are a global 
problem and not restricted to any one country. The future enhanced awareness 
and attitudes of the health care professionals to ADRs may help develop a 
database of problems the pilgrims may experience as was found in other 
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circumstances which are mentioned above  by Van Grootheest et al., 2004, Al-
Sultan and Bawazir, 2009 and  Ghosh et al., 2010.  
 The data obtained for this thesis has shown that, like most countries 
around the world there are several negative factors which may affect and 
prevent the health professional in Makkah from reporting ADRs. These may be 
simple to adjust/reduced/eliminate by simplifying the ADR forms, clarifying 
where they are to be sent and making them more available in the workplace.   
 Alternative methods do exist to encourage participation. In 1999 Colodny 
and Spillane suggested that one of the best methods might be to encourage 
health professionals to both initiate and continue reporting ADRs would be to 
use form of ‘rewards’. These ideas ranged from more traditional ideas of 
rewarding participation such as a certificate or an individual written ‘thank you 
letter’ for  reporting ADRs or to more unusual ‘ideas’ such as using ‘chocolate 
frogs’ ,or an ADR pen and movie ticket or some other kind of gifts. These 
unusual ideas were not limited to the USA as one study in one Finnish hospital 
promoted the encouragement for health professionals to report ADRs by 
providing a ‘free dessert at the employee’s cafeteria’! Surprisingly, this idea led 
to a great improvement in the number of ADR reports within one year of study 
period as they increased by 53% (Colodny and Spillane, 1999).  
 Nine years before in Rhode Island, Scott et al. (1990), carried out a study 
to try and find ways to increase the reporting of suspected ADRs to the FDA by 
doctors within the Rhode Island Department of Health. They formulated a 
systematic 5 point plan, based on a telephone Notification System and other 
efforts during a three year period. The interventions were given: 
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1. The local doctors were asked to send the ADR reports to an ADR 
committee, which were then forwarded to the FDA by the committee. 
2. A simple and convenient -to-complete ADR form was created. 
3. Telephone information and reporting line was established. 
4. The promotion and education of the new ADR reporting system was 
carried on through direct mailing, presentations to doctors, 
advertisements and regular articles in the local periodicals. 
5. Individual acknowledgments to the reporter were given in a formal 
letter. 
 
          Before this project had been established, for the 2000 doctors in the 
Rhode Island Department of Health only 11 ADRs reports had actually been 
submitted to the FDA. At the end of the project the reports to the FDA rose to 
201. The figures speak for themselves and to the effectiveness of the project 
and re-emphasise again the problem which exits in the under-reporting of ADRs 
even in a developed country. Furthermore in the study with such 
encouragement to report such events there was also found to be a positive 
change in the doctor’s attitude and knowledge toward ADRs (Scott et al., 1990).   
        At the end of the same decade, Finland and Spillane (1999) published a 
study about the effectiveness of establishing an ADR task force which consisted 
of clinical coordinators from four hospitals in 1996.They also, implemented a 
Notification System with other efforts to try and achieve higher ADRs reporting 
rates and their objectives were:   
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• To adopt ADR definition acceptable to all pharmacists in the district. 
• To design an ADR form. 
• To create a written ADR policy. 
• To implement the new changes at each facility. 
 
The ADR policy was then implemented in the largest district hospital in the area 
and included: 
• An ADR in -service training. 
• A certificate of recognition for reporting an ADR. 
• a ‘free dessert reward’ for reporting ADR (initiated in April 1997) 
• Distribution of the ADR forms to each unit in the hospital. 
• 24 hour telephone line where the reports could be submitted or reports 
could be submitted to the pharmacy department. 
• Reminders of the ADR reporting, in a form of posters and flyers were 
posted in all patient care areas including a poster which promoted the 
"free dessert reward". 
 
         Before the commencement of this new ADR policy there were 168 reports 
made in 1996. In 1997 the reports increased by 53% to 257 reports. In addition, 
ADR in-service training, was implemented, positive recognition for reporting an 
ADR was made part of the system and  rewards were made for reporting an 
ADR and  finally, reminders or promotion of the ADR reporting were frequently 
published. All these innovations were thought to positively contribute to this 
53% increase in the reporting rate in the North Broward hospital in Finland 
(Colodny and Spillane, 1999). 
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 In Makkah hospitals some comments can be made as to how such 
positive inducements could be made. In the clinical setting it is not always easy 
to decide whether a report is related to a particular reaction(s) linked to a 
specific drug or more than one drug. Sometimes to simplify such reports it is 
possible to quantity whether the reactions are usual, unusual, minor, moderate 
or severe. Information and/ or education on how to specifically define a reaction 
and a series of comprehensive ADR definitions would help all health 
professionals to decide when and what to report and thus improve ADR 
reporting. 
According to a number of studies in the UK and elsewhere:  Scott et al. (1990), 
Etzel J et al. (1995), Smith et al. (1996), Colodnyl and Spillane J(1999), and 
Ferguson and Dhillon (1999), Nita et al.(2004) found that: 
A. Nurses and pharmacists were more interested and involved in ADRs 
reporting. 
B. Doctors had a lower involvement but provided a higher quality of reports. 
C. The education programme - active promotion, continuing education and 
feedback - by regular presentations, direct mailing, relevant articles, 
newsletters, meetings, ‘hands on’ training and workshop sessions  all of 
which would  identify, enhance, improving, quality and quantity of ADRs 
reporting. 
 Finally, similar barriers relating to individuals knowing the concepts and 
understanding the necessity of ADR reporting were found to be well expressed 
in this thesis as individuals considered the process as being too time 
consuming, was outside their area of expertise and where to actually report 
them to were all given as potential problems. These very issues were evident in 
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the semi structured interviews where all interviewees mentioned time 
constraints.  They also thought that all serious ADR were already known for a 
newly marketed drug and so reporting them was unnecessary. The second 
interviewee actually mentioned that ADR reporting was not so important as 
pharmaceutical companies should have identified these during clinical trials. 
These areas of concern and providing additional clinical knowledge could be a 
focus of future educational updates to health professionals in Makkah. It is of 
interest to note that pharmacy graduates from Umm Al-Qura University in 
Makkah are currently receiving tuition in ADRs and Pharmacovigilance and so 
when they graduate in 2012 this may significantly help in the reporting of ADR 
in Makkah by pharmacists working in the hospital service.  
 
6.2 Makakh Community pharmacist experience of ADRs 
 This is the first study which has evaluated the awareness and attitudes of 
private community pharmacists towards Pharmacovigilance and ADRs reporting 
in Holy city of Makkah, Saudi Arabia during the time of the Hajj. There are only 
two previous studies which have been reported from Saudi Arabia about the 
topic of Pharmacovigilance in contrast to reports from many other countries all 
of which have commonly emphasized the problem of the ADR under-reporting 
among pharmacists. For example, Davis and Coulson (1999), Backstrom et 
al.(2000), and more recently, Toklu and Uysal (2008) assessed ADR reporting, 
and found a common reluctance to report such events due to a simple lack of 
awareness of the specified medication being able to cause an ADR. 
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 In this thesis, the detailed analysis made on a random sample of 170 
community pharmacists in Makkah, who were authorized by the Saudi MOH to 
serve both the general public, pilgrims or any other visitor to Makkah, formed 
one aspect of this study. The finding that most of them were middle-aged, 
Egyptians nationals with bachelors’ degrees was perhaps not too unsurprising 
given the nature of previous Pharmacy education throughout Saudi Arabia. A 
new development is the School of Pharmacy in Makkah, at Umm Al-Qura 
University, which is only just (2012) beginning to produce ‘domestic’ graduates. 
Also, although other Schools of Pharmacy within the Kingdom have produced 
graduates for a number of years, for example the College of Pharmacy in the 
King Saud University in Riyadh , most of these graduates join the government 
sector because of a better salary and other fringe benefits.  
The situation may however improve in the future with the establishment of more 
than twelve new Colleges of Pharmacy at Universities throughout Saudi Arabia.    
 One of the main reasons perhaps why so many Egyptians are employed 
in community Pharmacies in Makkah is that the owners of the Pharmacies 
employ them because of their availability, as Egypt is currently a country with a 
population of 80 million people, their ability to speak Arabic which is understood 
by the general public, pilgrims or any other visitor to Makkah, attached to which 
is a suitable salary. They also find the ‘environment’ of the city to their great 
liking as it is the centre of the Muslim faith.  
 This manpower situation may change in the future as in the past the 
Saudi MOH had contributed to a lack of Saudi pharmacists by a pharmacy law 
was did not restrict community pharmacy ownership to pharmacists. However, 
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in the future a new law will be implemented which would restrict ownership for 
all community pharmacies to either Saudi pharmacists or Saudi pharmacists in 
conjunction with a Saudi partner.  
 The lack of female Pharmacists in the community setting may have been 
unexpected for the reader of this thesis to find. However due to a number of 
social and cultural factors of Saudi Arabia, female pharmacists are prevented 
from working in the retail sector and so consequently at present, only male 
pharmacists only are allowed to be employed in community pharmacies.  
 So, despite the Egyptians average age and being educated in a system 
in which Pharmacovigilance never was a formally taught subject, it was very 
good to find that they were all strongly in agreement that ADR reporting being 
part of their professional duties and responsibilities. However there was a 
problem as the study found that the majority of community pharmacists 
surveyed, 86 %, was not aware of the ADR reporting program in Makkah. This 
finding is similar to the results reported in similar studies in Hong Kong where 
the figure was 87.7% (Lee et al., 1994) and for community pharmacists in 
Riyadh, Saudi Arabia where it was 86.8% (Bawazir, 2006). In geographical 
nearby Iran, in another study conducted in community pharmacists the figure 
was 87% (Vessal et al., 2009). In the Netherlands, a country which has had an 
ADR system in place for many years and where it is perhaps better discussed 
and documented and even considered in undergraduate education the 
comparable figure was only 1% (Van Grootheest et al., 2002a).  
 The Makkah findings suggest that greater cooperation between all 
sectors and organizations are required  to work together so as to formulate and 
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develop programmes and planning for long-term to development for 
pharmacists  regarding ADRs reporting and Pharmacovigilance to achieve a 
better awareness in the community setting. This should allow them to be 
educated about the subject which their first degrees did not actually cover. 
 This study’s finding that only 12% of the community pharmacists had 
online Internet access at their workplace perhaps may explain why the reporting 
rate to the NPC was so low. A further complication was that even if they had 
Internet access, a lack of awareness (56%) by the community pharmacists of 
the existence of the Saudi NPC within the SFDA they may still not have been 
able to report any suspected ADRs. Finally, their lack of knowledge about the 
mechanisms of reporting ADR through the appropriate channels and filling in 
the necessary forms all suggest a fundamental education would be a very 
useful development to make to improve the success of the system.  
 In contrast to the hospital system, the low participation rate by the 
community pharmacists in Makkah and even those who did complete the vast 
majority of the questions failed to respond to one question in particular namely 
the definition of Pharmacovigilance and ADRs. This may be a consequence of 
poor prior knowledge of the term ‘Pharmacovigilance’. Thus, when the request 
was made to the pharmacists to participate in a study about Pharmacovigilance, 
the reason for declining to participate may simply have been a poor 
understanding of and little interest in the topic. Therefore, we may speculate 
that even fewer pharmacists have sufficient knowledge about 
Pharmacovigilance than the figures would suggest. This perhaps means the 
problem is even more serious than the data suggests. A very similar finding has 
also been made by (Toklu and Uysal, 2008). 
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 One of the most encouraging findings of this part of the study was the 
very positive attitude of those community pharmacists who actually contributed 
to the study towards ADR reporting. The vast majority, 94.11%, regarded 
reporting suspected ADR as a professional obligation and considered ADR 
reporting the responsibility of all people involved with the use of drugs, namely, 
physicians, pharmacists and patients. The finding that 88.23% of respondents 
considered ADR reporting an integral part of pharmaceutical care suggests that 
they were more aware of this concept than Pharmacovigilance and shows 
promise for the future. These results were very similar to figures reported for 
community pharmacists over the last decade in the Netherlands (Van 
Grootheest et al., 2002a) in Riyadh city Saudi Arabia (Bawazir, 2006), the UK 
(Green et al., 2001) and in Norway (Granas et al., 2007).  
 In Makkah, their knowledge of Pharmaceutical care is very important to 
have as the 339 community pharmacies are located outside hospitals and a 
fairly uniform distribution throughout the entire city.  During the Hajj when the 
number of people in the city increases by millions, the pharmacists’ awareness 
of and knowledge about pharmaceutical care plays a vital role in maintaining 
and perhaps improving the quality of services provided to the pilgrims and 
general public.  This is a major challenge, as previous explained above, the vast 
number and diversity of origins of pilgrims places a great pressure on all the 
medical services including the pharmaceutical services and their response has 
to be very professional. A knowledge of ADRs would therefore seem essential 
to form part of any pharmacy professionals ‘knowledge base’ so as to be able to 
both recognize and report any such events and so aid both individuals and the 
wider community. 
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 There is a small problem before such a state will be fully developed. 
Although pharmacy practice in community pharmacies in Saudi Arabia has 
become better organized and implemented and has gained a vital role in 
promoting patient healthcare in community, some problems still exist. Perhaps 
the major problem is one of ‘trust’ by the general public. ‘Trust’ is a very 
desirable quality for all community pharmacists to have but which takes time 
and effort to acquire. Factors which mitigate against such trust are the 
perceived lack of professionalism by some pharmacists being reflected on the 
majority. This is very unfortunate and is made worse by the commercial 
pressure placed on community pharmacies when the pharmacist is a paid 
employee rather than the owner. This may be improved by the new legislation 
about the limitations of ownership of pharmacies which is currently being 
enacted. Finally standards have not only to be practiced but have to be 
enforced by regular checking and verification by the enforcement of all the 
existing regulations governing pharmacy practice which currently needs to be 
improved. These suggestions are not all new since the studies of (Bawazir, 
2006 , Al-Hassan, 2009) suggested that the community pharmacist throughout 
Saudi Arabia should be trained in appropriate fashion to meet such goals. It 
would be logical to apply such suggestions to Makkah as well as to other Saudi 
Arabia cities. 
 If professionalism is improved then ADR reporting may increase but one 
feature of the survey which this thesis found was the overwhelming concern 
(96%) of the pharmacists that they must be sure of the clear relationship 
between the ADR and the drug(s) the individual was taking, before they would 
report the effect. This reluctance to report possible ADRs  were very similar to 
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previous findings reported by pharmacists and physicians in different countries 
such as:  Saudi Arabia (Bawazir, 2006), the UK (Green et al., 2001) Iran 
(Vessal et al., 2009) and the Netherlands (Van Grootheest et al., 2002a). This is 
perfectly understandable as the pharmacist fear that if the make unnecessary 
reports then this may reflect on their professional competence. To solve this 
problem requires a two stage solution. The first is to increase the pharmacist 
students’ knowledge during their degree course and the second, is to provide 
some form of education – either new or refreshment – of existing pharmacists. 
Exposing pharmacy student during their degree course is no major problem, 
mainly one of fitting the material into a very crowded curriculum. The use 
practical ‘hands on’ types of  ‘workshops to reduce the pharmacist concern and 
to strengthen clinical confidence in reporting of an ADR would seem very 
suitable The second is perhaps more complicated to achieve and would require 
greater resources but would have greater benefits to the wider community.  
 One aspect may be to increase their pharmacological knowledge to give 
them greater confidence in determining a real ADR from one which is not. This 
have great benefits as the data from the study showed that the majority 77%of  
the community pharmacists in Makkah considered it essential to discuss any 
potential reporting of an ADR  with a physician before submitting it to a higher 
authority. This may indicate a number of concerns of the pharmacist. Firstly, 
due to a lack of confidence/knowledge the pharmacist is unsure as to the 
significance of the reported events. Secondly, they may be very worried as to 
the consequences of their actions as regards to any potential legal action which 
may follow. Thirdly, they may feel that if the report is not actually related to a 
specific drug then their professional competence may be called into question. 
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All these are very justifiable concerns all of which have been raised in previous 
studies both in Saudi Arabia and elsewhere such as the Netherlands (Van 
Grootheest et al., 2002a , Bawazir, 2006 , Bawazir and Al-Sultan, 2009). 
 Perhaps these three concerns are the major reasons for the very low 
actual participation rate, 6%, of ADR reporting found in this study. This small 
number of individuals had actually filed ADRs to the MOH and a further 6% of 
the community pharmacists claimed that they had submitted ADR reports 
directly to a pharmaceutical company. The way they reported results, or 
perhaps did not report any ADRs, may indicate that the pharmacists had 
instructions, specific or implicit, from their employers, which could be a manager 
or owner, not to do so. Or perhaps they were confused as to where their reports 
should actually go to.  Perhaps, no reports were sent to the SFDA simply due a 
lack of knowledge about this recently established organization. Surprisingly, 
despite such problems 29% of community pharmacists claimed that they had 
submitted ADR report to the SFDA. Finally, none of community pharmacists in 
Makkah indicated that during the last month they had not come across an ADR 
they wished to report to the SFDA.   
 The data acquired for this thesis and the reports of other published 
studies in both community and hospital settings suggests that although 
pharmacists in Saudi Arabia had a low awareness  of the ADR reporting 
programme  this was similar to the experiences in other countries when their 
systems of reporting were introduced. If the data in the published studies proves 
to be true in Saudi Arabia then the work of Grootheest et al, may come to be the 
norm in Saudi Arabia. They found that Pharmacists in several countries make a 
major contribution to ADR reporting For example in Canada, Australia, 
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Netherlands, Japan, Spain and Portugal, the combination of community and 
hospital pharmacists contribute respectively,  88.3%, 40.3%, 40.2%, 39%, 
25.9%, and 23.4%, to the total of ADR reports received by their national 
programs. This finding should encourage the administration in Saudi Arabia not 
to be too worried about the low reporting arte at this time as all systems have a 
slow build-up to achieve these reporting rates and even after many years there 
are still major differences between the reporting rates across the world. To 
achieve a greater reporting rate they have all have had to make significant 
investments in their healthcare programmes so by investing in education and 
training programs for their pharmacists, whether in  community pharmacy or the 
hospital system, the number of reports of ADRs will represent those that 
actually occur. Consequently the provision of suitable education, training and 
practice in reporting ADRs could make the medicines use by the citizens and 
visitors to Makkah a safer process.  
 There are several of negatively factors were may affecting and prevents 
the community pharmacist in Makkah to report ADR one to reporting such as;  
• The reporting of ADR forms were unavailable in the workplace, unknown 
the address, forms were too complicated.  
• The second barrier relating to pharmacists knowing for concept and 
appreciation about reporting programme like; the reporting is too time 
consuming, nonsufficient clinical knowledge and don’t know how to 
report.  
 
These include uncertainty regarding the causality relationship; the belief that all 
serious ADR are already known for a newly marketed drug.  This belief was 
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found in a number of the interviews, e.g. (Interview 2 Appendix 8.7) where the 
interviewee considers that ADR reporting should not be necessary due to the 
pharmaceutical cpmpany conducting their own clinical trials. 
 To overcome the barriers may require the urgent introduction of training 
packages for community pharmacists in Makkah which specifically focus on the 
necessity for, and rationale behind, ADR reporting and Pharmacovigilance. This 
approach has been necessary in many other countries in the early stages of 
their implementation of ADR reporting for health professional here shown are 
such studies given in chronological order. (Bawazir and Al-Sultan, 2009 , 
Bawazir, 2006 , Green et al., 2001 , Van Grootheest et al., 2002a , Granas et 
al., 2007 , Toklu and Uysal, 2008 , Vessal et al., 2009 , Lee et al., 1994) 
Bawazir and Al-Sultan, 2009, Vessal et al., 2009 ) 
 
6.3 The experiences of the potential pharmacists of tomorrow 
 The student’s experience of Pharmacovigilance at Umm Al-qurah 
University which is the only college of pharmacy available in Makkah shows 
great potential for the future.  Educating students before they graduate in 
Pharmacy and showing them how the ADR system of effective coordination and 
cooperation between MOH, SFDA and the Ministry of Higher Education actual 
benefits the patient would prepare them for their future role and can only be of 
great benefit to everybody. It will of course require imaginative teaching 
methods and materials to be developed together with a well-designed overall 
programme to show the importance and relevance of what some might consider 
a purely academic subject especially when the students may have very little 
experience as to how pharmacy practice actually is carried out in the workplace. 
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In addition, it would be insufficient to stop at the undergraduate level and so 
continuous education of existing pharmacists by symposium, lectures and 
workshops would be recommended as being very desirable. If all these could 
be implemented then the knowledge of healthcare professional about ADRs and 
their reporting would be taken to a higher level of success.  
6.4 Overall conclusions 
 The ultimate goal of Pharmacovigilance is to decrease drug morbidity 
and mortality by early detection of drug safety problems in patient and 
improving the selection and rational use of drugs by health professionals. 
 In this process pharmacists can play an important role as they are 
intimately involved with dispensing medications and are in a position to be 
contacted by patients should any adverse effects occur.  Sometimes the role of 
the patients in the process is almost overlooked but they do form a vital part of 
the system.  
 In many countries of the world the success of this system is widely 
documented and a similar degree of success should be attainable in countries 
such as Saudi Arabia which are making rapid progress to become more 
developed especially in areas of health care for their population. The 
establishment of the SDFA was therefore a logical step on this pathway of 
development to try and ensure the best possible use of drugs for its citizens, 
expatriate workers and visitors to Saudi Arabia including the pilgrims at the time 
of the Hajj and Ummrah. Essential to this system is that all healthcare 
professionals have to be actively involved in such a system in all types of 
medical facilities such as government hospitals and clinics, private hospitals 
251 
 
and clinics. Furthermore it is essential to involve pharmaceutical companies and 
patients to report ADRs. Community pharmacists also have a major role to play 
in this system especially in Makkah, where they not only play a major role in 
providing daily services to the general public with a range of professional 
services but make a positive contribution during the time pilgrims are visiting the 
country. 
 The majority of the respondents to the questionnaires which were used in 
this thesis stated that they felt their knowledge of the existing reporting 
programmes and the general concept of Pharmacovigilance was rudimentary. 
Despite this the findings of the questionnaire was that 72% of those admitting 
insufficient knowledge were agreed about the importance of ADR reporting. To 
improve the situation it should perhaps be required for all Saudi health 
organizations such as the MOH, SFDA and SCHS to co-operate together and 
adopt an educational strategy to stimulate the pharmacists’ and other health 
care professional participation in the ADR reporting program. Such changes 
may enable some of the existing barriers to be overcome by using suitable 
educational ‘efforts’ and by instigating proper management ‘tools’ along with 
electronic ‘tools’ may significantly improve the ADRs reporting process which as 
a consequence would become a more accurate and useful  resource. 
 Finally, most systems which require to be improved need to consider 
their day-to-day, week-to-week and month-to-month communication and co-
operation between health professionals and health organizations. This 
communication should be encouraged at all levels so as to reduce any existing 
‘gaps’ of awareness of ADR reporting among medical professionals.  An 
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improvement in the training, using workshops and sessions of continuous 
education relevant to ADRs reporting, would facilitate a better reporting culture.   
Such developments it is hoped may lead to the establishment of an 
effective Pharmacovigilance center in the region involving Pharmacists playing 
a greater role in this critically important area of medicine. 
 
We hope that the result of this project will give MOH incentive to make 
healthcare reengineering system in Makkah that ensures safer prescribing and 
dispensing medication through national network. Thus, pilgrims will receive as 
safe drugs as possible during Hajj 
The need for training at all levels and the inclusion of Pharmacovigilance in 
University programmes is a key finding of this study.  This would not preclude 
the need for regular programmes of in service training and continuing 
professional development. 
 
6.5 Recommendations 
The recommendations made as a result of the studies reported in this thesis will 
give incentive to MOH to improve IT and computerized facilities to overcome all 
constraints and barriers of ADRs reporting. In addition, all Saudi health 
organizations such as the MOH, SFDA and SCHS should co-operate together 
and adopt an educational strategy to stimulate the pharmacists’ and other 
health care professional participation in the ADR reporting program. Such 
changes may enable some of the existing barriers to be overcome.  
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MOH responsibility in this aspect is summarized by emblemizing the 
following improvement:  
1. MOH should provide internet and IT facilities to all health professional 
(pharmacy and physician) with drug database integrated with safer 
prescribing and dispensing system. 
2. MOH should provide physician with computerize physician ordinary entry 
(CPOE) and decision support system (CDSS) that will provide alert on 
known ADRs and provide safer and effective therapy.   
3. To avoid and overcome fear of reporting: MOH or SFDA should allow 
assessing PV reporting form and filling it without need to sign or show 
any identification, to encourage reporting. 
4. Encourage MOH to implement E-Claim system similar to that 
implemented in Abu Dhabi Health Authority (HAAD). This will implement 
transparency and provide postmarking surveillance of any drug under-
question.  
(http://www.shafafiya.org/,http://www.haad.ae/satisticsandhttp://www.sha
fafiya.org/dictionray/standards/datastandard/standdards). 
 
We summarize the educational strategy to stimulate ADR reporting 
program in the following points: 
1. The development of an easier voluntary system of reporting ADRs:  
In all the hospitals systems should exist which are designed to have a 
structure which involves "easy-report" so as to save time and effort for 
all health professionals who have been aware of or actually observed a 
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potential ADR. An advantage of this method is both the low cost involved 
and the ability to cover a wide range of ADRs in the hospital 
environment without detracting from the necessary clinical services. One 
disadvantage is the under reporting and difficulty in obtaining follow-up 
by the pharmacy department (Nita et al., 2004). 
 
2. Notifications system:  
 The Hajj and Ummrah seasons place a great strain on the health 
care system in Makakh and any suspected ADR could be reported by 
leaving a message on telephone hotline, no lesser online available and 
putting in different parts of hospital TV screen to display how to report 
ADRs for healthcare professionals, patients and public or by completing 
an ADR reporting form then forwarding the report to the pharmacy 
department due to ADRs reporting is mostly a centralised system in the 
pharmacy department. A role of pharmacist to check answering machine 
to fill forms regularly and completing the ADRs form which is signed by 
responsible doctors. In side hospital have committee reviews the ADR 
reports and decided to necessary to make an ADR alert, then 
summarised reports presented at the pharmacy and therapeutics 
committee meeting and copy ADR report is forward SFDA.  
 
3. Training, workshops and more education:  
 These could include ideas as the extensive use of traditional 
bulletin boards, drug bulletins - real or electronic using an Intranet 
system, ward reports, case presentation meetings and a newsletter for 
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all health professionals. Information could be made available for patients 
in a similar way so as to involve them more in their own treatment.  All 
such suggestions could enhance the promotion and awareness about 
ADRs. 
 
4. Feedback and impact:  
 All pharmacists believed that  to improve the ADRs reporting rates 
and impact for individual who make an ADR report  including health 
professionals staff, patient or public is very important to use all types of 
positive feedback such as a formal letter, SMS, e-mail, verbal or 
hospital-pharmacy website. These would all make a positive contribution 
to an increased awareness of ADRs and also an increase in the quality 
and quantity of such ADR reports. 
 
5. Barrier and facilities:  
       The pharmacist also commented that, some hospitals in Makkah do 
not have on easy availability all the necessary facilities to file an ADRs. 
This may be due to a lack of online access on-line, non-availability of the 
suitable forms, or the staff being so busy simply does not have the time 
to fill in the necessary forms. Where such forms should be sent if they 
are completed – SAFD needs to be much better advertised. Moreover, 
the forms are considered to be too complicated owing to a lot of 
information is required in order to fill the form in correctly. In hospitals in 
Makkah during Hajj and Ummrah seasons where there are more than 3 
million people it is very difficult to find free time. 
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6. Motivation to overcome confusion as to who should complete an 
ADRs report:  
 Using the reward technique of Colodny and Spillane (1999), such 
as a certificate or individual acknowledgement for reporting ADRs by 
thank-you letter or the forms of reward which increased the reporting 
rate by 53% has to be seriously considered.  Motivation was one of the 
three major categories to emerge from the semi structured interviews.  
There, the importance of reward and recognition were highlighted for 
extrinsic as well as intrinsic motivation.  Motivation is an effective means 
of overcoming resistance.  
 
7. Reporting by mobile phone 
Using the very new technology of reporting ADRs by using mobile phone 
applications is a very new development in the FDA of the USA and in 
NZ. 
If such systems could be implemented then the future of ADR reporting in 
Makkah may be enhanced and future patient safety assured. 
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A. Demographic information: (Please tick  the appropriate box) 
 
1. Gender:   
A. Male    
B. Female 
 
2. Age range:    
A. 23 -30    
B. 31- 40           
C.  +40 
 
3. Nationality:   
A. Saudi 
B. Non-Saudi                     Please identify…………… 
 
4.  Specialist: 
A. Physician              
B. Dentist              
C. Pharmacy      
D. Nurse 
 
5. Educational qualification:     
A. Diploma        
B. Bachelor                                        
C. Master                  
D. PhD 
E. Other qualification 
 
6. Professional Experience in years:      
A. 1-5    
B.  6-10     
C. 11-20        
D.  +20 
310 
 
7. How many hours of Training and continuing education do you spend per month: 
A.  None           
B.  1 - 5                   
C. 6 - 10                 
D. 11 - 20               
E.  +20  
 
8. Do you have an internet facility in your work place:     
A. Yes      
B. No 
 
9. Are any of the following reference books available to you: 
 
A. British National Formulary (BNF)      
B. Middle East Drug Index  
C. Martindale    
D. Saudi National Formulary (SNF)   
E. MIMS 
F. None 
 
B. Familiarity of ADR reporting system: (Please tick  the appropriate box) 
 
1. Are you aware of the ADRs Reporting:   
A.  Yes                 
B.   No     
C.  Not sure 
2. Did you have an ADRs reporting program:      
A. Yes                  
B. No         
C. Not sure  
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3. if yes, how did you become aware about the ADR reporting: 
A.  Officials at work       
B.  I Read about it            
C.  From Colleagues 
D.  From Conferences or Symposia            
E.  Internet ‘websites’                
F. Others  
 
4. Which Department do you think is Responsible for Receiving and 
Interpreting ADRs Reports: 
A. Department of Medicine                    
B.  Pharmacy   
C. External organisation               
D. Don’t know 
 
C. Purpose of  ADR reporting system: (Please tick  the appropriate 
box) 
 
Statement Yes     No Not sure 
Consider  ADR  reporting will identify safe drug    
Consider  ADR reporting calculate rate of incidence    
Consider the reporting system will identify ADRs variations 
with the same therapeutics class  
   
To detect potential ADRs    
Consider the present ADRs reporting system to be 
comprehensive 
   
Additional comment : 
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D. Healthcare professional Attitude toward ADRs reporting system 
(Please tick  the appropriate box) 
 
 
1. I report ADRs that causes:      
A. Hospitalization   
B. A life threatening situation          
C. A congenital anomaly    
D. Persistent disability or incapacity             
E.  Death of the patient  
 
2. Submitting ADR Reports to   
A. Ministry of Health                          
B. pharmaceutical Company     
C. Saudi Food and Drug Authority (SFDA) 
D. Others                       
E. Don’t know      
 
 
Statement 
 
Completely 
agree 
 
Agree       
 
Neutral 
 
Disagree       
 
Completely 
disagree 
Reporting ADRs is the role of healthcare professional       
I believe that the science of monitoring drug safety  is 
important  
     
I want to be sure that the ADRs is related to the drug 
before reporting 
     
I report to get more information about ADRs questions 
that I come across in my practice   
     
I report to show the patient that their concerns are being 
taken seriously 
     
I always report ADRs because it is part of tasks.      
Consulting the physicians is important before reporting 
ADRs 
     
ADRs reporting should be compulsory      
ADRs reporting should be voluntary      
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3. Have you come across patient(s) with ADRs during last month and wished to 
report it?  
A. Yes                     
B.  No       
C.  I don’t know 
 
4. Is there an ADR reporting at your hospital?  
A. Yes          
B.  No                 
C. Don’t know  
 
5. Responsibility to Report ADR?  
A. Pharmacist’s          C. Physician               E.Nurses 
            B. Patients     D. Others 
 
E.  Constraint of study: (Please tick  the appropriate box) 
 
 
Statement 
 
 
Completely 
agree 
 
Agree   
 
Neutral 
     
 
Disagree       
 
Completely 
disagree   
No reporting forms available       
Reporting address unknown      
Reporting form too complicated      
Reporting ADRs is time consuming      
All ADR are known      
Insufficient clinical knowledge      
Do not know how to report      
Indifference       
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8.6 Correlations Cross Tabulations and 
t-test results 
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LIST OF VARIABLES ENTERED INTO SPSS 
 
1.     sex Numeric 8 0 Sex 
2.     agegrp Numeric 8 0 Age (grouped) 
3.     nationality Numeric 8 0 Nationality 
4.     specialism Numeric 8 0 Specialist 
5.     qual Numeric 8 0 Educational qualification 
6.     exper Numeric 8 0 Professional experience in years 
7.     condev Numeric 8 0 Training hours 
8.     internet Numeric 8 0 Internet 
9.     books Numeric 8 0 Reference books 
10. aware Numeric 8 0 Awareness of ADR 
11. trained Numeric 8 0 Had ADR program 
12. discover Numeric 8 0 How became aware of adr 
13. responsible Numeric 8 0 responsibility for ADR 
14. sagedrug Numeric 8 0 ADR to identify safe drug 
15. calrate Numeric 8 0 ADR to caculate rate of incidence 
16. variations Numeric 8 0 ADRS identify variations 
17. detection Numeric 8 0 to detect ADRs 
18. system Numeric 8 0 ADR system comprehensive 
19. role Numeric 8 0 reporting ADRs role of healthcare professional 
20. monitor Numeric 8 0 monitoring drug safety important 
21. check Numeric 8 0 Check ADR before reporting 
22. practice Numeric 8 0 Information about ADR about practice 
23. reassureNumeric 8 0 reassuring patient 
24. alwaysreport Numeric 8 0 always report ADR 
25. consult Numeric 8 0 consult physcian before reporting 
26. compuls Numeric 8 0 ADR reporting compulsory 
27. reasons Numeric 8 0 Reason for reporting ADRs 
28. submit Numeric 8 0 Submitting reports to 
29. reportlast Numeric 8 0 reported ADR in last month 
30. reporthosp Numeric 8 0 Reporting ADR at your hospital 
31. reportresp Numeric 8 0 reporting responsibility 
32. noforms Numeric 8 0 no forms 
33. noadd Numeric 8 0 address unknown 
34. compl Numeric 8 0 form too complicated 
35. time Numeric 8 0 time consuming 
36. prior Numeric 8 0 Already known 
37. lackclin Numeric 8 0 insufficient clinical knowledge 
38. lackknow Numeric 8 0 lack of reporting knowledge 
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Table 32.Summary Statistics 
Statistics 
 Age (grouped) Sex Nationality Specialist Educational 
qualification 
Professional 
experience in 
years 
N 
Valid 310 310 310 310 310 310 
Missing 0 0 0 0 0 0 
Mean 2.24 1.30 1.65 1.70 3.16 2.33 
Median 2.00 1.00 2.00 1.00 3.00 3.00 
Mode 3 1 2 1 2a 3 
Std. Deviation .804 .459 .478 1.070 1.131 1.107 
Minimum 1 1 1 1 1 1 
Maximum 3 2 2 4 5 4 
 
 
Table33: Frequency tables  for Age 
Age (grouped) 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
23-30 72 23.2 23.2 23.2 
31-40 93 30.0 30.0 53.2 
>40 145 46.8 46.8 100.0 
Total 310 100.0 100.0  
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Table 34: Frequency table for Sex 
Sex 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Male 217 70.0 70.0 70.0 
Female 93 30.0 30.0 100.0 
Total 310 100.0 100.0  
 
Table 35:Frequency table for Nationality 
Nationality 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Saudi 109 35.2 35.2 35.2 
Non-Saudi 201 64.8 64.8 100.0 
Total 310 100.0 100.0  
 
Table 36: Frequency table for Specialist 
Specialist 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Physician 207 66.8 66.8 66.8 
Dentist 21 6.8 6.8 73.5 
Pharmacy 51 16.5 16.5 90.0 
Nurse 31 10.0 10.0 100.0 
Total 310 100.0 100.0  
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Table 37: Frequency table for Education qualification  
 
Educational qualification 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Diploma 11 3.5 3.5 3.5 
Bachelor 93 30.0 30.0 33.5 
3 93 30.0 30.0 63.5 
4 62 20.0 20.0 83.5 
Other 51 16.5 16.5 100.0 
Total 310 100.0 100.0  
 
 
Table 38: Frequency table for Professional experience in years 
 
Professional experience in years 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
1-5 104 33.5 33.5 33.5 
6-10 50 16.1 16.1 49.7 
11-20 105 33.9 33.9 83.5 
>20 51 16.5 16.5 100.0 
Total 310 100.0 100.0  
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Table 39: Cross tabulation of Sex and  important of ADR reporting role 
 
 reporting ADRs role of healthcare professional Total 
completely 
agree 
Agree Neutral disagree 
Sex 
Male 124 30 16 47 217 
Female 46 16 31 0 93 
Total 170 46 47 47 310 
 
 
 
Table 40: Cross Tabulation of Sex and monitoring drug safety  
 
 monitoring drug safety important Total 
Completely 
agree 
Agree Neutral Disagree Completely 
disagree 
Sex 
Male 84 47 31 47 8 217 
Female 55 0 0 30 8 93 
Total 139 47 31 77 16 310 
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Table 41: Cross tabulation  between Age and reporting ADRs role of healthcare professional  
 
 reporting ADRs role of healthcare professional Total 
completely agree Agree Neutral disagree 
Age (grouped) 
23-30 46 21 5 0 72 
31-40 67 5 5 16 93 
>40 57 20 37 31 145 
Total 170 46 47 47 310 
 
 
Table 42: Cross tabulation between Age and importance of monitoring drug safety  
 
 monitoring drug safety important Total 
Completely 
agree 
Agree Neutral Disagree Completely 
disagree 
Age 
(grouped) 
23-30 29 17 0 26 0 72 
31-40 37 19 5 23 9 93 
>40 73 11 26 28 7 145 
Total 139 47 31 77 16 310 
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Table 43: Cross tabulation between Nationality and reporting ADRs role of healthcare 
professional  
 
 reporting ADRs role of healthcare professional Total 
completely 
agree 
agree Neutral disagree 
Nationality 
Saudi 78 15 16 0 109 
Non-Saudi 92 31 31 47 201 
Total 170 46 47 47 310 
 
 
Table 44: Cross tabulation of insufficient clinical knowledge and reporting 
ADRs role of healthcare professional 
 
 reporting ADRs role of healthcare professional Total 
completely 
agree 
agree Neutral disagree 
insufficient clinical 
knowledge 
Completely agee 85 30 39 16 170 
Agree 8 0 0 8 16 
Neutral 39 8 8 8 63 
completely 
disagree 
38 8 0 15 61 
Total 170 46 47 47 310 
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Table 45: Cross tabulation  of insufficient clinical knowledge and  monitoring drug safety important  
 monitoring drug safety important 
Completely 
agree 
Agree Neutral Disagree Completely 
disagree 
insufficient clinical 
knowledge 
Completely agree 77 16 31 46 0 
agree 0 0 0 0 16 
Neutral 16 31 0 16 0 
completely 
disagree 
46 0 0 15 0 
Total 139 47 31 77 16 
 
Table 46: T-tast for samples of Nationality and Awareness of ADR  
Paired Samples Test 
 Paired Differences  
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence Interval of the Difference 
Lower Upper 
Pair 1 
Nationality - 
Awareness of 
ADR 
-.146 1.094 .062 -.268 -.023 
 
 df Sig. (2-tailed) 
Pair 1 
Nationality - Awareness of 
ADR 
308 .020 
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Table 47: correlation of specialist and reporting responsibility  
 
 Specialist reporting 
responsibility 
Specialist 
Pearson Correlation 1 -.328 
Sig. (2-tailed)  .000 
N 310 310 
reporting responsibility 
Pearson Correlation -.328 1 
Sig. (2-tailed) .000  
N 310 310 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
333 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.7 Interview chiefs pharmacists 
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Exhibit 1:  Sample of short hand notes  from interview in Arabic 
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Exhibit 2 Sample Transcript of English translation of a semi-structured interview 
Transcript for interviewee No 2 
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(Translated from Arabic) 
Key: R = RESEARCHER;   I = Interviewee 
XXXXXX =  Interviewee’s name blocked;  YYYYYY = The organisation 
 
 
BEGIN 
 
R:  Good morning! My name is Naif  
I:  A very good morning to you Naif.  My name is XXXXXX 
R: well XXXXXX,  as I explained to you over the phone, I am conducting some 
research on behalf of the University of Bradford in the United Kingdom.  This is for my 
thesis which is a major work of research which I am undertaking for my Doctorate 
degree.  Thank you for agreeing to be interviewed.   
I hope you don’t mind if I scribble down some rough notes during the interview.  I 
prefer this way to making a recording so if you can keep a gentle pace during the 
interview just to give me time to get it down.  But I will use shorthand so it shouldn’t 
slow us down really. 
I:  I don’t mind.  Use a recorder if it makes life easier.  I have one in my desk if you 
need it. 
R:  thank you.  Honestly, I prefer to take brief notes and then write them up in full soon 
after the interview. 
Would you like to introduce yourself and just give me a few details about yourself and 
your role in pharmacy and how much experience you have.  Your name will be kept 
anonymous during the analysis stage so I hope you do not have any fears like that. 
I:  Well um...my name is XXXXXX.  I work as the chief pharmacist for YYYYYYY.  I 
have held this post for over 20 years now, and as well as preparing prescriptions I have 
a sort of management role here.  I got my Bachelors Degree in Pharmaceutical Sciences 
oh...maybe 30 years ago.... 
R:  Where did you get your degree? 
I:  That was from the University of Riyadh.  Of course a lot has changed since then so I 
have had to keep updating myself.... 
R:  Thank you XXXXXXX.  Before I continue let me give you a small bit of 
background to the research.  I am trying to find out people’s attitude to ADR reporting.  
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ADR is Adverse Drug Reaction, when a patient exhibits some kind of reaction to the 
use of a certain drug.  This reaction can be mild or serious...even life 
threatening...thankfully life threatening reactions don’t happen often....anyhow, the 
point of reporting these reactions can have a number of purposes.  Firstly, if reactions 
were severe, this can be reported to be kept on the patient’s medical record.  If the 
patient ever needs drug treatment in the future, by checking the records, the pharmacist 
knows to avoid that drug or family of drugs.  Secondly, if there are many ADR reports 
to the pharmaceutical company, they can withdraw the drug altogether.  So, you will be 
helping in this research. 
I:  My pleasure to be of help 
R:  So, there are no right or wrong responses, please feel free to be as honest as you can 
and that will be a great help 
I:  OK 
R:  One last point, the interview will probably last about 40 to 45 minutes.  Is it possible 
to switch your mobile off so we are not interrupted? 
I:  Sure.  (Switches mobile off) 
R:  If you need a break for any reason please just raise your hand and I will stop. 
I:  Ok!  But I should be OK for that period of time 
R:  So, let’s begin.  Before today, have you ever heard of ADR reporting? 
I:  Well of course I know about ADR’s....what they are.  It’s like some people are 
allergic to penicillin...but I never knew anything about reporting...I mean everyone 
knows that some people have a bad reaction to penicillin...but there’s not much we can 
do about it only to change the treatment 
R:  But have you ever had to report any medicines 
I:  Report?  Report to whom? 
R:  All I want to know is if you’ve ever had to report ADR’s anywhere 
I:  No.  I don’t think that would be my responsibility... I mean our job is already busy 
enough.  And the pharmaceutical firms...well they carry out lots of trials on new drugs 
first with animals and then with human volunteers...so reactions don’t happen that 
much...at least not that I’m aware about it. 
R:  But what about historical cases...for example thalidomide? 
I:  Well that treatment was mostly used in Europe...and it was very sad that babies were 
affected...and had disabilities for life...but pharmaceutical companies are a lot more 
careful nowadays 
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R:  What about medicines that only affect a very small percentage of people...like 
maybe one in twenty or thirty thousand....it might not show up in clinical trials? 
I:  Um...well everything has some risk...you drive your car to work...you don’t expect to 
have an accident 
R:  But suppose you heard that one of your patients became ill after taking medicine that 
you prescribed? 
I:  well sure...that happens...um...but it could be anything...need not be the medicine...I 
mean some people have allergic reactions to almond nuts...in fact we get people here 
with allergic reactions and they are looking for a cure but we don’t even know what 
caused the allergy in the first place. 
R:  Have you had a recent example of that 
I:  Well yes, we had a person coming for weeks complaining about breaking out in skin 
rashes.  So they tried cutting out nuts...it wasn’t that...then eggs...it wasn’t that...then 
cheese....it wasn’t that...Finally, we found out that it was a kind of plant growing in his 
house...so you see it wasn’t food or medicine 
R:  Interesting 
I:  So you see reactions can have many different possible causes and it can be hard to 
identify it sometimes 
R:  So was ADR ever covered in your University course?  Was it ever mentioned about 
reporting ADR’s 
I:  Well, I can’t say I remember...you know it was quite a while ago...Of course I kept 
notes from lectures but a lot of it is out of date now 
R:  So, do you have any policy about reporting here? 
I:  Not that I’m aware of.  I mean I am in a supervisory role...but things like reporting 
ADR’s...I don’t think would be part of my job role 
R:  So whose role would that be, then? 
I:  I can’t say i ever heard about it from anyone.  Maybe the physcians of the clinic  but i 
wouldn’t really like to say 
R:  So what would you do if a number of patients told you they were having reactions to 
a certain new medicine? 
I:  I can’t say I can think of that ever happening...maybe it did...but I would mention it 
to the physician if it did 
R;  But would you not report it yourself 
340 
 
I:  Well, as I said, I would tell the physician Well all our physicians should have "a safer 
computerised physician order entry (CPOE) to support them in reporting.  Also they 
need this to check out any drug or medicine for dosage and possible reactions by online 
drug database integrated with safer prescribing and dispensing system. 
R:  So you have this system in place? 
I:  I only wish we had….we've been waiting for MOH to install this for ages.  I really 
wish we did have internet provided .     
R:  OK, now just suppose someone was having a violent reaction to some drug or 
treatment? 
I:  Well, the reaction might not be to the medicine...I don’t think I am qualified to make 
that kind of judgment.   
R:  So other than mentioning it to the physician..... 
I:  Well, who else?  I mean I don’t know where else to report it 
R:  Do you think if there was some kind of reporting system and policy,,,you would 
follow it? 
I:  You know this is already a very busy place....a big case load of patients and already 
many reports to be filled out...if it would help then I would do it...but it seems like a lot 
of work for only a very small number of people who have reactions...and even then...the 
reaction might be something else, not the medicine. 
R:  What I’m trying to get you to think about is a simple reporting system, where you 
just enter a few details on a form or on a template on the computer...it should only take 
three or four minutes 
I:  Well I guess if that’s how simple and easy it is I suppose I could do it...Oh..speaking 
of computers I've already mentioned that we do have IT support by MOH and if all 
these people you're talking about would have access to a PC.   
 
R:  Ok, I understand…. 
  
I: But what if I blame a certain drug and it later turns out that it wasn’t that drug at all 
R:  That wouldn’t be a problem...the pharmaceutical firm would only take action if they 
were getting quite a few reports from different sources. 
R:  How would you feel about the introduction of ADR reporting in your department? 
I:  I think it would be just more paperwork ...we’re already overloaded as it is 
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R:  But if reactions don’t happen that frequently, it wouldn’t really add any strain to 
your workload 
I:  Maybe not.  But if I forgot to report...then I would have to take responsibility 
R:  Would you be interested in a workshop on ADR reporting as part of your continuing 
development 
I:  Look, at my age, it’s not very likely I will rise any higher in responsibilities...it seems 
to me that there are many more important things than reporting skin rashes to the 
pharmaceutical company 
R:  But what about if the reaction was more serious? 
I:  How do you mean? 
R:  Say respiratory problems...or even a heart attack 
I:  Well, as I say, I would bring it to the attention of the physician 
R:  But as you are in the front line..with prescriptions and dispensing the medicines, 
would you not be best placed to pick up on these kinds of reactions? 
I:  Well, yes, I suppose I am...but what if the patient never reported back to me...how 
would I know? 
R:  Good point.  You see what is being considered is a kind of comprehensive system 
where people can report adverse reactions in a simple way.  When the medicine is being 
dispensed to the patient they could be given a form or contact number to report any 
adverse reactions...or if they reported it to you...there would be a simple system for you 
to report it online to the company and all other medical professionals involved.  And it 
would go on the patient’s  medical history record so that use of that particular medicine 
would never be prescribed to him again. 
I:  Well of course that would be good but don’t you think we are already burdened 
enough? 
R:  I understand that XXXXX.  However, you would first need training to come to see 
its importance. Then the simple reporting system would be explained and you would 
have a chance to try it out...you know...in a simulation exercise...and this would count 
towards your continuing professional development. 
I:  Yes, I am open to that.  I mean everything can help...its just making sure my staff are 
not overloaded with work. 
R:  But would you be willing to encourage your colleagues to take part in the training? 
I:  Well yes...but let me tell you something...I would be willing to receive the training 
but I can see a lot of my staff being against it....they already asked for training this year 
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on  latest advances in the treatment of diabetes....that’s already been arranged.  We can’t 
cancel it just for ADR reporting and there just isn’t time for yet another training 
event...at least this year. 
R: Yes 
I:  another thing....You mentioned about putting in the report on the computer...but my 
staff don't have access to a PC....that’s another problem. 
R:  What if MOH were to provide better access to the internet...think about the benefits 
as they can quickly check out any drugs online.   
I:  But why can’t people working in administration or the physician do the ADR 
reporting...I don’t know if you appreciate how busy we get in here sometimes  (Knock 
on door) 
I:  Can I just answer that please? 
R: OK, we haven’t got much more to cover (Pause as XXXXX steps out into 
hallway....2 minutes later XXXXX  comes back into the office 
I:  Sorry about that, I just had to deal with something...er something private and urgent 
R:  Have you got to leave? 
I:  No its ok I can stay a little while longer 
R:  Thank you.  I really appreciate that because it just gives me time to put an important 
point to you.  And then we will conclude. 
I:  OK 
R:  The full benefits of an ADR reporting system really takes a bit of time to explain 
and consider.  But, the ADR system could actually relieve you of some of your current 
workload.  I understand your position that it should be a job for administration.  But 
have you ever thought that the pharmacist has a key role in this.  Without the 
pharmacist....it will not be successful.  Do you understand why that is the case? 
I:  Well, I suppose its because we are often the first point of contact with the patient. 
R:  Yes.  But not only that.  The pharmacist often knows the patient personally.  At least 
he knows the patient better than administration staff who might only know him as a 
name or number and never actually meet face to face. 
I:  Um Ok I accept that but what about nurses...they often know the patient face to face 
R:  True.  And it would not be the pharmacist’s duty to report ADR’s entirely.  Nurses 
will also need to be trained. Doctors, physicians and even administrators.  But the key 
role is the pharmacist because he is the dispenser of the drug or medicine.  And its not 
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just skin rashes....although they can be irritable...but some ADR’s can be serious, even 
life threatening. 
I:  Look I am willing to take part in the training but its going to be hard to get my staff 
involved.  Unless it comes down as a directive...like mandatory 
R:  It could be done that way but I don’t think it would be a good approach do you? 
I:  Well if it was made mandatory training, they would have to attend, but I bet some of 
them would book in a holiday on the date of the training or else call in sick that day 
R:  That’s exactly why I don’t want it to be approached as mandatory.  I would be 
relying on you to sell the idea to your staff.  What do you think? 
I:  I’ll give it a try...but I don’t think I have enough knowledge of ADR’s 
R:  We can give you some information and leaflets.  But we would really want you to be 
committed to promoting it. 
I:  Yeah OK.  Send me the information package and I’ll see what I can do, then 
R:  Well i think we have pretty much covered what I was hoping would be covered.  Is 
there anything you would want to add or any questions? 
I: Er no, I don’t think so 
R:  Or any question you think your staff might throw at you? 
I:  Mmmm Oh Yes.  What if someone says: “well, seeing as we are being given more 
responsibilities, will we also be getting a rise in our rate of pay?”  Yes, I can see them 
asking that, and I don’t know what to say if they do. 
R:  Well pay rates are not within my remit.  You would have to raise that with the HRM 
department.   
I:  I’m not saying it will be raised....just wondering what I can say to them if they do 
ask? 
R:  Well try and get them to see that this is a system which will help many patients and 
could even save lives.  But, you know, if it was set up properly, it might even reduce 
your workload as patients will not be presenting themselves with adverse reactions. 
I:  Well, OK.  Send me the package and I will try and push it...you know...try and sell 
the idea.  I can’t promise anything though.  I guess it depends on the mood of the day. 
R:  Ok. Well i think that wraps it up then.  Thank you XXXXX for giving of your time 
I:  Well its nice that someone thinks of consulting us...I mean we are on the front line of 
things 
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R:  That’s why your input is so valuable.  Just to remind you that your input is 
confidential and will be presented in an anonymous way. 
R:  (Rises)  Well thank you  XXXXXX.  I will be happy to hear from you if you think 
of anything else  you want to add or suggest.  I will leave you this card.  Its got my 
mobile and email address. 
I:  Ok Thank you so much 
R:  Thank you for your time again.  Goodbye. 
END 
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8.8 Comments of students pharmacist 
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